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Synthetic Biology Approaches to Engineering Human Cells  
Abstract  
The field of synthetic biology seeks to revolutionize the scope and scale of what is 
currently feasible by genetic engineering. By focusing on engineering general signal 
processing platforms using modular genetic parts and devices rather than ‘one-off’ 
systems, synthetic biologists aim to enable plug-and-play genetic circuits readily 
adaptable to different contexts. For mammalian systems, the goal of synthetic biology is 
to create sophisticated research tools and gene therapies. While several isolated parts and 
devices exist for mammalian systems there are few signal processing platforms available. 
We addressed this need by creating a transcriptional regulatory framework using 
programmable zinc finger (ZF) and TALE transcription factors and a conceptual 
framework for logical T-cell receptor signaling. 
 We first engineered a large set of ZF activator and repressor transcription factors 
and response promoters. ZFs are scalable elements as they can be engineered to bind to 
given DNA sequences. We demonstrated that we could ‘tune’ the activity of the ZF 
transcription factors by fusing them to protein homo-dimerization domains and by 
modifying their response promoters. We also created OR and NOR logic gates using 
hybrid promoters and AND and NAND logic gates by reconstituting split zinc finger 
activators and repressors with split inteins.  
Next, using a computational algorithm we designed a series of TALE 
transcriptional activators and repressors predicted to be orthogonal to all 2kb human 
 iv 
promoter regions and thus minimally interfere with endogenous gene expression. TALEs 
can be designed to bind to even longer DNA sequences than ZFs, however off-target 
binding is predicted to occur. We tested our computationally designed TALEs in human 
cells demonstrating that they activated their intended target genes, but not their likely 
endogenous off-target genes, nor synthetic promoters with binding site mismatches. 
 Finally, we created a conceptual framework for logical T-cell-mediated killing of 
target cells expressing combinations of surface antigens. The systems consist of 
conventional and novel chimeric antigen receptors (CARs) containing inhibitory or co-
stimulatory cytoplasmic signaling domains. In co-incubation assays of engineered T-cells 
with target cells we demonstrated a functioning OR-Gate system and progress toward 
development of a functional NOT-Gate system using the CD300a and CD45 inhibitory 
receptor domains.  
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Chapter I 
 
Introduction: transcription factor-based mammalian synthetic gene circuits: design 
strategies and outlook 
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ABSTRACT 
Mammalian synthetic gene circuits have the potential to directly impact human 
health in the form of sophisticated new research tools and gene therapies. Transcription 
factor-based circuits represent some of the most common and best-studied mammalian 
gene circuits, and recent technological advances have made their future appear even more 
promising. Much progress has been made toward expanding the repertoire of 
biomolecules that transcriptional circuits can interrogate. Additionally, several different 
types of computations have now been implemented with these circuits, including: logic 
devices, feedback loops, half-adders, and switches. In creating these circuits many key 
design strategies and considerations have emerged, offering genetic engineers a veritable 
toolkit for circuit generation. While thus far the scale and predictability of mammalian 
synthetic gene networks has been limited, the recent development of computational 
frameworks and targeted genome engineering tools will help to overcome some of these 
challenges. This chapter reviews current approaches to designing transcription factor-
based mammalian synthetic gene circuits and discusses the future outlook of these 
circuits while highlighting mammalian-specific engineering challenges and potential 
solutions.  
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A promising outlook for mammalian synthetic gene networks 
Already established as indispensible research tools and beginning to enter the 
clinic, mammalian synthetic gene networks are now poised to play an even greater role in 
human health. Researchers created the first mammalian synthetic gene circuit over 25 
years ago when they demonstrated that the Lac repressor (LacI) from lambda phage could 
control transgene expression in mammalian cells in an IPTG-responsive manner (Brown, 
Figge et al. 1987). Since that time this LacI system and similar tramscription factor (TF) 
inducible gene expression systems, most namely the tetracycline/doxycycline inducible 
systems, have revolutionized studies of mammalian gene function, granting control over 
the timing and expression level of transgenes (Gossen and Bujard 1992; Urlinger, Baron 
et al. 2000). The scope of what circuits can do has also expanded far beyond these 
inducible systems. Circuits can now interrogate and respond to a vast array of 
biomolecular inputs, including: promoter-specific transcription, miRNAs, intracellular 
and surface proteins, light, post-translational modifications, and various chemical 
inducers (Culler, Hoff et al. 2010; Nissim and Bar-Ziv 2010; Toettcher, Voigt et al. 2011; 
Xie, Wroblewska et al. 2011; Leisner, Bleris et al. 2012). Researchers have developed 
several different approaches to integrate and process these signals. Using various genetic 
computing elements such as TFs, catalytic RNAs, and post-translational effector proteins, 
researchers have created a variety of circuit architectures including logic networks, 
feedback loops, and genetic switches (Deans, Cantor et al. 2007; Rinaudo, Bleris et al. 
2007; Chen, Jensen et al. 2010; Leisner, Bleris et al. 2010; Burrill, Inniss et al. 2012). 
The recent development of general computing frameworks, large sets of mutually 
orthogonal genetic regulatory components, will likely lead to the development of higher-
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order gene circuits that will grant even greater specificity and timing of gene expression 
(Khalil, Lu et al. 2012; Leisner, Bleris et al. 2012; Lohmueller, Armel et al. 2012). 
Researchers are now using many of these genetic components to create applied 
circuits with clinical significance, most notably in immune cells. In one recent study by 
Chen et al. RNA-based controllers were used to accomplish small molecule-regulated 
control over engineered T-cell proliferation in mice (Chen, Jensen et al. 2010). The use of 
RNA-controllers in the study was important, as unlike proteins RNAs don’t undergo 
antigen presentation. In another recent study, Wei and Wong used bacterial effector 
proteins to tune T-cell activation and to create a synthetic pause switch to temporarily 
inhibit T-cell activation. These circuits could serve as safety switches for immune 
therapies (Wei, Wong et al. 2012). In yet another recent study, Kloss et al. constructed an 
AND gate using chimeric antigen receptors (CARs) to lyse target cells that have a 
combination of two antigens on their surface in mice (Kloss, Condomines et al. 2012). 
While single CAR systems have been in clinical trials for some time, this new system 
could be used to greatly enhance the specificity of CAR-based T-cell therapies (Porter, 
Levine et al. 2011). Other notable, non-immunological systems include circuits by Ye et 
al. and Kemmer et al. in which TF and receptor-based circuits were used to sense and 
prevent the onset of the metabolic diseases of hyperuricemia and metabolic syndrome, 
respectively, in animal models (Kemmer, Gitzinger et al. 2010; Ye, Daoud-El Baba et al. 
2011; Ye, Charpin-El Hamri et al. 2013). Looking forward, there are also many 
challenges to address before realizing the full potential of mammalian synthetic gene 
networks. In general mammalian systems are inherently complex making the engineering 
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process slower and circuit behaviors more difficult to predict. Some of these challenges 
are beginning to be addressed while others are still awaiting solutions.  
In this chapter we review current approaches to generating mammalian 
transcription factor-based synthetic gene circuits. We focus on general design principles 
including the types of inputs, design of regulatory components, and different circuit 
architectures while discussing important circuit parameters. Finally, we contemplate the 
future of mammalian synthetic gene circuits including potential future approaches and 
and mammalian-specific engineering challenges and potential solutions. 
 
TRANSCRIPTION-BASED GENE CIRCUITS 
Transcriptional Regulators 
By far the largest number of mammalian synthetic circuits have been 
transcription-based systems. This is probably because transcription factors were the first 
synthetic regulators used in mammalian circuits and conceptually, transcription-based 
systems are intuitive and relatively simple to design and implement (Kramer, Fischer et 
al. 2004; Kramer, Fischer et al. 2005; Kramer and Fussenegger 2005). Transcriptional 
circuits consist primarily of well-defined defined positive and negative transcription 
factor (TF) regulators and their cognate regulatory promoters. TFs are most often 
comprised of DNA binding domains (DBDs) fused to transcriptional activation or 
repression domains for positive and negative regulators, respectively. The most 
commonly used activation domains are the VP16 activation domain from Herpes Simplex 
Virus TK activator, VP64 four tandem copies of VP16, and the activation domain from 
the p65 protein of the NFkB transcriptional activator (Hurt, Thibodeau et al. 2003). The 
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most common negative regulatory domain is the KRAB repression domain (Beerli and 
Barbas 2002; Haynes and Silver 2011). The underlying biochemical regulatory 
mechanisms of these domains have largely been worked out, however, several papers 
suggest roles for these domains in chromatin remodeling. The mechanisms for these 
functions and impact on circuit behavior have not been fully uncovered (Urrutia 2003; 
Haynes and Silver 2011). 
The bulk of DBDs in the first synthetic regulators were derived from lower 
organisms such as bacteria and yeast and more recently from programmable DBDs such 
as zinc finger and TALE proteins. Of the early synthetic regulators LacI, TetR, and Gal4. 
LacI and TetR are unique as there are small molecule inhibitors IPTG, and doxycycline 
that can act to reduce their DNA binding activity activity. TetR was also modified 
through mutagenesis to create the reverse tetracycline transactivator (rtTA) such that its 
DNA binding activity is instead induced by doxycycline (Gossen and Bujard 1992). 
These factors have well defined DNA binding sequences that are used in generating 
response promoters. Other non-programmable synthetic TFs used in mammalian circuits 
include the streptogramin and macrolide inducible factors PIP, and ETR (Kramer, Viretta 
et al. 2004). 
Recent TF regulator designs have focused on the construction and use of DBDs 
that are ‘programmable’ in the sense that researchers can design them to bind to different 
DNA sequences. The most prominent examples are zinc finger (ZF) and TALE proteins. 
ZF DBDs most often consist of arrays of 3-4 individual fingers that each bind to 3bp of 
DNA sequence (9-12bp DNA binding sequence in total) (Hurt, Thibodeau et al. 2003). 
While the original modular assembly hypothesis positing that fingers known to bind to 3-
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peat sequences can be strung together to create larger binding proteins with combined 
specificity was discredited, this theory was recently re-written and validated including 
new rules taking into account context-dependent effects of positions of the fingers 
(Sander, Reyon et al. 2010; Sander, Dahlborg et al. 2011). Now three finger ZF proteins 
can be efficiently generated without the need for lengthy selection processes. Several 
positive and negative ZF TFs regulators have been generated and shown to function in 
mammalian cells. ZF TFs have been shown to be regulated by small molecules through 
the use of induced dimerization protein domains, and tunable by adding constitutive 
homo-dimerization domains of different strengths on the ZFs (Beerli, Schopfer et al. 
2000; Lohmueller, Armel et al. 2012). As ZFs can only bind to 9-12bp sequences with 
specificity they will likely have off-target binding in the host cell’s genome. On the 
upside, ZFs are relatively small proteins, and each 3-finger ZF is encoded by only 
~300bp of DNA.  
TALE proteins represent another class of programmable DBDs. TALEs were 
recently discovered to have a well-defined binding code in which the individual repeat 
domains that make up TALE DBDs each have a preference for binding to a single 
nucleotide with high specificity (Boch, Scholze et al. 2009; Moscou and Bogdanove 
2009). By stringing together the repeat domains with known specificities, researchers can 
very easily design TALEs that can bind specifically to longer sequences. Researchers 
traditionally design TALEs to bind 18-20bp meaning they are capable of binding to DNA 
sequences twice as long as ZFs (Garg, Lohmueller et al. 2012). The caveat however, is 
that the TALE repeats do not have perfect specificity for a single nucleotide, and thus 
some off-target binding is expected to occur (Moscou and Bogdanove 2009). Both TALE 
 8 
activators and repressors have been shown to work effectively in mammalian cells (Garg, 
Lohmueller et al. 2012). In one of our papers we used a computational approach to 
generate TALEs that are not expected to bind to any endogenous human promoter 
regions even after taking predicted off-target binding into account, creating an ideal set of 
regulators to use in circuits. As the research on TALE DBDs is still in its infancy, it is 
possible that large scale expression studies will be useful in determining the effects of 
these regulators on the cells’ endogenous gene expression. Like most TFs the strength of 
TALE expression can be modulated by increasing the number of binding sites in the 
TALE promoter. To decrease activity, one can created mutated binding sites at different 
positions. One downside to using TALEs is that they are very large proteins to work with, 
and contain highly repetitive DNA sequences. To reduce this difficulty there have been 
several effective cloning schemes developed for TALE assembly (Morbitzer, Elsaesser et 
al. 2011; Reyon, Tsai et al. 2012; Schmid-Burgk, Schmidt et al. 2012). However, TALEs 
are still too long to work effectively in viral vectors with limited sizes or high sensitivity 
to repetitive DNA (Holkers, Maggio et al. 2012). 
 
Response Promoters 
To create activatable response promoters TF binding sequences are placed 
upstream of a minimal/core mammalian promoter. The most common minimal promoters 
are TATA boxes derived from the CMV promoter and HSV-TK viral promoters and or 
the CMVmin promoter which contains extra core promoter elements (Agha-Mohammadi, 
O'Malley et al. 2004). The strength of this minimal promoter is an important factor for 
regulating both the background transcriptional activity in the absence of a TF and the 
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final maximum activated transcriptional activity in the presence of a TF. The choice of 
the minimal promoter is an often-underappreciated design consideration. In an interesting 
study Juven-Gershon et al. created a high expressing ‘super core’ promoter by combining 
all known mammalian core promoter elements (Juven-Gershon, Cheng et al. 2006). 
These elements could perhaps be used to individually or in combination to create new 
minimal promoters with variable activities.  
Repressible promoters consist of constitutive promoters containing TF binding 
sites somewhere in the promoter, most often at the transcriptional start sites or at known 
endogenous TF binding sites. The repressor TF acts by binding to the sequence in the 
promoter and inhibiting the transcription either through binding or through the activity of 
its repression domain (Beerli and Barbas 2002). The maximum activity of the repressible 
promoter is defined by the upstream constitutive promoter. The rules for the ‘activity 
range’ of repression domains such as the KRAB domain, where the TF needs to bind to 
inhibit transcription, have not been elucidated. Future studies using designer TFs, for 
which TFs could be designed to bind anywhere in a promoter, will likely uncover some 
of these characteristics. For both activatable and repressible promoters, the number of 
binding sites in the promoter is an important design variable that defines the response 
strength of the promoter to the TF (Lohmueller, Armel et al. 2012). 
 
Inputs to TF Circuits 
Inputs for transcriptional circuits are diverse and can in theory include anything 
capable of affecting the expression or activity of a TF regulator. That being said while 
linking an input to a TF regulator can be conceptually simple, in practice the generation 
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of a properly functioning circuit often requires precise tuning and an input with a wide 
dynamic range. Experimentally demonstrated inputs include: endogenous promoter 
activities, endogenous TF activities, miRNAs, small molecules, light, proteases and cell 
surface receptor ligands (Wehr, Laage et al. 2006; Xie, Wroblewska et al. 2011; Li, 
Moore et al. 2012). While some of these circuits have intermediary steps between the 
original signal and the final transcriptional output, we are considering anything that can 
eventually affect the TF regulator as a potential circuit input. Potential inputs that as of 
yet have not been demonstrated are also discussed. 
Promoter activity can be used as an input by placing the promoter upstream of a 
TF-regulator to drive its expression. Endogenous gene expression data is a powerful 
classifier for many different biological states including cell type and various disease 
states. There are many promoters that have been discovered from such data and cloned 
and experimentally verified to regulate a transgene in a specific manner (Trinklein, 
Aldred et al. 2003; Kim, Barrera et al. 2005; Zhang, Markus et al. 2012). These are ideal 
promoters to use as inputs as they have already been isolated. Potential promoters from 
qPCR data or large expression sets such as microarrays or RNAseq can also be used, 
however there are several considerations in this case. First, the gene’s RNA expression is 
the result of a promoter and other factors such as RNA stability, miRNAs targeting the 
transcript, and chromatin modifications. By only taking a gene’s promoter, it is possible 
that some of this regulation will be lost. Including the UTRs or introns of the gene in the 
expression of the TF could help to recapitulate some of this regulation, however this 
approach has not yet been reported. It is also often difficult to define the full regulatory 
regions of the promoter. Enhancer elements containing endogenous TF sites can be 
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located up to 100kb away from the expressed gene, and it is difficult to define DNA 
elements necessary to recapitulate native chromatin structure of the gene (Zhang, Markus 
et al. 2012). In general it is better to err on the long side when designing promoter 
sequences, however this option is not always possible as DNA sequence size is often a 
major limitation when making a circuit.  
Endogenous TFs have also been used as circuit inputs by creating synthetic 
promoters responsive to the endogenous TFs. These promoters are generally created like 
synthetic circuit TF promoters with the endogenous TF binding sites upstream of a 
minimal promoter (Li, Moore et al. 2012). Many endogenous TF binding sites have been 
experimentally discovered, however, TF binding is not always enough to induce or 
repress transcription. The regulation of genes by endogenous TFs is complex and TFs 
often regulate genes in combination with other endogenous factors. Thus, for some TFs it 
could be better to use endogenous promoters known to respond strongly to the TF in 
question (Whitfield, Wang et al. 2012). 
Small inhibitory RNAs such as miRNAs can be interrogated as inputs by placing 
RNA recognition sites in the 3’ UTR of the TF transcript. Perfectly matching sequences 
will regulate TF expression by degrading the transcript while slightly mismatched 
sequences will inhibit translation of the TF regulator from the transcript. These sites can 
be multimerized to increase the inhibitory effect of the small RNAs (Leisner, Bleris et al. 
2010). 
Small molecules and metabolites have also been interrogated as TF circuit inputs. 
These are most often interrogated by directly acting on a TF-regulator inducing or 
inhibiting its DNA binding or assembly of split-TF protein fragments. Interrogated small 
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molecules include IPTG, Doxycycline, 4HT, uric acid, rapamycin, macrolide, and 
streptogramin (Deans, Cantor et al. 2007; Kemmer, Gitzinger et al. 2010; Leisner, Bleris 
et al. 2010; Ye, Charpin-El Hamri et al. 2013). Light has also been used to trigger 
assembly of split-TF protein fragments to serve as an input in this way (Bacchus and 
Fussenegger 2012). Expanding the number of TFs inducible by metabolites is an active 
field of interest.  
Finally, cell surface signaling can also serve as an input to a synthetic TF circuit. 
While this sensing must be indirect there are a couple of different methods developed for 
interrogating cell surface signaling. In some cases these methods have been demonstrated 
for a very specific set of regulators, but some could be adopted as general strategies for 
other receptors. In some of the most general methods, the TEV protease is split into two 
fragments with one fragment fused to the receptor along with a TEV-cleavage sequence 
and a TF. For G-Protein Coupled Receptors (GPCRs) the TEV is re-consituted using a 
recruitment method, in which beta-arrestin is fused to the other half of split TEV. Upon 
receptor activation the beta-arrestin TEV is recruited to the receptor leading to cleaving 
the TEV cleavage peptide and release of the tethered TF. Similar methods splitting TEV 
and fusing it to two receptors that dimerize upon activation has also been demonstrated. 
One can also indirectly measure the cell-surface activation by monitoring activity of 
endogenous TFs known to be activated by cell surface receptor signaling. This strategy 
can potentially lead to false positives as multiple cell signals can lead to TF activation, 
but there are often endogenous gene promoter sequences specific to certain cell-signaling 
pathways (Wehr, Laage et al. 2006; Barnea, Strapps et al. 2008). 
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Other potential inputs for a TF circuit that have not yet been used in TF circuits 
include endogenous nuclear proteins and small molecules/ metabolites that can bind to 
RNA molecules (Yen, Svendsen et al. 2004; Murphy, Mostoslavsky et al. 2006). In a 
recent study by Culler et al. transgenes were fitted with an exon containing a protein-
binding aptamer sequence flanked on either side by two introns (Culler, Hoff et al. 2010). 
In the presence of the protein being sensed this protein binds to the aptamer and either 
leads to splicing or inhibition of splicing depending on the intron-exon-inton design. This 
system could be adapted to regulate a TF as part of a circuit. 
 
TF computation 
Transcriptional regulators have been shown to be modular and combining these 
regulators to generate logic gates, feedback loops, and larger-scale circuits is 
conceptually simple. After linking the desired inputs to the presence or activity of the TF 
regulators then the response promoters must be configured and tuned to perform the 
desired computation. The most common types of circuits built to date are logic circuits. 
These circuits allow the activation of an output gene or genes in response to the presence 
or absence of multiple inputs in a logical fashion. Two- input OR, NOR, AND, NAND, 
and A AND NOT B gates, and most recently half-adder circuits, have been demonstrated 
using TF-regulators (Kramer, Fischer et al. 2004; Auslander, Auslander et al. 2012; 
Lohmueller, Armel et al. 2012). OR logic gates are the simplest to design and have been 
generated by multiple groups by linking the presence of two inputs to two distinct TFs 
while fitting the activatable output promoter with binding sites for both TFs. It has also 
been generated by having 2 output promoters, each individually activated by the single 
 14 
TFs (Benenson 2011). This design leads to a more analogue response in which the total 
output gene expression is higher when both TFs are present. A NOR gate can be created 
in a similar fashion to an OR gate by connecting inputs to two distinct repressor TFs. 
Creating AND and NAND logic is less conceptually straightforward, and cannot be 
accomplished simply by engineering response promoters, but there are a established 
methods available. The most common method is to use a 2-hybrid approach in which a 
TF is split into two proteins, most often into a DBD fragment and an activation domain 
fragment, and each protein is fused to a protein known to bind to the other protein. Upon 
expression of both proteins the two TF halves interact and form a complete factor turning 
on expression of the output gene. We have demonstrated another similar method using 
split inteins to splice together the TF halves into a complete TF factor. We also 
demonstrated creating a NAND gate using the split intein method, by instead splitting a 
repressor TF. Only when both fragments are present is the output protein repressed. The 
intein method has the advantage of performing computation with a complete TF factor, 
however this approach has the disadvantage of requiring use multiple intein-based AND 
gates in a cell, multiple, orthogonal split inteins would be required (instead of multiple 
protein-interaction domains in the case of the 2-hybrid approach.) In one study by 
different positive and negative TFs were used to integrate miRNA signals (Nissim and 
Bar-Ziv 2010; Lohmueller, Armel et al. 2012). 
Another type of circuit that has been demonstrated is a feedback loop. Positive 
feedback loops can be used to amplify or sustain a response, whereas negative feedback 
loops can be used to generate pulses or pauses in output. A transcriptional positive 
feedback loop has been generated in mammalian cells and used as a ‘memory loop’ 
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circuit. In this circuit a transient stimulus leads to the activation of an activator TF 
activates an output gene and more expression of itself (Burrill, Inniss et al. 2012). This 
system was used to effectively track cells that had experienced hypoxia and mutagen in 
culture. One downside to the circuit compared to other memory circuits such as 
recombinase circuits is that the stable signal is eventually lost over time. However these 
systems have the advantage of being tunable and reversible. While a TF-based negative 
feedback loop has not yet been shown in mammalian cells, one such circuit has been 
demonstrated in bacterial cells and the design could be transferrable to mammalian cells 
(Basu, Mehreja et al. 2004). 
 Many switches have also been developed using TF circuits. In the simplest case 
inducible TFs such as LacI and TetR can be considered switches as they have low 
leakiness and can be strongly induced. A tight repression switch was also created by 
Deans et al. combining TF repression with RNAi greatly minimizing leakiness in the Off-
state (Deans, Cantor et al. 2007). We also demonstrated that this double regulation is 
possible using a dual expression miRNA and TALE module that would allow for tight 
regulation of any transgene or endogenous gene (Garg, Lohmueller et al. 2012). The 
positive feedback loop can also be thought of a stable switch as stable expression results 
from a transient stimulus. A bi-stable toggle switch has also been demonstrated using TF 
repressors. This system consists of two repressors, each inhibiting the activity of the other 
repressor. When one stimulus is given it induces one of the repressors leading repression 
of the other factor stably locking the system into that expression state. When the other 
stimulus is given the currently active TF repressor is inhibited, allowing the 2nd TF to be 
expressed and simultaneously repress the first TF similarly maintain the expression state.  
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Challenges for TF Circuits 
While much progress has been made constructing transcription-based mammalian 
synthetic gene networks, many challenges remain. Recent technological advances will 
address some of these challenges while others will likely require new approaches. Many 
of these challenges are universal to the engineering of synthetic gene networks across all 
organisms, however there are also several challenges specific to mammalian circuits. The 
mammalian specific challenges are largely the result of the higher complexity of 
mammalian cells compared to lower organisms. 
 New general genetic engineering approaches from outside the field of synthetic 
circuits will likely address many current technical problems. The process of testing 
systems stably in mammalian cells is inherently difficult and lengthy as they do not 
generally maintain stable episomal DNA and mammalian genome engineering is 
difficult. Advances to recombinant DNA cloning such as the various isothermal DNA 
assembly methods are already helping to speed up the circuit generation process (Gibson, 
Young et al. 2009). Additionally, advances to mammalian cell genome engineering 
including zinc finger and TALE nucleases methods and the even more recent Cas9 
system should greatly improve the ability to make targeted genome modifications (Miller, 
Tan et al. 2011; Sander, Dahlborg et al. 2011; Mali, Yang et al. 2013). These methods 
will be integral for enabling clinical-grade therapies in which genes and circuits can be 
integrated in safe harbor loci, ensuring that they interfere minimally with endogenous 
gene regulation. Researchers working on mammalian circuits should also take advantage 
of more stable cell line creation methods such as lentivirus, adenovirus, and the various 
transposon-mediated integration methods available (Bakota, Brandt et al. 2012; Di 
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Matteo, Matrai et al. 2012). Circuit copy number is currently an under-investigated 
system variable, especially given the major impact of human gene copy number on 
endogenous gene regulation.  
In lieu of stable integration, currently many circuits and circuit components are 
tested or demonstrated entirely using transient transfections of DNA plasmids. While 
these methods offer quick system readouts, generally 24-48hrs post-transfection, in 
general transient circuit behaviors aren’t always representative of a stable integrated 
system. This result is largely due to the issue that cells receive different numbers of 
plasmids, and in the case of multi-plasmid transfections cells will not always receive all 
plasmids being transfected. Additionally, transfection can be inefficient for some cell 
lines and primary cell types. There are potentially some scenarios where transient 
transfections are the final desired product, such as in the case of a transient therapeutic 
like something involving liposome-delivered DNA plasmids (Kim and Eberwine 2010). 
Additionally, there are efforts to predict more information from transients using advanced 
mathematical modeling. However in general stable cell lines are desirable and plasmid 
transfections will shift to being used more as first-pass check for qualitative component 
or system performance.  
The issue of cell type heterogeneity is another major mammalian-specific 
problem. In general most mammalian systems networks have been demonstrated in an 
easy to work with cell line such as HEK293 cells or HELA cells. While the assumption is 
that circuits will perform similarly in different cell types this assumption is of course not 
always true. This issue is especially prominent when creating circuits to interrogate 
endogenous inputs. Once again genome engineering methods will help to allow 
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researchers to create circuits in more cell types including primary cells. Hopefully 
researchers will also be able to move beyond proof-of-principle circuit generation and 
instead build off of existing computing frameworks to create applied systems in desired 
cell types.  
The issue of scale is faced when creating synthetic circuits across all organisms, 
Currently, few mammalian circuits with more than two inputs have been constructed, and 
circuits that can perform complex functions such as counting have not yet been 
demonstrated. The small circuit size is the result of many factors including the genome 
engineering challenges already mentioned. The issues of interacting circuit elements, 
through gene read-through, chromatin silencing, and chromosomal position effects are 
also important hindrances for multi-component circuits. Of note the largest scale circuits 
to date have been demonstrated using transient methods which in addition to being quick 
to test are not subject these challenges (Auslander, Auslander et al. 2012). It is well 
documented that neighboring transgenes on plasmids or integrated near each other in a 
chromosome tend to interfere through transcriptional read through or anti-sense 
mechanisms. There are a few safe-harbor loci known for getting rid of endogenous gene 
effects on mammalian circuits (Hermann, Maeder et al. 2012). However this doesn’t 
account for circuit element interference, and it would be way more time efficient to insert 
entire circuits into a single locus. There have been insulator sequences reported to reduce 
this interference, however, these elements have not been widely used and they appear to 
have general silencing effects (Walters, Fiering et al. 1999). The selection of synthetic 
sequences or deeper analysis of mammalian insulator elements would greatly help this 
scaling process for which there is currently no clear-cut solution. There is also the issue 
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of how many circuit parts cells can handle without inducing cellular toxicity. Most 
circuits currently use high-expressing promoters as circuit components whereas 
endogenous gene regulation is often more subtle. It is very possible that multiple strong 
promoters in a cell will always test the limits of transcription and translation and prove to 
be toxic. It is ideal therefore to create circuits that will generate circuit outputs more in 
accordance with endogenous regulation. For instance it would be desirable in some cases 
to stably down-regulate genes using induced heterochromatin rather than constant high 
expression of an inhibitory TF. Currently the largest scale circuits use regulatory 
components that act at different levels of circuit activity, rather than relying solely on TFs 
(Auslander, Auslander et al. 2012). It is possible that as diverse regulator approach will 
be the prevailing approach to generating large-scale circuits in the future.  
Of yet, no large-scale screening of circuit configurations have been demonstrated 
on a circuit-level scale for mammalian circuits, however, as creating complex circuit 
architectures is attempted, and finer tuning of circuit elements is required, it is likely that 
screening will become an important element of mammalian circuit generation.  Retroviral 
and lentiviral mammalian libraries mammalian gene and shRNA libraries have been 
demonstrated, and thus the technical capability to create circuit libraries exists (Silva, Li 
et al. 2005). Additionally, the framework generation of many components with variable 
activities provides elements to use in such screening. 
Circuits aiming for the clinic face yet another set of safety and efficacy 
challenges. One major safety challenge includes minimizing the effect of the circuit 
elements on endogenous gene expression, for example so as to not up-regulate oncogenic 
gene expression. Genome engineering methods and orthogonal factors like the orthogonal 
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TALEs that we demonstrated will be helpful toward creating insulated circuits with 
minimal effects on gene regulation. There is also the overlooked challenge of immune 
tolerance of non-self circuit components by a patient’s immune system. Most circuits are 
more immediately useful as research tools and so this isn’t a major concern, however as 
the field advances and more circuits intended for the clinic, it will be a challenge. It is 
likely that a patient’s immune system would be activated to kill off the cells expressing 
circuit components. The immune system is likely to be more tolerant to RNA-based gene 
circuits, researchers working on circuits with proteins don’t yet take this into account. It 
could be possible to engineer circuit components that are not recognized by the immune 
system. The new focus on immune circuits should help to start discussions in the 
synthetic biology community about clinical-ready circuits to overcome these challenges. 
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ABSTRACT 
The ability to perform molecular-level computation in mammalian cells has the 
potential to enable a new wave of sophisticated cell-based therapies and diagnostics. To 
this end, we developed a Boolean logic framework utilizing artificial Cys2-His2 zinc 
finger transcription factors (ZF-TFs) as computing elements. Artificial ZFs can be 
designed to specifically bind to different DNA sequences and thus comprise a diverse set 
of components ideal for the construction of scalable networks. We generate ZF-TF 
activators and repressors and demonstrate a novel, general method to tune ZF-TF 
response by fusing ZF-TFs to leucine zipper homodimerization domains. We describe 15 
transcriptional activators that display 2-463 fold induction and 15 transcriptional 
repressors that show 1.3-16 fold repression. Using these ZFs we compute OR, NOR, 
AND, and NAND logic, employing hybrid promoters and split intein-mediated protein 
splicing to integrate signals. The split intein strategy is able to fully reconstitute the ZF-
TFs, maintaining them as a uniform set of computing elements. Together these 
components comprise a robust platform for building mammalian synthetic gene circuits 
capable of precisely modulating cellular behavior.     
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INTRODUCTION 
 Mammalian synthetic gene circuits have the potential to directly impact human 
health in applications such as cell- and animal-based disease models, gene therapies, and 
smart therapeutics. Significant progress has been made to generate such networks, 
including: RNAi-based systems to interrogate siRNAs, microRNAs and synthetic 
transcription factors, RNA aptamer systems to sense multiple small molecules and 
metabolites, and transcription factor-based systems to sense synthetic small molecules 
(Kramer, Fischer et al. 2004; Rinaudo, Bleris et al. 2007; Win and Smolke 2008; Leisner, 
Bleris et al. 2010; Nissim and Bar-Ziv 2010; Xie, Wroblewska et al. 2011). However, 
despite the efficacy of these systems several engineering challenges remain. The majority 
of published systems rely on the use of a small set of specialized factors such as LacI, 
Gal4, and TetR and are not amenable to the design of large-scale networks. Methods to 
tune system responses over a wide dynamic range are lacking and are often specific to 
specialized system components. Finally, many signal integration strategies are limited by 
their input modularity and are not amenable to the facile generation of different types of 
logic gates. In this work we address these issues by developing a computational platform 
consisting of Cys2-His2 ZF-TF computing elements, general strategies to tune these ZF-
TFs, and general strategies to integrate transcriptional input signals. 
 Cys2-His2 zinc fingers are small protein domains sharing a common zinc atom 
coordinating structural motif, many of which are capable of binding to specific DNA 
sequences with high affinities. Recent advances in the ability to engineer ZF DNA 
binding domains (DBDs) to recognize new nucleotide sequences have made them a rich 
potential source of independently - functioning system components (Maeder, Thibodeau-
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Beganny et al. 2008; Sander, Dahlborg et al. 2011). As most artificial ZFs are constructed 
from a single canonical ZF, Zif268, they are also similar in amino acid composition and 
structure and are likely to share similar biological properties. In our systems we use a set 
of five previously developed ZF DBDs that target three orthogonal 9bp DNA sequences 
with high specificity: BCR_ABL-1, BCR_ABL-2, erbB2, HIV-1, and HIV-2 (Hurt, 
Thibodeau et al. 2003).  
 Because biological signals vary greatly in strength and composition it is desirable to 
have a set of tunable computing elements to interrogate these signals. A common cellular 
strategy to modulate transcription factor activity is through cooperative binding between 
TFs, a process often mediated by leucine zipper (LZ) protein-protein interaction domains 
(Burz, Rivera-Pomar et al. 1998). While the effect of LZs on the structure and function of 
ZF DBDs has been characterized biochemically, the use of LZs to modulate ZF-TF 
activity in cells has not been explored (Pomerantz, Wolfe et al. 1998; Wolfe, Ramm et al. 
2000; Wolfe, Grant et al. 2003). We chose two well-characterized homodimerizing LZ 
domains with different binding affinities, the protein interaction domains of human c-Jun 
(Kd=448µM) and S. cerivisiae GCN4 (Kd=8nM), to tune our engineered ZF-TFs 
(Zitzewitz, Bilsel et al. 1995; d'Avignon, Bretthorst et al. 2006). We combine and 
compare this new tuning strategy to a previously shown method to modulate TF activity, 
altering the number of binding sites in ZF response promoters, further increasing the 
range of system tunability. 
 To date, relatively few transcriptional logic gates have been demonstrated, and 
gates have largely been pursued outside the context of a general computational 
framework. To compute OR and NOR logic using transcriptional networks previous 
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researchers have used hybrid transcription factor response promoters containing binding 
sites for multiple TFs (Kramer, Fischer et al. 2004). We demonstrate that it is also 
possible to create and tune ZF-TF based OR and NOR gates using this architecture. 
Previous efforts to create individual AND gates have relied on the association of split TF 
fragments in 2-hybrid systems, potentially limiting the activation strength of these 
systems and scalability (Nissim and Bar-Ziv 2010). To our knowledge, a NAND gate has 
not been constructed using split transcription factors in mammalian cells.  
 We chose to pursue split intein-mediated protein splicing as an attractive alternative 
approach to perform both AND and NAND computations. Split inteins, when fused to 
separate protein fragments, auto-catalytically splice the two fragments into a single 
protein without leaving a peptide scar. They have been shown to function at high 
efficiency in mammalian cells and in a wide range of proteins, and over 500 inteins have 
been discovered to date (Liu and Hu 1997; Perler 2002; Li, Sun et al. 2008). We chose to 
use the dnaB mini-intein from Rhodothermus marinus as it has been previously 
demonstrated to display near 100% splicing efficiency in mammalian cells (Li, Sun et al. 
2008). Utilizing this protein splicing strategy we can reconstitute ZF-TFs for AND and 
NAND gates allowing logic computations to be enacted by complete factors, potentially 
yielding stronger and more uniform system responses.  
MATERIALS AND METHODS  
Recombinant DNA constructs 
 Constructs encoding zinc finger DBDs were codon-optimized for mammalian 
expression and synthesized (Genscript). The rma intein fragments and the GCN4 leucine 
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zipper sequences were codon optimized for mammalian expression and synthesized 
(Integrated DNA Technologies). Intein-zinc finger fusion parts were cloned using PCR 
and BbsI Type-IIS restriction enzyme methods. All experimental DNA constructs were 
generated by combining BioBrick subparts using Biobrick assembly (Knight 2003; 
Phillips and Silver 2006). Each final construct and its constituent Biobrick subparts is 
listed in Appendix I. Sequences of all Biobrick subparts are listed in Appendix I.  For 
expression constructs, coding regions cut with XbaI and NotI were cloned into the NheI 
and NotI sites of a modified version of pCDNA5/FRT/TO (Invitrogen), 
“pCDNA5insVector.” pCDNA5insVector was generated by cloning the subpart 
“pCDNA5ins” between the two PmeI sites of pCDNA5/FRT/TO. All reporter constructs 
were cut with SpeI and NotI and cloned between the SpeI and NotI sites of 
pCDNA5/FRT/TO.  
Cell culture 
The human osteosarcoma-derived epithelial cell line U-2 OS (ATCC #HTB-96) was 
maintained at 37°C, 5% CO2 in growth medium (McCoy’s 5A medium supplemented 
with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 !g/ml streptomyocin). A 
summary of the plasmid amounts used for transfections can be found in Appendix I. All 
transfections were performed in 12-well plates seeded with approximately 150,000 cells 
using 3 µl Lipofectamine LTX transfection reagent and 1 µl PLUS reagent (Invitrogen) 
with 1µg total DNA per well in 1 ml of growth medium. Transfection reagent was 
washed out and replaced with fresh growth media 6 hours post transfection. 
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Microscopy 
Microscopy was performed on live cells in glass-bottomed wells (MatTek) in phenol red-
free growth medium 48 hours post-transfection. Cells were imaged by a Nikon TE-2000 
microscope with a 20x PlanFluor NA = 0.5, DIC M/N2 objective and an ORCA-ER 
charge-coupled device camera. Data collection and processing were performed using 
Metamorph 7.0 software (Molecular Devices). All images within a given experimental 
set were collected using the same exposure times, averaged over 3 frames, and underwent 
identical processing. 
Flow cytometry 
Approximately 30,000 live cells from each transfected well were analyzed using an 
LSRII cell analyser (BD Biosciences) in three biological replicates. Cells were 
trypsinized with 0.1 ml of 0.25% trypsin-EDTA, pelleted, and resuspended in 100 µl of 
Dulbecco’s phosphate buffered saline containing 0.1% FBS. Output was assayed 48 
hours post-transfection. First, the total CFP signal of mCh+ cells was calculated by 
multiplying the frequency of CFP+ cells in the mCH+ population by the mean CFP signal 
of these double positive cells. Fold change was calculated by dividing the total CFP of 
mCH+ experimental cells by the total CFP values of mCH+ off-target control cells. 
Values were averaged over three replicates and standard deviations were determined. In 
assays containing multiple off-target experiments, fold changes were calculated using the 
average of all off-target control wells to compare the background leakiness of the 
different reporter constructs. 
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RESULTS   
Tuning ZF transcription factors 
We first generated a set of 15 ZF transcriptional activators and demonstrated the ability to 
increase their activity with increasing LZ strength. Each activator was comprised of a ZF 
DBD, either no LZ motif, a Jun LZ, or a GCN4 LZ, the synthetic transcriptional activator 
VP64, and the SV40 nuclear localization signal (NLS). Activators were expressed from 
the CMV promoter and tagged with co-translationally cleaved t2a:mCherry to monitor 
expression (Figure 2.1A).  
 We assayed activator function by co-transfection with reporter plasmids containing 
different numbers of ZF binding sites driving expression of AmCyan fluorescent protein 
(CFP) (Figure 2.1A). We first tested the BCR_ABL-1 activators and observed a wide 
range of signal output (2-163 fold) that increased with both the strength of the LZ binding 
domain and the number of ZF binding sites (Figure 2.1B, Appendix I). We then 
compared the activity of ZF activators generated using different DBDs by co-transfection 
with the corresponding 6x BS reporter (Figure 2.1C, Appendix I). A strong induction 
from all ZFs was observed (up to 463 fold), with HIV TFs displaying the strongest 
activation. No cross-reactivity was observed with activators co-transfected with off-target 
reporters, demonstrating the specificity of our ZF-TFs (Appendix I). 
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Figure 2.1 Engineering and characterization of ZF transcriptional activators 
(A) Schematic representation of the assay used to test ZF activator function. Each 
transcriptional activator is expressed from the CMV promoter and tagged with a co-
translationally cleaved mCherry fluorescent protein to monitor expression. ZF activator 
function is measured by the ability to activate the expression of cyan fluorescent protein 
from a reporter containing a minimal promoter and a variable number of 9bp ZF target 
sites. (B) Characterization of the role of leucine zipper addition and target site copy 
number on ZF-TF transcriptional activation. BCR_ABL-1 activators fused to either no 
LZ (ZF-only), the c-Jun LZ (Jun), or the GCN4 LZ (GCN4) were co-transfected into U-
2OS cells along with reporter plasmids containing either 2, 4, or 6 copies of the 
corresponding 9bp target site. CFP reporter expression as measured by flow cytometry 
and expressed as fold change over an off-target expression control. (C) Functional 
characterization of all ZF-activators co-transfected with reporter plasmids containing 6 
copies of their 9bp target sites.  
 
 The modular nature of our ZF elements allowed for the facile construction of a set 
of transcriptional repressors. These repressors can be tuned by altering the LZ 
dimerization domain and number of target sites analogous to our ZF activator constructs. 
We created 15 artificial ZF repressors by combining ZF DBDs, the SV40 NLS, and LZs 
with the Krüppel-associated Box (KRAB) transcriptional repression domain (Figure 
RESULTS
Tuning ZF-TFs
We first generated a set of 15 ZF transcriptional activators
and demonstrated the ability to increase their activity with
increasing LZ strength. Each activator was comprised of a
ZF DBD, either no LZ motif, a Jun LZ, or a GCN4 LZ,
the transcriptional activation domain VP64 and the SV40
nuclear localization signal (NLS). Activators were ex-
pressed from the CMV promoter and tagged with
co-translationally cleaved t2a:mCherry to monitor expres-
sion (Figure 1A) (21). We assayed activator function by
co-transfection with reporter plasmids containing differ-
ent numbers of ZF binding sites driving expression of
AmCyan fluorescent protein CFP (Figure 1A). We first
tested the BCR_ABL-1 activators and observed a wide
range of signal output (2- to 163-fold) that increased
with both the strength of the LZ binding domain
and the number of ZF binding sites (Figure 1B and
Supplementary Figure S2). We then compared the
activity of ZF activators generated using different DBDs
by co-transfection with the corresponding 6! Binding site
(BS) reporter (Figure 1C and Supplementary Figure S3).
A strong induction from all ZFs was observed (up to
463-fold), with HIV TFs displaying the strongest activa-
tion. No cross-reactivity was observed with activators
co-transfected with off-target reporters, demonstrating
the specificity of our ZF-TFs (Supplementary Figures S4
and S5).
The modular nature of our ZF elements allowed for the
facile construction of a set of transcriptional repressors.
These repressors can be tuned by altering the LZ dimer-
ization domain and number of target sites analogous to
our ZF activator constructs. We created 15 artificial ZF
repressors by combining ZF DBDs, the SV40 NLS and
LZs with the Kru¨ppel-associated Box (KRAB) transcrip-
tional repression domain (Figure 2A). To assay for repres-
sion, we generated CFP reporter constructs containing
variable numbers of copies of a 9 bp ZF binding site
directly downstream of the TATA box within the CMV
promoter (Figure 2A). We first tested BCR_ABL-1 repres-
sors and observed a significant decrease in output signal
(2- to 9-fold), strengthening with the number of ZF
binding sites and the presence of a LZ (Figure 2B and
Supplementary Figure S6). All ZF repressors were then
tested with corresponding 6! reporters, and displayed a
similar pattern—higher levels of repression for ZF repres-
sors with a LZ domain (Figure 2C and Supplementary
Figure 1. Engineering and characterization of ZF transcriptional activators. (A) Schematic representation of the assay used to test ZF activator
function. Each transcriptional activator is expressed from the CMV promoter and tagged with a co-translationally cleaved t2a:mCherry fluorescent
protein to monitor expression. ZF activator function is measured by the ability to activate the expression of 2 fused copies of cyan fluorescent protein
from a reporter containing a minimal promoter and a variable number of 9 bp ZF target sites. (B) Characterization of the role of leucine zipper
addition and target site copy number on ZF-TF transcriptional activation. BCR_ABL-1 activators fused to either no LZ (ZF-only), the c-Jun LZ
(Jun), or the GCN4 LZ (GCN4) were co-transfected into U-2 OS cells along with reporter plasmids containing either 2, 4 or 6 copies of the
corresponding 9 bp target site. CFP reporter expression as measured by flow cytometry and expressed as fold change over an off-target expression
control. (C) Functional characterization of all ZF-activators co-transfected with reporter plasmids containing 6 copies of their 9 bp target sites.
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2.2A). To assay for repression, we generated CFP reporter constructs containing variable  
 
Figure 2.2 Engineering and characterization of ZF transcriptional repressors 
(A) Schematic representation of the assay used to test ZF repressor function. Each 
transcriptional repressor is expressed from the CMV promoter and tagged with a co-
translationally cleaved mCherry fluorescent protein to monitor expression. ZF repressor 
function is measured by the expression of cyan fluorescent protein from a CMV promoter 
engineered to have a variable number of 9bp ZF target sites inserted into the 
transcriptional start site. (B) Functional characterization of the role of target site copy 
number and leucine zipper addition on ZF repressor activity. BCR_ABL-1 activators 
fused to either no LZ (ZF-only), the c-Jun LZ (Jun), or the GCN4 LZ (GCN4) were co-
transfected into U-2OS cells along with reporter plasmids containing either 2, 4, or 6 
copies of the corresponding 9bp target site. The activity of each ZF repressor was 
determined by CFP expression measured by flow cytometry and expressed as fold change 
over an off-target expression control. (C) Functional characterization of all ZF-repressors 
co-transfected with reporter plasmids containing 6 copies of their 9bp target sites. 
 
numbers of copies of a 9bp ZF binding site directly downstream of the TATA box within 
the CMV promoter (Figure 2.2A). We first tested BCR_ABL-1 repressors and observed a 
significant decrease in output signal (2-9 fold), strengthening with the number of ZF 
binding sites and the presence of a LZ (Figure 2.2B, Appendix I). All ZF repressors were 
Figure S7). The HIV repressors were the only exception
displaying no LZ-mediated inc e se. As expected, no re-
pression was seen for off-target reporters (Supplementary
Figures S8 and S9).
ZF-based Boolean logic computation
Using this set of synthetic ZF-TFs, we next sought to
construct a set of Boolean logic gates. We divided the
logic architecture into three general components: (i) a
sensory module that senses inputs and converts the
signals into ZF expression, (ii) a computational module
comprised of ZFs and corresponding response promoters
and (iii) an output module consisting of a gene encoding a
given protein.
Within this framework, we began by generating
response constructs that exhibited OR gate behavior.
OR gates were developed by utilizing hybrid promoters
consisting of various copies of binding sites for two
distinct ZF DBDs. To determine the effect of binding
site architecture on signal output, constructs containing
either 2, 4 or 6 copies of the BCR_ABL and erbB2
binding sites were generated in multiple configurations
(Figure 3A and Supplementary Figures S10 and S11).
We characterize all of our Boolean logic systems using
artificial inputs in which the CMV promoter drives expres-
sion of the computational proteins for a positive input or a
negative control protein for a negative input. Each OR
gate configuration was tested by co-transfection with
either the BCR_ABL-1:GCN4 activator, the erbB2:Jun
activator or both activators in tandem. All promoter
architectures functioned as OR gates, with either a single
activator alone or both factors present together resulting
in signal output. The presenc of both activators in
tandem resulted in an additional 7-fold increase in
output signal, likely due to the increased occupancy of
reporter t rget sites by the tr nscriptional activators
(Figure 3A). We also observed minor position effects,
with activator constructs having corresponding binding
sites more proximal to the TATA box displaying higher
induction (Supplementary Figures S10 and S11). The
varying outputs for different promoter architectures
allow for an additional potential layer of tunability.
A similar approach was employed using ZF repressors
to compute NOR logic. As with our OR gates, NOR gates
were generated by placing binding sites for two different
ZFs within the repressor reporter plasmids. Reporters
were constructed with either 2, 4 or 6 binding sites in
multiple configurations, and tested by transfecting with
Figure 2. Engineering and characterization of ZF transcriptional repressors. (A) Schematic representation of the assay used to test ZF repressor
function. Each transcriptional repressor is expressed from the CMV promoter and tagged with a co-translationally cleaved t2a:mCherry fluorescent
protein to monitor expression. ZF repressor function is measured by the expression of 2 fused copies of cy n fluorescent pr tein from a CMV
promoter engineered to have a variable number of 9 bp ZF target sites inserted into the transcriptional start site. (B) Functional characterization of
the role of target site copy number and leucine zipper addition on ZF repressor activity. BCR_ABL-1 activators fused to either no LZ (ZF-only), the
c-Jun LZ (Jun), or the GCN4 LZ (GCN4) were c -transfected into U-2 OS cells along with reporter plasmids containing either 2, 4 or 6 copies of the
corresponding 9 bp target site. The activity of each ZF repressor was determined by CFP expression measured by flow cytometry and expressed as
fold change over a off-target expression control. (C) Functional characterization of all ZF-repr ssors co-transfecte with reporter plasmids con-
taining 6 copies of their 9 bp target sites.
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then tested with corresponding 6x reporters, and displayed a similar pattern - higher 
levels of repression for ZF repressors with a LZ domain (Figure 2.2C, Appendix I). The 
HIV repressors were the only exception displaying no LZ-mediated increase. As 
expected, no repression was seen for off-target reporters (Appendix I). 
ZF-based Boolean logic computation  
 Using this set of synthetic ZF-TFs, we next sought to construct a set of Boolean 
logic gates. We divided the logic architecture into three general components: (i) a sensory 
module that senses inputs and converts the signals into ZF expression, (ii) a 
computational module comprised of ZFs and corresponding response promoters, and (iii) 
an output module consisting of binding sites controlling expression of a given protein. 
 Within this framework we began by generating response constructs that exhibit OR 
gate behavior. OR gates were developed by utilizing hybrid promoters consisting of 
various copies of binding sites for two distinct ZF DBDs. To determine the effect of 
binding site architecture on signal output, constructs containing either 2, 4, or 6 copies of 
the BCR_ABL and erbB2 binding sites were generated in multiple configurations (Figure 
2.3A). Each configuration was tested by co-transfection with either BCR_ABL-1:GCN4 
activator, erbB2:Jun activator, or both activators in tandem. All promoter architectures 
functioned as OR gates, with either a single activator alone or both factors present 
together resulting in signal output. The presence of both activators in tandem resulted in 
an additional 7 fold increase in output signal, likely due to the increased occupancy of 
reporter target sites by the transcriptional activators (Figure 2.3A). We also observed 
minor position effects, with activator constructs having corresponding binding sites more 
proximal to the TATA box displaying higher induction (Appendix I). The varying 
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outputs for different promoter architectures allow for an additional potential layer of 
tunability. 
 
Figure 2.3 Engineering and characterization of ZF-based OR and NOR Boolean 
logic gates 
In the sensory module, input signals lead to expression of corresponding ZF-based 
transcription factors. In the computational module, transcription factors act on response 
promoters. (A) OR gate response promoters contain target sites for two different ZF 
activators, and the logical operation is computed as TRUE (CFP expression) when either 
one or both inputs is present. For the response data shown BCR_ABL-1:GCN4 and 
erbB2:Jun activators were used as ZF-1 and ZF-2, respectively, and the response 
promoter contains 6 copies of the BCR_ABL target site upstream of 6 copies of the 
erbB2 target site. CFP expression was measured by flow cytometry and expressed as fold 
change over an off-target expression control. (B) NOR gate response promoters contain 
the binding sites for two different ZF repressors, and the logical operation is computed as 
TRUE when neither input is present. For the response data shown BCR_ABL-1:GCN4 
and erbB2:Jun repressors were used as ZF-1 and ZF-2, respectively, and the response 
promoter contains 6 copies of the BCR_ABL target site upstream of 6 copies of the 
erbB2 target site. CFP expression was measured by flow cytometry.  
 
 A similar approach was employed using ZF repressors to compute NOR logic. As 
with our OR gates, NOR gates were generated by placing binding sites for two different 
ZFs within the repressor reporter plasmids. Reporters were constructed with either 2, 4, 
either the BCR_ABL-1:GCN4 repressor, the erbB2:Jun
repressor or both repressors. All promoter architectures
functioned as NOR gates, with repression levels ranging
from 2- to 23-fold. We again observ d a minor position
effect with higher levels of repression corresponding to
ZF binding site proximity to the CMV TATA box.
Thus, NOR gates can also be tuned to have different
response properties (Figure 3B and Supplementary
Figures S12 and S13).
We next sought to compute AND and NAND logic
using our transcriptional activators and repressors. To
use our split intein protein splicing strategy, we first set
out to determine the optimal amino acid residue at which
to split our ZF-TFs. We created twelve pairs of
BCR_ABL-1:Jun activator split proteins. Each pair con-
tained an amino- (N-) and carboxy-terminal (C-) fragment
fused to the appropriate intein. These fragments were
co-transfected, either to ether or separ tely, with the 6!
BCR_ABL activator reporter (Figure 4A, B and C). Fold
induction was calculated relative to CFP activation by the
C-terminal fragment alone. Five out of twelve ZF split
pairs displayed >3-fold signal output (Figure 4D and
Supplementary Figure S14). The split site between
residues 30 and 31 resulted in the highest activity,
"19-fold, and was therefore chosen for further logic gate
generation. Interestingly, all functional split sites are pre-
dicted to be located in protein loop regions of the ZF,
suggesting the importance of the secondary structure on
efficient protein splicing (Supplementary Figure S15).
After performing this assay we discovered that a truncated
form of the N-terminal intein fragment, intN*, lacking
four C- rminal amin acids d splayed higher splicing ef-
ficiency, and we used this intein fragment in all further
experiments.
Next, we generated an AND gate using split
BCR_ABL-1:GCN4. Cells were transfected with each
fragment alone or both fragments together, and an
off-target ZF DBD was used as a negative control.
When both N-terminal and C-terminal fragments of
BCR_ABL-1:GCN4 activator were present, we observed
a 154-fold signal induction, a level that is comparable with
that of the parental BCR_ABL-1:GCN4 activator
(Figure 5A and Supplementary Figure S16). A NAND
gate or ‘NOT AND’ gate is the opposite of an AND
gate, returning ‘TRUE’ as long as both inputs are not
present to ether. To compute NAND logic, we sought
to splice together fragments of the BCR_ABL-1:GCN4
repressor. The repressor was split in the same location
as the BCR_ABL activators. We assayed for NAND
activity by co-transfection of the 6! BCR_ABL repressor
reporter with either fragment alone or both fragments
together. No repression was seen when either the
N-terminal or C-terminal fragment was transfected
alone, and when both fragments were present, a 3-fold
repression was observed (Figure 5B and Supplementary
Figure S17).
Figure 3. Engineering and characterization of ZF-based OR and NOR Boolean logic gates. In the sensory module, input signals lead to expression
of corresponding ZF-based transcription factors. In the computational module, transcription factors act on response promoters. (A) OR gate
response promoters contain target sites for two different ZF activators, and the logical operation is computed as TRUE (CFP expression) when
either one or both input is present. For the response data shown BCR_ABL-1:GCN4 and erbB2:Jun activators were used as ZF-1 and ZF-2,
respectively, and the response promoter contains six copies of the BCR_ABL target site upstream of 6 copies of the erbB2 target site. CFP expression
was measured by flow cytometry and expressed as fold change over an off-target expression control. (B) NOR gate response promoters contain the
binding sites for two different ZF repressors, and the logical operation is computed as TRUE when neither input is present. For the response data
shown BCR_ABL-1:GCN4 and erbB2:Jun repressors were used as ZF-1 and ZF-2, respectively, and the response promoter contains six copies of the
BCR_ABL target site upstream of 6 copies of the erbB2 target site. CFP expression was measured by flow cytometry and expressed as fold change
over an off-target expression control.
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or 6 binding sites in multiple configurations, and tested by transfecting with either 
BCR_ABL-1:GCN4 repressor, erbB2:Jun repressor, or both repressors. All promoter 
architectures functioned as NOR gates, with repression levels ranging from 2-23 fold. We 
again observed a minor positional effect with higher levels of repression corresponding to 
ZF binding site proximity to the CMV TATA box. Thus, NOR gates can also be tuned to 
have different response properties (Figure 2.3B, Appendix I).  
 We next sought to compute AND and NAND logic using our transcriptional 
activators and repressors. To use our split intein protein splicing strategy we first set out 
to determine the optimal amino acid residue at which to split our ZF-TFs. We created 
twelve pairs of BCR_ABL-1:Jun activator split proteins. Each pair contained an amino- 
(N-) and carboxy-terminal (C-) fragment fused to the appropriate intein. These fragments 
were co-transfected, either together or separately, with the 6x BCR_ABL activator 
reporter (Figure 2.4A,B,C). Fold induction was calculated relative to CFP activation by 
the C-terminal fragment alone. Five out of twelve zinc finger split pairs displayed greater 
than 3 fold signal output (Figure 2.4D, Appendix I).  
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Figure 2.4 Determining the optimal ZF-TF split site  
(A) Schematic representation of the plasmids used to test for ZF activator split function. 
Each ZF-N:int-N or Int-C:ZF-C fragment is expressed from a CMV expression plasmid. 
Activity is measured by the ability of each fragment pair to activate a cyan fluorescent 
protein reporter containing 6x copies of 9bp ZF target sites versus activation by the Int-
C:ZF-C fragment alone. (B) Schematic of the ZF-TF reconstitution process. After 
expression, the two split ZF-intein fragments bind together and undergo protein splicing 
to cleave away intein fragments and reconstitute the full ZF activator leading to 
activation of the BCR_ABL-1 reporter. (C) BCR_ABL-1 amino acid sequence labeled 
with the 12 split sites assayed. (D) Characterization of the 12 ZF-intein activator pairs 
assayed by transient transfection in U2 OS cells. CFP reporter expression was measured 
by flow cytometry and reported as total CFP expression. Fold changes in total CFP are 
listed for the activation of each split pair compared to activation by the corresponding Int-
C:ZF-C fragment alone.  
 
 The split site between residue 30 and 31 resulted in the highest activity, 
approximately 19-fold, and was therefore chosen for further logic gate generation. 
Interestingly, all functional split sites are predicted to be located in protein loop regions 
of the ZF, suggesting the importance of the secondary structure on efficient protein 
splicing (Appendix I). After performing this assay we discovered that a truncated form of 
DISCUSSION
We developed large set of tunable ZF-TF computi g
elements and ge eral transcriptional framework to
perform Boolean logic operations in mammalian cells.
ZF-TFs present a scalable alternative to common syn-
thetic biology transcriptional regulators such as LacI,
Gal4 and TetR with >100 ZF DBDs that target
mutually orthogonal DNA seque ces available (7,8). We
created activators and repressors using five previously de-
veloped ZF DBDs that target three orthogonal 9 bp DNA
sequences and corresponding response promoters. As
these ZF DBDs are highly similar in structure to other
artificial ZF DBDs, it is likely that these too can be
readily integrated into our system architectures. In order
to generate system components that interrogate signals of
different strengths and yield responses of different
strengths, we developed methods to tune ZF-TFs. We
employed two general strategies borrowed from naturally
occurring systems: fusing ZF-TFs to LZ homo-
dimerization domains and altering the number of ZF
binding sites in response promoters. We created a large
set of parts and elucidated general design rules based on
the behaviors of these parts. Activators displayed an
increase in activity correlating with both the number of
promoter binding sites and the strength of the LZ inter-
action domain. The repressors behaved similarly display-
ing an increase in repression corresponding to the number
of binding sites and the presenc of a LZ. Whereas the
strength of the LZ domain did not impact the repression
levels, this could be the result of weaker repressors
reaching a maximum repression level for the transient
transfection repressor assay. Both tuning methods could
be employed together to obtain maximum ZF-TF activity
levels. The identity of the ZF DBD also affected ZF-TF
activity, potentially due to differences in DNA binding
strength or subtle differences in ZF-TF expression levels.
This element provides yet another way to tune ZF-TF.
Whereas the precise mechanism of LZ-enhanced ZF-TF
activity is unclear, we speculate that it could be the
result of cooperative transcription factor binding or
LZ-mediated recruitment of additional ZF-TFs to the
promoter region. Both mechanisms would lead to
increased promoter occupancy by the ZF-TFs and a cor-
responding increase in activity.
To integrate signals for logic computations, we
employed hybrid promoter and novel split intein protein
splicing integration architectures. We observed strong
ON/OFF ratios for idealized CMV-expressed inputs for
OR, NOR, AND and NAND gates. The hybrid promoter
strategy used for OR and NOR computations effectively
integrated ZF-TF signals and showed tunability depend-
ent on ZF binding site number and LZ strength. Whereas
all inductions were high, the OR gate behavior was
somewhat analog as the presence of two inputs showed
Figure 4. Determining the optimal ZF-TF split site. (A) Schematic representation of the plasmids used to test for split ZF activator function. Each
ZF-N:int-N or Int-C:ZF-C fragment is expressed from a CMV expression plasmid. Activity is measured by the ability of each fragment pair to
activate a cyan fluorescent protein reporter containing 6 copies of 9 bp ZF target sites versus activation by the Int-C:ZF-C fragment alone.
(B) Schematic of the ZF-TF reconstitution process. After expression, the two split ZF-intein fragments bind together and undergo protein
splicing to cleave away intein fragments a d reco stitute the full ZF activator leading to activation of the BCR_ABL reporter. (C) BCR_ABL-1
amino acid sequence labeled with the 12 split sites assayed. (D) Characterization of the 12 ZF-intein activator pairs assayed by transient transfection
in U-2 OS cells. CFP reporter expression was measured by flow cytometry and reported as total CFP expression. Fold changes in total CFP are listed
for the activation of each split pair compared with act vati n by the corresponding Int-C:ZF-C fragm nt alone.
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the N-terminal intein fragment, intN*, displayed higher splicing efficiency and used this 
intein fragment in all further experiments. 
 
 
Figure 2.5. Engineering and characterization of ZF-based AND and NAND Boolean 
logic gates 
In the sensory module, the presence of an input signal leads to the expression of the 
corresponding ZF-TF:split intein fragment, either ZF-N:Int-N or Int-C:ZF-C. In the 
computation module splicing of  ZF:intein fragments leads to production of a complete 
ZF-TF that acts upon its cognate promoter. (A) For AND gates, a ZF activator is spliced, 
and the logical operation is computed as TRUE only when both input signals are present. 
For the response data shown BCR_ABL-1:GCN4 activator split fragments were used and 
the response promoter contains 6 copies of the BCR_ABL target site. CFP expression 
was measured by flow cytometry and expressed as fold change over an off-target 
expression control. (B) For NAND gates, the computational module splices a ZF 
repressor, and the logical operation is computed as TRUE as long as both inputs are not 
present together. For the response data shown BCR_ABL-1:GCN4 repressor split 
fragments were used and the response promoter contains 6 copies of the BCR_ABL 
target site. CFP expression was measured by flow cytometry and expressed as fold 
change over an off-target expression control. 
 
 Next, we generated an AND gate using split BCR_ABL-1:GCN4. Cells were 
transfected with each fragment alone or both fragments together, and an off-target ZF 
a 7-fold increase over the presence of each single input.
Interestingly, this result suggests that the individual
ZF-TF respon e promoters could perhaps be further
enhanced by the addition of more ZF binding sites
beyond the 6! BS systems we report in Figure 1. The
position of the ZF binding sites also affected OR gate
activity with higher activation levels observed from
ZF-TFs with binding sit s closer to the TATA Box. The
NOR gates showed comparable repression levels for single
and double inputs but also displayed a position effect with
stronger repression levels observed for ZF binding sites
located directly on the putative transcription start sites.
To compute AND and NAND logic we combined split
intein protein splicing with our ZF-TF components.
Protein splicing provides a novel method to efficiently
combine signals that has the advantage of generating
fully formed transcription factors. We first found the
optimal split site for the ZF-TF activators among 12
putative split sites assayed. Interestingly, 7 out of 12
split sites were successful at activating reporter function
>3-fold demonstrating the modularity of the split inteins.
All successful split sites were located in protein loop
regions suggesting the importance of secondary structure
on splicing efficiency. The most efficient split site showed
activity levels matching that of the complete factor. As the
split sites are located within the constant region of the
BCR_ABL-1 ZF DBD it is likely they can be used in
ZF-TFs containing different ZF DBDs. Finally, the
optimal ZF split site was effective in the context of ZF
activators with different LZ domains and also in the con-
text of a repressor to perform NAND logic. The NAND
gate showed around a 3-fold repression of the reporter.
Whereas significantly lower than the complete factor
(9-fold repression), this is po ibly due to a delay caused
by intein splicing that leads to expression from the CMV
promoter before it can be efficiently repressed.
Together these system components greatly expand the
repertoire of parts and devices available to mammalian
synthetic biologists. The tuning methods were effective
at generating a large variation in ZF-TF activities and
could potentially be generalized to tune other transcrip-
tion factors. While the reported systems can stand on their
own, the parts and architectures could also be used in
conjunction with other existing logic computational
methods that rely on the use of synthetic transcription
factors. While we characterize our systems using the tran-
sient transfection format, we expect that they should also
function in the context of stable cell lines with qualita-
tively similar system behaviors. The logic framework de-
veloped utilizing these factors provides a powerful new
and general method for computing Boolean logic in mam-
malian cells. Through the use of modular ZF DBDs and
Figure 5. Engineering and characterization of ZF-based AND and NAND Boolean logic gates. In the sensory module, the presence of an input
signal leads to the expression of the corresponding ZF-TF:split intein fragment, either ZF-N:Int-N or Int-C:ZF-C. In the computation module
splicing of ZF:intein fragments leads to production of a complete ZF-TF that acts upon its cognate promoter. (A) For AND gates, a ZF activator is
spliced and the logic l operation is computed as TRUE only when both input signals are present. For the response data shown BCR_ABL-1:GCN4
activator split fragments were used and the response promoter contains 6 copies of the BCR_ABL target site. CFP expression was measured by flow
cytometry and expressed as fold change over an off-target expression control. (B) For NAND gates, the computational module splices a ZF
repressor, and the logical operation is computed as TRUE as long as both inputs are not present together. For the response data shown
BCR_ABL-1:GCN4 repressor split fragments were used and the response promoter contains 6 copies of the BCR_ABL target site. CFP expression
was measured by flow cytometry and expressed as fold change over an off-target expression control.
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DBD was used as a negative control. When both N-terminal and C-terminal fragments of 
BCR_ABL-1:GCN4 activator were present we observed a 154-fold signal induction, a 
level that is comparable to that of the parental BCR_ABL-1:GCN4 activator (Figure 
2.5A, Appendix I). To compute NAND logic we sought to splice together fragments of 
the BCR_ABL-1:GCN4 repressor. The repressor was split in the same location as the 
BCR_ABL activators. We assayed for NAND activity by co-transfection of the 6x 
BCR_ABL repressor reporter with either fragment alone or both fragments together. No 
repression was seen when either the N-terminal or C-terminal fragment was transfected 
alone, however, when both fragments were present a 3 fold repression was observed 
(Figure 2.5B, Appendix I). 
 Next, we generated an AND gate using split BCR_ABL-1:GCN4. Cells were 
transfected with each fragment alone or both fragments together, and an off-target ZF 
DBD was used as a negative control. When both N-terminal and C-terminal fragments of 
BCR_ABL-1:GCN4 activator were present we observed a 154-fold signal induction, a 
level that is comparable to that of the parental BCR_ABL-1:GCN4 activator (Figure 
2.5A, Appendix I). To compute NAND logic we sought to splice together fragments of 
the BCR_ABL-1:GCN4 repressor. The repressor was split in the same location as the 
BCR_ABL activators. We assayed for NAND activity by co-transfection of the 6x 
BCR_ABL repressor reporter with either fragment alone or both fragments together. No 
repression was seen when either the N-terminal or C-terminal fragment was transfected 
alone, however, when both fragments were present a 3 fold repression was observed 
(Figure 2.5B, Appendix I). 
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DISCUSSION 
 We developed large set of tunable ZF-TF computing elements and general 
transcriptional framework to perform Boolean logic operations in mammalian cells. ZF-
TFs present a scalable alternative to common synthetic biology transcriptional regulators 
such as LacI, Gal4, and TetR with over a hundred ZF DBDs that target mutually 
orthogonal DNA sequences available.(7,8) We created activators and repressors using 5 
previously developed ZF DBDs that target 3 orthogonal 9bp DNA sequences and 
corresponding response promoters. As these ZF DBDs are highly similar in structure to 
other artificial ZF DBDs it is likely that these too can be readily integrated into the 
reported system architectures. In order to generate system components that interrogate 
signals of different strengths and yield responses of different strengths we developed 
methods to tune ZF-TFs. We employed two general strategies borrowed from naturally - 
occurring systems: fusing ZF-TFs to LZ homo-dimerization domains and altering the 
number of ZF binding sites in response promoters. We created a large set of parts and 
elucidated general design rules based on the behaviors of these parts. Activators 
displayed an increase in activity correlating with both the number of promoter binding 
sites and the strength of the LZ interaction domain. The repressors behaved similarly 
displaying an increase in repression corresponding to the number of binding sites and the 
presence of a LZ. While the strength of the LZ domain did not impact the repression 
levels, this could be the result of weaker repressors reaching a maximum repression 
levels for the transient transfection repressor assay. Both tuning methods could be 
employed together to obtain maximum ZF-TF activity levels. The identity of the ZF DBD 
also affected ZF-TF activity, potentially due to differences in DNA binding strength or 
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subtle differences in ZF-TF expression levels. This element provides yet another way to 
tune ZF-TF. While the precise mechanism of LZ-enhanced ZF-TF activity is unclear, we 
speculate that it could be the result of cooperative transcription factor binding or LZ-
mediated recruitment of additional ZF-TFs to the promoter region. Both mechanisms 
would lead to increased promoter occupancy by the ZF-TFs and a corresponding increase 
in activity.  
 To integrate signals for logic computations we employed hybrid promoter and 
novel split intein protein splicing integration architectures. We observed strong ON/OFF 
ratios for idealized CMV-expressed inputs for OR, NOR, AND, and NAND gates. The 
hybrid promoter strategy used for OR and NOR computations effectively integrated ZF-
TF signals and showed tunability dependent on ZF binding site number and LZ strength. 
While all inductions were high, the OR gate behavior was somewhat analog as the 
presence of two inputs showed a 7 fold increase over the presence of each single input. 
Interestingly, this result suggests that the individual ZF-TF response promoters could 
perhaps be further enhanced by the addition of more ZF binding sites. The position of the 
ZF binding sites also affected OR gate activity with higher activation levels observed 
from ZF-TFs with binding sites closer to the TATA Box. The NOR gates showed 
comparable repression levels for single and double inputs but also displayed a position 
effect with stronger repression levels observed for ZF binding sites located directly on the 
putative transcription start sites.  
 To compute AND and NAND logic we combined split intein protein splicing with 
our ZF-TF components. Protein splicing provides a novel method to efficiently combine 
signals that has the advantage of generating fully formed transcription factors. We first 
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found the optimal split site for the ZF-TF activators among 12 putative split sites assayed. 
Interestingly 7 out of 12 split sites were successful at activating reporter function greater 
than 3 fold demonstrating the modularity of the split inteins. All successful split sites 
were located in protein loop regions suggesting the importance of secondary structure on 
splicing efficiency. The most efficient split site showed activity levels matching that of 
the complete factor. As the split sites are located within the constant region of the 
BCR_ABL1 ZF DBD it is likely they can be used in ZF-TFs containing different ZF-
DBDs. Finally, the optimal ZF split site was effective in the context of ZF activators with 
different LZ domains and also in the context of a repressor to perform NAND logic. The 
NAND gate showed around a 3 fold repression of the reporter. While significantly lower 
than the complete factor (9-fold repression) this is possibly due to a delay caused by 
intein splicing that lead to leakiness from the CMV promoter before it can be efficiently 
repressed.  
 Together these system components greatly expand the repertoire of parts and 
devices available to mammalian synthetic biologists. The tuning methods were effective 
at generating a large variation in ZF-TF activities and could potentially be generalized to 
tune other transcription factors. While the reported systems can stand on their own the 
parts and architectures could also be used in conjunction with other existing logic 
computational methods that rely on the use of synthetic transcription factors. The logic 
framework developed utilizing these factors provides a powerful new and general method 
for computing Boolean logic in mammalian cells. Through the use of modular ZF DBDs 
and LZ dimerization domains we have developed an approach that should be readily 
scalable to different input/output requirements and tolerances. Components in the system, 
 
 
 45 
while orthogonal in specificity, share common structural and functional qualities, 
promising to make optimization of networks more streamlined and different networks 
more comparable. The potential modularity of cellular inputs and the tunability of output 
response within this framework lends itself to the processing of multiple cellular signals 
and the future rewiring of intrinsic network topologies to engineer precise biological 
responses. Future scaling up of these systems can follow our elucidated design principles 
and take advantage of the many additional LZ’s, ZF DBDs and split inteins available. 
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ABSTRACT  
The ability to engineer biological circuits that process and respond to complex 
cellular signals has the potential to impact many areas of biology and medicine. 
Transcriptional activator-like effectors (TALEs) have emerged as an attractive 
component for engineering these circuits, as TALEs can be designed de novo to target a 
given DNA sequence. Currently, however, the use of TALEs is limited by degeneracy in 
the site-specific manner by which they recognize DNA. Here, we propose an algorithm to 
computationally address this problem. We apply our algorithm to design 180 TALEs 
targeting 20 bp cognate binding sites that are at least 3 nucleotide mismatches away from 
all 20 bp sequences in putative 2kb human promoter regions. We generated 8 of these 
synthetic TALE activators and showed that each is able to activate transcription from a 
targeted reporter. Importantly, we show that these proteins do not activate synthetic 
reporters containing mismatches similar to those present in the genome nor a set of 
endogenous genes predicted to be the most likely targets in vivo. Finally, we generated 
and characterized TALE repressors comprised of our orthogonal DNA binding domains 
and further combined them with shRNAs to accomplish near complete repression of 
target gene expression. 
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INTRODUCTION 
A central goal of synthetic biology is the creation of gene regulatory circuits that 
specifically and robustly control gene expression in response to cell state and 
environmental cues (Andrianantoandro, Basu et al. 2006; Haynes and Silver 2009; Tabor, 
Salis et al. 2009; Khalil and Collins 2010). While much progress has been made toward 
developing genetic systems that detect biological signals, the ability to integrate these 
signals has been limited by the lack of modular and mutually orthogonal genetic elements 
available for use. Additionally, the functionality of these systems can be hampered by 
unwanted interference with the host cell machinery. The generation of high-fidelity gene 
circuits would thus benefit from a set of mutually orthogonal synthetic regulatory 
components that have minimal effects on endogenous cell machinery. In the case of 
transcriptional systems it would be ideal to have a set of transcriptional regulators that 
would only target DNA sequences that exist within the artificial circuit. Such regulators 
would have minimal affinity for DNA sequences present in the endogenous promoter 
regions of the host cell, thus minimizing unwanted effects on host gene expression 
(Figure 3.1). Transcription factors with programmable DNA binding domains offer one 
potential approach toward this goal. Transcription activator-like effector (TALE) proteins 
have been recently demonstrated to have modular and predictable DNA binding domains, 
thereby allowing for the de novo creation of synthetic transcription factors that bind any 
DNA sequence of interest (Christian, Cermak et al. 2010; Morbitzer, Romer et al. 2010; 
Li, Huang et al. 2011; Miller, Tan et al. 2011; Deng, Yan et al. 2012; Mak, Bradley et al. 
2012). 
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Figure 3.1 Orthogonal TALEs as ideal regulatory components for insulated 
synthetic gene circuits 
(A) Non-orthogonal TALEs designed to bind and regulate gene expression of a synthetic 
gene circuit may also bind to cognate and off-target (containing mismatches) binding 
sequences in the endogenous promoter regions in the genomic DNA. (B) Orthogonal 
TALEs bind and regulate gene expression of a synthetic gene circuit and have no 
predicted binding sites in the endogenous promoter regions. 
Originally discovered in phytopathogenic bacteria of the genus Xanthomonas, 
TALE proteins are made up of three distinct regions; (i) an N-terminal region housing the 
protein secretion and translocation signals, (ii) a central repeat domain composed of a 
series of tandem repeats containing repeat variable di-residues (RVDs) that specifically 
recognize and bind DNA, and (iii) a C-terminal domain containing two nuclear 
localization signals (NLSs) and a transcriptional activation domain (Figure 3.2A) 
(Herbers, Conrads-Strauch et al. 1992; Van den Ackerveken, Marois et al. 1996; Zhu, 
Yang et al. 1998; Boch and Bonas 2010). The central DNA binding domain is composed 
of a variable number of 33 - 35 amino acid repeats such that each binding domain 
recognizes a different DNA base pair (bp) and can be recombined to recognize any given 
DNA sequence (Boch and Bonas 2010; Scholze and Boch 2011). Recent studies have 
deciphered the code by which the repeat elements bind to DNA, showing that the 
preferentially bound (Figure 2B) (16,17). The mo ularity
of these repeat elements has enabled TALEs to become a
powerful tool, allowing for the creation of synthetic
transcriptional activators that can target a specific DNA
sequence and activate a desired gene (6,7). Furthermore,
because of the proteins’ modular nature, TALEs are
amenable to hierarchical ligation-based construction
strategies, enabling the development of large libraries of
proteins (5,7,18–20).
At present, however, drawbacks to the use of TALEs as
targeted transcription factors exist. Most notably, each
TALE repeat does not bind to a given DNA base pair
with perfect complementarity (Figure 2B) (21,22). While
it has been shown that in some cases including a single
mismatch in the binding site of a given TALE can signifi-
cantly inhibit its off-target activity, there are known
instances where designed TALEs have been demonstrated
to bind to uni tended off-target DNA sequences that
differ from their cognate target sequence by up to 3 bp
(as defined by the TALE binding code) (16,17). These
observations indicate that while a synthetic TALE can
be designed to efficiently target a given DNA sequence,
unintended off-target effects can frequently occur and m y
limit the utility of TALEs for specifically controlling the
expression of a targeted gene (Supplementary Methods).
This limitation also restricts the application of TALEs
as components of synthetic circuits where orthogonality
to the host cell’s genome is an important constraint.
We have developed an algorithm that allows one to
computationally design TALEs with cognate binding
sites that are at least a given number of mismatches
away from a set of DNA sequences. We apply our algo-
rithm to design TALEs with 20 bp cognate binding sites
that are at least 3 nt mismatches away from all 2000 bp
putative human promoter sequences and at least 4 nt
mismatches from 500 bp putative human promoter
sequences. These TALEs represent a potentially
powerful set of insulated transcriptional regulators for
the construction of synthetic gene circuits. We generated
DNA constructs encoding eight of these TALEs as
transcriptional activators and assessed their function in
human cells. We demonstrate that each TALE effectively
activates transcription from its targeted binding site and
that the TALE activators are mutually orthogonal in their
activities. We also show that the TALEs do not activate
transcription from artificial promoters containing binding
sites comparable to potential off-target sites in human
Figure 1. Orthogonal TALEs as ideal regulatory components for insulated synthetic gene circuits. (A) Non-orthogonal TALEs designed to bind and
regulate gene expression of a synthetic gene circuit may also bind to cognate and off-target (containing mismatches) binding sequences in the
endogenous promoter regions in the genomic DNA. (B) Orthogonal TALEs bind and regulate gene expression of a synthetic gene circuit and have no
predicted binding sites in the endogenous promoter regions.
Figure 2. TALE protein architecture and DNA binding specificities.
(A) Schematic of a representative TALE protein with 18.5 repeat
variable di-residue (RVD) domains. Each RVD domain is composed
of 34 amino acids and differs only in the variable amino acids high-
lighted in red. The C-terminal RVD domain is a 15 amino acid half
repeat domain. The two endogenous NLS domains and the endogenous
activation domain (AD) present in naturally occurring TALEs were
replaced with SV40 NLSs and the VP64 activation domain, respect-
ively. (B) The amino acid sequences and the preferred target nucleotides
of RVD domains NI, HD, NG from AvrBs3 and RVD domain NK
from pthA2.
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residues at amino acid positions 12 and 13 in each repeat determine which nucleotide is 
preferentially bound (Figure 3.2B) (Boch, Scholze et al. 2009; Moscou and Bogdanove 
2009). The modularity of these repeat elements has enabled TALEs to become a powerful 
tool, allowing for the creation of synthetic transcriptional activators that can target a 
specific DNA sequence and activate a desired gene (Morbitzer, Romer et al. 2010; Miller, 
Tan et al. 2011). Furthermore, because of the protein’s modular nature, TALEs are 
amenable to hierarchical ligation-based construction strategies, enabling the development 
of large libraries of proteins (Cermak, Doyle et al. 2011; Li, Huang et al. 2011; Miller, 
Tan et al. 2011; Morbitzer, Elsaesser et al. 2011; Weber, Gruetzner et al. 2011). 
 
Figure 3.2 TALE protein architecture and DNA binding specificities 
(A) Schematic of a representative TALE protein with 18.5 Repeat Variable Di-residue 
(RVD) domains. Each RVD domain is composed of 34 amino acids and differs only in 
the variable amino acids highlighted in red. The C-terminal RVD domain is a 15 amino 
acid half repeat domain. The 2 endogenous NLS domains and the endogenous activation 
domain (AD) present in naturally occurring TALEs were replaced with SV40 NLSs and 
the VP64 activation domain, respectively. (B) The amino acid sequences of the AvrBs3 
NI, HD, NG, and NK RVD domains and their preferred target nucleotides. 
preferentially bound (Figure 2B) (16,17). The modularity
of these repeat elements has enabled TALEs to become a
powerful tool, allowing for the creation of synthetic
transcriptional activators that can target a specific DNA
sequence and activate a desired gene (6,7). Furthermore,
because of the proteins’ modular nature, TALEs are
amenable to hierarchical ligation-based construction
strategies, enabling the development of large libraries of
proteins (5,7,18–20).
At present, however, drawbacks to the use of TALEs as
targeted transcription factors exist. Most notably, each
TALE repeat does not bind to a given DNA base pair
with perfect complementarity (Figure 2B) (21,22). While
it has been shown that in some cases including a single
mismatch in the binding site of a given TALE can signifi-
cantly inhibit its off-target activity, there are known
instances where designed TALEs have been demonstrated
to bind to unintended off-target DNA sequences that
differ from their cognate target sequence by up to 3 bp
(as defined by the TALE binding code) (16,17). These
observations indicate that while a synthetic TALE can
be designed to efficiently target a given DNA sequence,
unintended off-target effects can frequently occur and may
limit the utility of TALEs for specifically controlling the
expression of a targeted gene (Supplementary Methods).
This limitation also restricts the application of TALEs
as components of synthetic circuits where orthogonality
to the host cell’s genome is an important constraint.
We have developed an algorithm that allows one to
computationally design TALEs with cognate binding
sites that are at least a given number of mismat hes
away from a set of DNA sequences. We apply our algo-
rithm to design TALEs with 20 bp cognate binding sites
that are at least 3 nt mismatches away from all 2000 bp
putative human promoter sequences and at least 4 nt
mismatches from 500 bp putative human promoter
sequences. These TALEs represent a potentially
powerful set of insulated transcriptional regulators for
the construction of synthetic gene circuits. We generated
DNA constructs encoding eight of these TALEs as
transcriptional activators and assessed their function in
human cells. We demonstrate that each TALE effectively
activates transcription from its targeted binding site and
that the TALE activators are mutually orthogonal in their
activities. We also show that the TALEs do not activate
transcription from artificial promoters containing binding
sites comparable to potential off-target sites in human
Figure 1. Orthogonal TALEs as ideal regulatory components for insulated synthetic gene circuits. (A) Non-orthogonal TALEs designed to bind and
regulate gene expression of a synthetic gene circuit may also bind to cognate and off-target (containing mismatches) binding sequences in the
endogenous promoter regions in the genomic DNA. (B) Orthogonal TALEs bind and regulate gene expression of a synthetic gene circuit and have no
predicted binding sites in the endogenous promoter regions.
Figure 2. TALE protein architecture and DNA binding specificities.
(A) Schematic of a representative TALE protein with 18.5 repeat
variable di-residue (RVD) domains. Each RVD domain is composed
of 34 amino a ids and differs only in the variable amino acids high-
lighted in red. The C-terminal RVD domain is a 15 amino acid half
repeat domain. The two endogenous NLS domains and the endogenous
activation domain (AD) present in naturally occurring TALEs were
replaced with SV40 NLS and the VP64 activation domain, respect-
ively. (B) The amino acid sequences and the preferred target nucleotides
of RVD domains NI, HD, NG from AvrBs3 and RVD domain NK
from pthA2.
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At present, however, drawbacks to the use of TALEs as targeted transcription 
factors exist. Most notably, each TALE repeat does not bind to a given DNA base pair 
with perfect complementarity (Figure 3.2B) (Romer, Recht et al. 2009; Scholze and Boch 
2010). While it has been shown that in some cases including a single mismatch in the 
binding site of a given TALE can significantly inhibit its off-target activity, there are 
known instances where designed TALEs have been demonstrated to bind to unintended 
off-target DNA sequences that differ from their cognate target sequence by up to 3bp (as 
defined by the TALE binding code) (Boch, Scholze et al. 2009; Moscou and Bogdanove 
2009). These observations indicate that while a synthetic TALE can be designed to 
efficiently target a given DNA sequence, unintended off-target effects can frequently 
occur and may limit the utility of TALEs for specifically controlling the expression of a 
targeted gene (Appendix II). This limitation also restricts the application of TALEs as 
components of synthetic circuits where orthogonality to the host cell’s genome is an 
important constraint. 
We have developed an algorithm that allows one to computationally design 
TALEs with cognate binding sites that are at least a given number of mismatches away 
from a set of DNA sequences. We apply our algorithm to design TALEs with 20 bp 
cognate binding sites that are at least 3 nucleotide mismatches away from all 2000 bp 
putative human promoter sequences and at least 4 nucleotide mismatches from 500 bp 
putative human promoter sequences. These TALEs represent a potentially powerful set of 
insulated transcriptional regulators for the construction of synthetic gene circuits. We 
generated DNA constructs encoding 8 of these TALEs as transcriptional activators and 
assessed their function in human cells. We demonstrate that each TALE effectively 
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activates transcription from its targeted binding site and that the TALE activators are 
mutually orthogonal in their activities. We also show that the TALEs do not activate 
transcription from artificial promoters containing binding sites comparable to potential 
off-target sites in human promoter regions and provide additional evidence that the 
TALEs do not activate their closest off-target endogenous genes. Finally, we use two of 
the TALE DNA binding domains to generate TALE repressors and demonstrate strong 
TALE-mediated repression of a reporter gene. We further combine these TALE 
repressors with synthetic shRNAs targeting the same reporter to obtain even stronger, 
near complete gene repression. Our methodologies and TALE transcription factors 
address a major gap in synthetic biology and provide a new set of tools toward the design 
of robust genetic circuits that function orthogonally to the cells in which they are utilized 
(An and Chin 2009; Lu, Khalil et al. 2009; Barrett and Chin 2010; Wang, Kitney et al. 
2011).  
MATERIAL AND METHODS 
Human Genome DNA sequences  
 The sequences corresponding to the 2000 bp regions upstream of all annotated 
transcription start sites in human RefSeq genes with annotated 5’ untranslated regions 
(UTRs) were downloaded from the UCSC Genome browser website 
(http://genome.ucsc.edu/). If multiple upstream regions per RefSeq gene were found due 
to multiple annotates transcription start sites, then all upstream regions were used for 
computing orthogonal 20-mers. Downloaded sequence files correspond to the Feb. 2009 
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assembly of the human genome (hg19, GRCh37 Genome Reference Consortium Human 
Reference 37).  
Recombinant DNA constructs of TALEs and reporters 
Amino acid sequences encoding all TALE constructs were derived from the 
AvrBs3 amino acid sequence (GenBank locus id. CAA34257.1), including sequences 
encoding the sub-modules corresponding to the constant 5’ region, variable repeats 
regions (for di-residues HD, NI and NG) and the constant 3’ region. Within these 
sequences the naturally existing NLS regions and activation domains in AvrBs3 were 
identified in the 3’ constant region and replaced with mammalian SV40 NLS and VP64 
activation domains. For TALE repressors the VP64 activation domain was replaced with 
the KRAB transcriptional repression domain. DNA sequences encoding these 
components were codon-optimized for expression in human cells and synthesized by 
Integrated DNA Technology (Coralville, IA). The exact positions and sequences used are 
listed in Appendix II. These components were combined to generate TALE expression 
constructs using a hierarchal cloning scheme outlined in Appendix II. t2A and mCherry 
were combined to full length TALE activator coding regions and t2A and DsRed-shRNA 
consturcts were combined to full length TALE repressor coding regions using BioBrick 
cloning. These complete coding regions were cloned into the NheI and NotI sites of 
pCDNA5insVector for expression from the CMV promoter (Knight 2003; Phillips 2006; 
Lohmueller, Armel et al. 2012). 
Reporter constructs for activators and repressors were cloned using BioBrick 
assembly, cut with SpeI and NotI, and cloned between the SpeI and NotI sites of 
pCDNA5/FRT/TO for mammalian expression (Invitrogen, Carlsbad, CA). Finally, to 
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create combined TALE repressor and shRNA reporter constructs, shRNA target sites FF4’ 
and FF6’ were cloned into the NotI site of the CFP reporter constructs of the TALE 
repressors. 
Cell culture 
The human osteosarcoma-derived epithelial cell line U-2OS (American Type 
Culture Collection, Manassas, VA) was maintained at 37° C, 5% CO2 in growth medium 
(McCoy’s 5A medium supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml 
penicillin and 100 ug/ml streptomyocin). The human embryonic kidney cell line HEK293 
(American Type Culture Collection, Manassas, VA) was maintained at 37° C, 5% CO2 in 
growth medium (Dulbecco’s Modified Eagle Medium supplemented with 10% FBS, 2 
mM L-glutamine, 100 U/ml penicillin and 100 ug/ml streptomyocin). All transfections 
were performed in 12-well plates seeded with approximately 175,000 cells using 3 !l 
Lipofectamine LTX transfection reagent and 1 !l PLUS reagent (Invitrogen, Carlsbad, 
CA). All TALE activator transfections were performed in U-2OS cells and used 25 ng of 
TALE expression plasmid with 975 ng of reporter plasmid in 1 ml of growth medium. 
TALE repressor experiments were performed in HEK293 cells and used 100 ng of TALE 
expression plasmid with 10 ng of reporter plasmid and 890 ng of empty 
pCDNA5insVector in 1 ml of growth medium. 
Microscopy 
All microscopy was performed on live cells in glass-bottomed wells (MatTek, 
Ashland, MA) in phenol red-free growth medium 24 h post-transfection. Cells were 
imaged using a Nikon TE-2000 microscope with a 20x PlanFluor NA = 0.5, DIC M/N2 
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objective and collected with an ORCA-ER charge-coupled device camera. Data 
collection and processing were performed with Metamorph 7.0 software (Molecular 
Devices, Sunnyvale, CA). All images for a given experimental set and the corresponding 
controls were collected with the same exposure times, averaged over 3 frames, and 
underwent identical processing. 
Flow Cytometry 
Approximately 30,000 cells from each transfected well were analyzed using an 
LSRII cell analyzer (BD Biosciences, San Jose, CA) in three biological replicates. Cells 
were trypsinized with 0.1 ml of 0.25% trypsin-EDTA, pelleted, and resuspended in 100 
!l of Dulbecco’s phosphate buffered saline containing 0.1% FBS. For activator 
experiments output was assayed 24 h post-transfection. The total AmCyan fluorescent 
protein (CFP) signal of mCh+ cells was calculated by multiplying the frequency of CFP+ 
cells in the mCH+ population by the mean CFP signal of these double positive cells.  The 
fold change of AmCyan reporter fluorescence was then calculated as the ratio of total 
AmCyan fluorescence intensity of cells transfected with on-target TALE expression 
plasmids to cells transfected with reporter plus an off-target input. For repressor 
experiments output was assayed 48 h post-transfection and fold change of AmCyan 
reporter fluorescence was calculated as the ratio of total AmCyan fluorescence intensity 
of DsRED+ cells transfected with on-target TALE-shRNA expression plasmids to 
DsRED+ cells transfected with a reporter plus an off-target input. To isolate the effects of 
TALEs and shRNAs, expression constructs with different combinations of TALE5R, 
TALE8R, FF4 and FF6 represented different on- and off-target combinations depending 
on the co-transfected reporter (Appendix II). 
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Quantitative PCR 
For mRNA quantification, mCherry positive U-2OS cells were sorted and 
collected 48 h post transfection. RNA was extracted from mCherry positive cells using 
the RNeasy mini kit (Qiagen, Valencia, CA), and mRNA levels were quantified using the 
SYBR Green Assay (Applied Biosystems, Foster City, CA). The mRNA to cDNA 
conversion was performed using the SuperScript III RT kit (Invitrogen, Carlsbad, CA). 
Three biological replicates per sample and three technical replicates per assay were 
analyzed for absolute quantification of mRNA levels in transfected cells. Two biological 
replicates were analyzed for the mRNA levels quantification of OSGIN2 and ZC3H10 in 
cells transfected with TALE5 and TALE8 respectively. Relative transcript levels were 
assessed using the 2!""Ct method (16) with GAPDH as a reference gene. Statistical 
comparison between groups was made by the pairwise fixed reallocation randomization 
test using the publicly available Relative Expression Software Tool (REST) (Pfaffl, 
Horgan et al. 2002).The off-target and on-target DNA sequences of TALEs are detailed 
in Appendix II. Primer sequences used for qPCR are detailed in Appendix II. 
Algorithm Implementation 
 The algorithm was implemented in C++ and the software binaries are made 
available for download at http://silver.med.harvard.edu/tale.html. Further details about 
the algorithm are provided in Appendix II. All the results presented here were obtained 
by running our software on the Harvard Medical School shared research cluster of 
computation nodes. 
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RESULTS 
Design and implementation of an algorithm for finding orthogonal TALE binding 
sites 
We first sought to computationally design a set of TALEs that bind to 20 bp 
nucleotide sequences (20-mers) and are orthogonal to human promoter regions. A TALE 
is defined to be orthogonal to a set of sequences if it is not predicted to bind to any 
sequence in that set. In this context, the number of base pair mismatches between a 
TALE’s target sequence and a potential off-target sequence (also referred to as the 
hamming distance between the two sequences) is the main determinant of the 
orthogonality of the TALE. Thus, a large hamming distance between the TALE target 
site and a potential off-target sequence corresponds to a lower chance of the TALE 
binding to that off-target sequence. 
To design synthetic TALEs that function orthogonally to a set of non-intended 
target sites, we developed an algorithm based on the farthest string problem. Given a set, 
S, of n-mers defined over an alphabet, !, (e.g. ! = {A,C,G,T}), the objective of the 
farthest string problem is to find an n-mer (over the alphabet !) that has the largest 
minimum hamming distance to n-mers in set S. The farthest string problem belongs to a 
class of NP-hard problems for which no polynomial time solution is known to exist 
(Lanctot 2003). Therefore, it may take an exponential amount of time to enumerate all 
possible 420 nucleotide sequences and test each to find a 20-mer at a maximum hamming 
distance from the set of genomic 20-mers. At present no algorithm exists to efficiently 
compute a set of such n-mers. However, by designing careful heuristics, our algorithm 
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can efficiently find a list of 20-mers that are orthogonal to human genome promoter 
regions by a hamming distance of 3 bp or more.  
 
Figure 3.3 Flowchart enumerating the steps used in our algorithm to compute 
orthogonal 20-mers 
Steps 1-2 describe the process used to reduce the set of genomic 20-mers. Steps 2 and 3 
describe the process of obtaining 20-mers orthogonal to the genomic set. Steps 2 and 3 of 
the algorithm can be iterated until the desired number of orthogonal sequences has been 
computed. Finally, the resulting sets of TALEs are checked for mutual orthogonality to 
avoid cross-interference within the synthetic circuits. 
 
The steps followed by our algorithm are outlined in Figure 3.3. We began by 
using a sliding window approach to enumerate all possible 20-mers present across both 
DNA strands in the promoter region of all genes in the human genome. We define 
promoter regions as the 2000 bp regions upstream of the transcription start site (TSS) of 
each gene. Because the presence of a 5’ T has been demonstrated to be a necessary 
condition for efficient TALE binding, 20-mers that do not begin with T were not 
considered, yielding a total of 17x106 20-mers that are potential TALE binding sites 
(Boch, Scholze et al. 2009). To further reduce the number of 20-mers, the parental set of 
17x106 20-mers was divided into subsets, such that each subset could be represented by a 
ratio of total AmCyan fluorescence intensity of DsRED+
cells transfected with on-target TALE-shRNA expression
plasmids to DsRED+cells transfected with a reporter plus
an off-target input. To isolate the effects of TALEs and
shRNAs, expression constructs with different combin-
ations of TALE5R, TALE8R, FF4 and FF6 represented
different on- and off-target combinations depending on
the co-transfected reporter (Supplementary Table S9).
Quantitative PCR
For mRNA quantification, mCherry positive U-2OS cells
were sorted and collected 48 h post-transfection. RNA was
extracted from mCherry positive cells using the RNeasy
mini kit (Qiagen, Valencia, CA, USA), and mRNA levels
were quantified using the SYBR Green Assay (Applied
Biosystems, Foster City, CA, USA). The mRNA to
cDNA conversion was performed using the SuperScript
III RT kit (Invitrogen, Carlsbad, CA, USA). Three biolo-
gical replicates per sample and three technical replicates
per assay were analyzed for absolute quantification of
mRNA levels in transfected cells. Two biological repli-
cates were analyzed for the mRNA levels quantification
of OSGIN2 and ZC3H10 in cells transfected with TALE5
and TALE8, respectively. Relative transcript levels were
assessed using the 2!!!Ctmethod (45) with GAPDH as a
reference gene. Statistical comparison between groups was
made by the pair-wise fixed reallocation randomization
test using the publicly available Relative Expression
Software Tool (REST) (30).The off-target and on-target
DNA sequences of TALEs are detailed in Supplementary
Table S7. Primer sequences used for qPCR are detailed in
Supplementary Table S7.
Algorithm implementation
The algorithm was implemented in C++and the software
binaries are made available for download at http://silver
.med.harvard.edu/tale.html. Further details about the
algorithm are provided in Supplementary Methods. All
the results presented here were obtained by running our
software on the Harvard Medical School shared research
cluster of computation nodes.
RESULTS
Design and implementation of an algorithm for finding
orthogonal TALE binding sites
We first sought to computationally design a set of TALEs
that bind to 20 bp nucleotide sequences (20-mers) and are
orthogonal to human promoter regions. A TALE is
defined to be orthogonal to a set of sequences if it is not
predicted to bind to any sequence in that set. In this
context, the number of base pair mismatches between a
TALE’s target sequence and a potential off-target
sequence (also referred to as the hamming distance
between the two sequences) is the main determinant of
the orthogonality of the TALE. Thus, a large hamming
distance between the TALE target site and a potential
off-target sequence corresponds to a lower chance of the
TALE binding to that off-target sequence.
To design synthetic TALEs that function orthogonally to
a set of non-intended target sites, we developed an
algorithm based on the farthest string problem. Given a
set, S, of n-mers defined over an alphabet, ", (e.g.
"={A,C,G,T}), the objective of the farthest string
problem is to find an n-mer (over the alphabet ") that has
the largest minimum hamming distance to n-mers in set S.
The farthest string problem belongs to a class of NP-hard
problems for which no polynomial time solution is known
to exist (31). Therefore, it may take an exponential amount
of time to enumerate all possible 420 nucleotide sequences
and test each to find a 20-mer at a maximum hamming
distance from the set of genomic 20-mers. At present, no
algorithm exists to efficiently compute a set of such n-mers.
However, by designing careful heuristics, our algorithm can
efficiently find a list of 20-mers that are orthogonal to
human genome promoter regions by a hamming distance
of 3 bp or more.
The steps followed by our algorithm are outlined in
Figure 3. We began by using a sliding window approach
to enumerate all possible 20-mers present across bothDNA
strands in the promoter region of all genes in the human
genome.We define promoter regions as the 2000 bp regions
upstream of the TSS of each gene. Because the presence of a
50 T has been demonstrated to be a necessary condition for
efficient TALE binding, 20-mers that do not begin with T
were not considered, yielding a total of 17" 106 20-mers
that are potential TALE binding sites (16). To further
reduce the number of 20-mers, the parental set of 17" 106
20-mers was divided into subsets, such that each subset
could be represented by a single 20-mer within a 7 bp
hamming distance from all sequences in that subset
(Supplementary Figure S1). Due to the reverse triangle in-
equality property of hamming distances, all 20-mers that
Figure 3. Flowchart enumerating the steps used in our algorithm to
compute orthogonal 20-mers. Steps 1 and 2 describe the process used
to reduce the set of genomic 20-mers. Steps 2 and 3 describe the process
of obtaining 20-mers orthogonal to the genomic set. Steps 2 and 3 of
the algorithm can be iterated until the desired number of orthogonal
sequences has been computed. Finally, the resulting sets of TALEs are
ch cked for mutual orth gonality to avoid cross-int rference within th
synthetic circuits.
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single 20-mer within a 7 bp hamming distance from all sequences in that subset 
(Appendix II). Due to the reverse triangle inequality property of hamming distances, all 
20-mers that are at a minimum 10 bp hamming distance from these representative 
sequences will also be at a minimum hamming distance of 3bp from the parental set of 
17x106 genomic 20-mers (Appendix II). Our algorithm uses symbolic modeling 
techniques and Boolean algebra to find all possible 20-mers at a minimum hamming 
distance of 10 bp from representative sequences of each subset (Appendix II). Multiple 
solutions to finding such subsets exist and each solution is typically comprised of 12,000-
15,000 subsets, each having a representative 20-mers. By generating multiple sets of 
representative 20-mers and applying our algorithm iteratively, we identified over 180 
potential binding sites for synthetic TALEs at a minimum hamming distance of 3 bp from 
any 20-mer in the promoter regions of the human genome (Appendix II).  
We chose to generate and characterize 8 of these 180 TALEs predicted to be 
orthogonal to human promoter regions (Table 3.1). Chosen TALEs had a hamming 
distance of 3 bp from all 2000 bp genomic promoter regions and a hamming distance of 4 
bp from 500 bp genomic promoter regions. The hamming distance to the more stringent 
500 bp genomic promoter regions was used as an additional criterion as native 
transcription factor binding sites are known to be highly concentrated within these 500 bp 
regions proximal to the TSS (Xie, Lu et al. 2005; Carninci, Sandelin et al. 2006; 
Koudritsky and Domany 2008; MacIsaac, Lo et al. 2010). From our set of 150 synthetic 
TALEs, 100 proteins possessed a minimum hamming distance of 4 bp from 500 bp 
proximal promoter regions, while the remaining 50 proteins had a hamming distance of 3 
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bp. To minimize potential cross-activation between the selected TALEs, we also ensured 
that the 8 selected TALEs were predicted to be mutually orthogonal. 
Table 3.1 Constituent RVDs and cognate binding sites of the 8 TALEs that were 
constructed and functionally characterized   
 
In vivo characterization demonstrates activity and mutual orthogonality of synthetic 
TALE activators 
To generate each of our 8 computationally designed TALEs for assaying in vivo, a 
library of subparts was synthesized containing both individual di-residue repeats and each 
pairwise combination of repeats, codon-optimized for expression in mammalian cells. 
Individual TALEs were created using a hierarchical, modular cloning strategy that 
leverages type IIS restriction enzymes to readily combine members of a library of 
are at a minimum 10 bp hamming distance from these rep-
resentative sequences will also be at a minimum hamming
distance of 3 bp from the parental set of 17! 106 genomic
20-mers (Supplementary Figure S1). Our algorithm uses
symbolic modeling techniques and Boolean algebra to
find all possible 20-mers at a minimum hamming distance
of 10 bp from representative sequences of each subset
(Supplementary Methods). Multiple solutions to finding
such subsets exist and each solution is typically comprised
of 12 000–15 000 subsets, each having a representative
20-mers. By generating multiple sets of representative
20-mers and applying our algorithm iteratively, we
identified over 180 potential binding sites for synthetic
TALEs at a minimum hamming distance of 3 bp from
any 20-mer in the promoter regions of the human genome
(Supplementary Table S2).
We chose to generate and characterize 8 of these 180
TALEs predicted to be orthogonal to human promoter
regions (Table 1). Chosen TALEs had a hamming distance
of 3 bp from all 2000bp genomic promoter regions and a
hamming distance of 4 bp from 500bp genomic promoter
regions. The hamming distance to the more stringent 500 bp
genomic promoter regions was used as an additional criter-
ion as native transcription factor binding sites are known to
be highly concentrated within these 500 bp regions proximal
to the TSS (32–35). From our set of 150 synthetic TALEs,
100 proteins possessed aminimumhammingdistance of 4 bp
from500bpproximal promoter regions, while the remaining
50 proteins had a hamming distance of 3 bp. To minimize
potential cross-activation between the selected TALEs, we
also ensured that the eight selected TALEswere predicted to
be mutually orthogonal.
In vivo characterization demonstrates activity and mutual
orthogonality of synthetic TALE activators
To generate each of our eight computationally designed
TALEs for assaying in vivo, a library of subparts was
synthesized containing both individual di-residue repeats
and each pair-wise combination of repeats, codon-
optimized for expression in mammalian cells. Individual
TALEs were created using a hierarchical, modular cloning
strategy that leverages type IIS restriction enzymes to
readily combine members of a library of subparts into
any desired TALE (Supplementary Figure S2). The
modular cloning scheme we use is similar to the techniques
reported in the recent literature (18,19,20,36,37). For each
protein, both native NLSs were replaced with eukaryotic
versions, and the native activation domain was replaced
Table 1. Constituent RVDs and cognate binding sites of the 8 TALEs that were constructed and functionally
characterized
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
HD NI NI NG NI HD NG NG NI HD NI NI NI HD NG HD HD NG NG TALE 1 
T C A A T A C T T A C A A A C T C C T T
HD HD NI HD HD NI NI NI NG NG HD NI NI HD NI HD NG NG NG TALE 2 
T C C A C C A A A T T C A A C A C T T T
HD NI NG HD NG NI HD NI NI HD NI HD NG NI HD NG NI NG NG TALE 3 
T C A T C T A C A A C A C T A C T A T T
HD HD HD NI NI NG NI HD NI HD NG NI NG NI NI HD NI HD NI TALE 4 
T C C C A A T A C A C T A T A A C A C A
NI NI HD NG NG NI HD HD NG NG HD NG HD NI NI HD NI HD NI TALE 5 
T A A C T T A C C T T C T C A A C A C A
NI NG HD HD NG HD NG NG NI HD NI NI NG NI NG HD HD HD NI TALE 6 
T A T C C T C T T A C A A T A T C C C A
NI HD NG NG NI HD HD HD NG NI NI HD HD HD NI NI NG NG NG TALE 7 
T A C T T A C C C T A A C C C A A T T T
NI NG NI HD NG NI NG HD HD NI NI NG HD HD NI NI HD NG NG TALE 8 
T A T A C T A T C C A A T C C A A C T T
HD HD NG HD HD HD HD NI HD HD NG NG NG NI NI NG NG NG NGTALE
OSGIN2 T C C T C C C C A C C T T T A A T T T T
NI HD HD NI NG NI NG HD HD HD NI NG HD HD NI NI HD NG HDTALE 
ZC3H10 T A C C A T A T C C C A T C C A A C T C
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subparts into any desired TALE (Appendix II). The modular cloning scheme we use is 
similar to the techniques reported in the recent literature (Cermak, Doyle et al. 2011; 
Geissler, Scholze et al. 2011; Li, Huang et al. 2011; Morbitzer, Elsaesser et al. 2011; 
Weber, Gruetzner et al. 2011; Zhang, Cong et al. 2011). For each protein, both native 
NLSs were replaced with eukaryotic versions, and the native activation domain was 
replaced with the VP64 mammalian transcriptional activation domain. TALEs were 
expressed from the cytomegalovirus (CMV) promoter and tagged with an auto-
catalytically cleaved t2A peptide fused to mCherry fluorescent protein as a transfection 
control (Figure 3.4A).  
 
Figure 3.4 Schematic of TALE expression constructs  
(A) Schematic of TALE expression constructs. Each TALE coding region was cloned 
into a mammalian expression vector downstream of the CMV promoter. All synthetic 
TALEs were also tagged with an self-cleaving t2A:mCherry fluorescent protein as a 
transfection control. (B) Schematic of TALE reporter constructs. Reporter constructs 
were generated by cloning a 20 bp TALE target sequence upstream of a minimal TATA 
box separated by a 78 bp spacer region. Binding of a TALE activator to the 20 bp target 
sequence drives expression of 2 tandem copies of NLS-tagged CFP cloned downstream 
of the TALE-responsive promoter as an output for TALE functionality.  
 
The ability of our synthetic proteins to recognize a binding site and activate gene 
expression was tested by co-transfecting TALE expression constructs with reporter 
plasmids containing a 20-mer binding site driving expression of two tandem copies of the 
with the VP64 mammalian transcriptional activation
domain. TALEs were expressed from the cytomegalovirus
(CMV) promoter and tagged with an auto-catalytically
cleaved t2A peptide fused to mCherry fluorescent
protein as a transfection control (Figure 4A).
The ability of our synthetic proteins to recognize a
binding site and activate gene expression was tested by
co-transfecting TALE expression constructs with reporter
plasmids containing a 20-mer binding site driving expres-
sion of two tandem copies of the CFP fused to an NLS
(Figure 4B). Experiments were performed in the U-2OS
human osteosarcoma cell line and assayed by fluorescence
microscopy and flow cytometry 24 h post-transfection.
Each TALE was co-transfected with its corresponding
binding site reporter plasmid to determine if it was
capable of activating transcription from its targeted
reporter, as well as with reporter plasmids containing
binding sites for the seven other constructed TALEs in
order to ensure that all proteins are mutually orthogonal.
Results from fluorescence microscopy indicate that all
TALEs were efficiently expressed, as determined by
presence of mCherry positive cells (Supplementary
Figure S3). Furthermore, the TALEs efficiently activated
gene expression from promoters containing their cognate
binding site and not those targeted by other TALEs in the
set, indicating that our synthetic TALEs function in a
mutually orthogonal manner (Figure 5A). Flow cytometry
was performed to quantify TALE-activated CFP expres-
sion fro each promoter. Activity was measured as the
total CFP signal of mCherry positive cells. As a control,
an off-target TALE was co-transfected with each TALE
reporter plasmid and the level of activation for each syn-
thetic TALE was calculated relative to this off-target
control. These results confirmed our fluoresc nce
microscopy findings, with synthetic TALEs demonstrating
a 10 - to 102-fold induction of the CFP reporter with no
significant signal observed for off-target binding sites
(Figure 5B and Supplementary Table S1).
Synthetic TALEs do not activate transcription of a set of
off-target endogenous genes
To investigate the orthogonality of our TALEs to poten-
tial genomic promoter binding sites, we began by assessing
the effect of target site mismatches on the ability of
TALEs to bind a given 20-mer. It has previously been
shown that TALE activity generally decreases with the
number of mutations in its target site (18,22,37,38,39).
However, as positional and contextual effects of these mu-
tations have also been reported, it is important to analyze
the specific effect of mutations in the context of our
TALEs that have a different protein architecture and
bind to longer DNA sequences (20 bp) than those
previously studied. TALE8 was chosen as a representative
protein and reporter constructs were generated with
20-mers at a hamming distance of 1–7 from TALE8’s
on-target binding site. To avoid potential position-specific
bias, mismatches were distributed evenly throughout the
binding sites (Figure 6A). TALE8 was co-transfected with
each reporter construct, and reporter expression was
assayed by fluorescence microscopy and flow cytometry
with TALE5 serving as an off-target control. Expression
from reporter constructs was observed to decrease with
the hamming distance and 20-mers at a hamming
distance of 3 bp from the on-target site exhibited output
signal that was one-tenth of the full signal, and 20-mers at
a hamming distance of 4 bp or more from the on-target
site exhibited an output signal comparable to background
(Figure 6B).
We next sought to ascertain the influence of mismatch
position on protein function. Three additional reporter
plasmids were generated for TALE8 with a hamming
distance of 3 bp. The positions of these mismatches were
localized to either the 50-end, the 30-end or the center of the
target site (Figure 6A). Our results illustrate that
mismatches in the 50-end and center of the target site
abolish TALE activated expression, while mismatches in
the 30 end appear to have less of an impact, more closely
resembling mismatches uniformly distributed throughout
the binding site (Figure 6C). These results indicate that the
location of mismatches should be considered when design-
ing orthogonal TALEs. Within the 2 kb promoter regions,
the longest matching endogenous sequences to our
designed eight TALEs were at most 14 bp long and these
off-target sequences had four or more mismatches in pos-
itions 14–20. Thus, our constructed TALEs satisfy the
combined constraints set by number and position of
mismatches in Figure 6 (Supplementary Table S3).
To more directly characterize the orthogonality of our
synthetic TALEs to endogenous promoter regions in vivo,
we measured mRNA expression levels from the most
likely predicted target genes following transfection with
two representative TALEs, TALE5 and TALE8. The
nearest predicted off-target sequence for TALE5 was in
the promoter of oxidative stress induced growth inhibitor
family member 2 (OSGIN2), and for TALE8 the nearest
predicted off-target sequence was in the promoter of
Figure 4. (A) Schematic of TALE expression constructs. Each TALE
coding region was cloned into a mammalian expression vector down-
stream of the CMV promoter. All synthetic TALEs were also tagged
with an self-cleaving t2A:mCherry fluorescent protein as a transfection
control. (B) Schematic f TALE reporter constructs. Reporter con-
structs were generated by cloning a 20 bp TALE target sequence
upstream of a minimal TATA box separated by a 78 bp spacer
region. Binding of a TALE activator to the 20 bp target sequence
drives expression of two tandem copies of NLS-tagged CFP cloned
downstream of the TALE-responsive promoter as an output for
TALE functionality.
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AmCyan fluorescent protein (CFP) fused to an NLS (Figure 3.4B). Experiments were 
performed in the U-2OS human osteosarcoma cell line and assayed by fluorescence 
microscopy and flow cytometry 24 hours post-transfection. Each TALE was co-
transfected with its corresponding binding site reporter plasmid to determine if it was 
capable of activating transcription from its targeted reporter, as well as with reporter 
plasmids containing binding sites for the seven other constructed TALEs in order to 
ensure that all proteins are mutually orthogonal. Results from fluorescence microscopy 
indicate that all TALEs were efficiently expressed, as determined by presence of 
mCherry positive cells (Appendix II).  
Furthermore, the TALEs efficiently activated gene expression from promoters 
containing their cognate binding site and not those targeted by other TALEs in the set, 
indicating that our synthetic TALEs function in a mutually orthogonal manner (Figure 
3.5A). Flow cytometry was performed to quantify TALE-activated CFP expression from 
each promoter.  Activity was measured as the total CFP signal of mCherry positive cells. 
As a control, an off-target TALE was co-transfected with each TALE reporter plasmid 
and the level of activation for each synthetic TALE was calculated relative to this off-
target control. These results confirmed our fluorescence microscopy findings, with 
synthetic TALEs demonstrating a 10-fold to 102-fold induction of the CFP reporter with 
no significant signal observed for off-target binding sites (Figure 3.5B, Appendix II).   
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Figure 3.5 Functional characterization of TALE activators  
(A) Fluorescence microscopy images of TALE-induced CFP reporter expression. Each 
column of the 8x8 matrix represents U2-OS cells co-transfected with a synthetic TALE 
and reporter constructs for each 20-mer binding site (BS). The CFP signal is only visible 
along the diagonal of the matrix, indicating that the TALEs described here function in a 
mutually orthogonal manner. (B) Bar graphs representing mutually orthogonal TALE 
activity as determined by flow cytometry. The fold induction of CFP expression, as 
calculated relative to an off-target control TALE, displays values ranging from 
approximately 10-fold to 100-fold for cognate target sites, and demonstrates the 
functionality and mutual orthogonality of these TALEs. 
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Figure 5. Functional characterization of TALE activators. (A) Fluorescence microscopy images of TALE-induced CFP reporter expression. Each
column of the 8 ! 8 matrix represents U2-OS cells co-transfected with a synthetic TALE and reporter constructs for each 20-mer binding site (BS).
The CFP signal is only visible along the diagonal of the matrix, indicating that the TALEs described here function in a mutually orthogonal manner.
(B) Bar graphs representing mutually orthogonal TALE activity as determined by flow cytometry. The fold induction of CFP expression, as
calculated relative to an off-target control TALE, displays values ranging from approximately 10-fold to 100-fold for cognate target sites and
demonstrates the functionality and mutual orthogonality of these TALEs.
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Figure 6. Effect of binding site mutations on TALE-mediated transcriptional activation. (A) TALE8 activity in the presence of an increasing number
of uniformly distributed binding site mismatches. BS-8 is the corresponding binding site for TALE8 with additional binding sites tested at a hamming
distance (HD) of 1–7 bp from BS-8 (HD-1–HD-7). The ability of TALE8 to activate CFP expression from each binding site reporter was measured
by flow cytometry relative to TALE5 as an off-target control. The presence of two or more mismatches in the binding site significantly decreases the
ability of TALE8 to activate gene expression, with binding sites at a hamming distance of more than 3 bp displaying no reporter activity. (B) Effect
of binding site mismatch position on TALE activation. The ability of TALE8 to activate gene expression from binding sites with a hamming distance
of 3 bp was tested with the position of the mismatches either uniformly distributed, HD-3, localized to the 50-end of the binding site, HD-3(50), to the
middle of the binding site, HD-3(M) or to the end of the binding site, HD-3(30). (C) Tested DNA binding sequences. Underlined nucleotides
represent mismatches with respect to BS-8.
7590 Nucleic Acids Research, 2012, Vol. 40, No. 15
 by guest on January 15, 2013
http://nar.oxfordjournals.org/
Downloaded from 
 
 
66 
 
Figure 3.6. Effect of binding site mutations on TALE-mediated transcriptional 
activation 
(A) TALE8 activity in the presence of an increasing number of uniformly distributed 
binding site mismatches. BS-8 is the corresponding binding site for TALE8 with 
additional binding sites tested at a hamming distance (HD) of 1 bp to 7 bp from BS-8 
(HD-1 to HD-7). The ability of TALE8 to activate CFP expression from each binding site 
reporter was measured by flow cytometry relative to TALE5 as an off-target control. The 
presence of two or more mismatches in the binding site significantly decreases the ability 
of TALE8 to activate gene expression, with binding sites at a hamming distance of more 
than 3 bp displaying no reporter activity. (B) Effect of binding site mismatch position on 
TALE activation. The ability of TALE8 to activate gene expression from binding sites 
with a hamming distance of 3 bp was tested with the position of the mismatches either 
uniformly distributed, HD-3, localized to the 5’-end of the binding site, HD-3(5’), to the 
middle of the binding site, HD-3(M), or to the end of the binding site, HD-3(3’). (C) 
Tested DNA binding sequences. Underlined nucleotides represent mismatches with 
respect to BS-8. 
 
Synthetic TALEs do not activate transcription of a set of off-target endogenous 
genes 
To investigate the orthogonality of our TALEs to potential genomic promoter 
binding sites, we began by assessing the effect of target site mismatches on the ability of 
TALEs to bind a given 20-mer. It has previously been shown that TALE activity 
generally decreases with the number of mutations in its target site (Kay, Hahn et al. 2009; 
Romer, Strauss et al. 2009; Scholze and Boch 2010; Miller, Tan et al. 2011; Morbitzer, 
Elsaesser et al. 2011). However, as positional and contextual effects of these mutations 
have also been reported, it is important to analyze the specific effect of mutations in the 
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Figure 5. Functional characterization of TALE activators. (A) Fluorescence microscopy images of TALE-induced CFP reporter expression. Each
column of the 8 ! 8 matrix represents U2-OS cells co-transfected with a synthetic TALE and reporter constructs for each 20-mer binding site (BS).
The CFP signal is only visible along the diagonal of the matrix, indicating that the TALEs described here function in a mutually orthogonal manner.
(B) Bar graphs representing mutually orthogonal TALE activity as determined by flow cytometry. The fold induction of CFP expression, as
calculated relative to an off-target control TALE, displays values ranging from approximately 10-fold to 100-fold for cognate target sites and
demonstrates the functionality and mutual orthogonality of these TALEs.
Binding Site Target SequenceA B C
0
20
40
60
80
100
120
8 1 2 3 4 5 7
Fo
ld
 
In
du
ct
io
n
0
20
40
60
80
100
120
8 3 ) ) )
Fo
ld
 
In
du
ct
io
n
TALE 8
 TATACTATCCAATCCAACTT 
TALE 8 + HD-1
 TATACTATCCCATCCAACTT 
TALE 8 + HD-2
 TATACTCTCCAATACAACTT 
TALE 8 + HD-3
 TATAATATACAATCCCACTT 
TALE 8 + HD-4
 TATCATATCCAATCCCCCTT 
TALE 8 + HD-5
 TACCATATCCCATCCAACTC 
TALE 8 + HD-7
 TCTCATATAAAATAAAACTT 
TALE 8 + HD-3 (5`)
 TCCCCTATCCAATCCAACTT 
BS
-
BS
-
8 +
HD
-
BS
-
8 +
HD
-
BS
-8
+
HD
-
BS
-8
+
HD
-
BS
-
8 +
HD
-
BS
-
8 +
HD
-
BS
-
BS
-
8 +
HD
-
BS
-8
+ H
D-
3(5
'
BS
-8
+
HD
-
3(M
BS
-8
+
HD
-
1(3
'TALE 8 + HD-3 (M)
 TATACTATCCACCACAACTT  
TALE 8 + HD-3 (3`)
 TATACTATCCAATCCAAACC 
Figure 6. Effect of binding site mutations on TALE-mediated transcriptional activation. (A) TALE8 activity in the presence of an increasing number
of uniformly distributed binding site mismatches. BS-8 is the corresponding binding site for TALE8 with additional binding sites tested at a hamming
distance (HD) of 1–7 bp from BS-8 (HD-1–HD-7). The ability of TALE8 to activate CFP expression from each binding site reporter was measured
by flow cytometry relative to TALE5 as an off-target control. The presence of two or more mismatches in the binding site significantly decreases the
ability of TALE8 to activate gene expression, with binding sites at a hamming distance of more than 3 bp displaying no reporter activity. (B) Effect
of binding site mism tch position on TALE activation. The ability of TALE8 to activate gene expression fr m binding sites with a hamming distance
of 3 bp was tested with the position of the mismatches either uniformly distributed, HD-3, localized to the 50-end of the binding site, HD-3(50), to the
middle of the binding site, HD-3(M) or to the end of the binding site, HD-3(30). (C) Tested DNA binding sequences. Underlined nucleotides
represent mismatches with respect to BS-8.
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context of our TALEs that have a different protein architecture and bind to longer DNA 
sequences (20 bp) than those previously studied. TALE8 was chosen as a representative 
protein and reporter constructs were generated with 20-mers at a hamming distance of 1 
to 7 from TALE8’s on-target binding site. To avoid potential position-specific bias, 
mismatches were distributed evenly throughout the binding sites (Figure 3.6A). TALE8 
was co-transfected with each reporter construct, and reporter expression was assayed by 
fluorescence microscopy and flow cytometry with TALE5 serving as an off-target control. 
Expression from reporter constructs was observed to decrease with the hamming distance 
and 20-mers at a hamming distance of 3bp from the on-target site exhibited output signal 
that was one tenth of the full signal, and 20-mers at a hamming distance of 4 bp or more 
from the on-target site exhibited an output signal comparable to background (Figure 
3.6B).   
We next sought to ascertain the influence of mismatch position on protein 
function. Three additional reporter plasmids were generated for TALE8 with a hamming 
distance of 3 bp. The positions of these mismatches were localized to either the 5’-end, 
the 3’-end, or the center of the target site (Figure 3.6A). Our results illustrate that 
mismatches in the 5’-end and center of the target site abolish TALE activated expression, 
while mismatches in the 3’-end appear to have less of an impact, more closely resembling 
mismatches uniformly distributed throughout the binding site (Figure 3.6C). These results 
indicate that the location of mismatches should be considered when designing orthogonal 
TALEs. Within the 2kb promoter regoins, the longest matching endogenous sequences to 
our designed 8 TALEs were at most 14 bp long and these off-target sequences had 4 or 
more mismatches in positions 14 to 20. Thus, our constructed TALEs satisfy the 
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combined constraints set by number and position of mismatches in Figure 3.6 and 
Appendix II. 
 
 
Figure 3.7. Characterization of TALE-mediated off-target endogenous gene 
activation in vivo  
Fold change in mRNA levels of potential target genes following TALE expression. 
mRNA levels of the most likely target genes of TALE5 and TALE8 were measured by 
qPCR 48 h post-transfection with the corresponding TALE construct and plotted as fold 
change over mock-transfected cells. TALE-OSGIN2 and TALE-ZC3H10 are the positive 
control TALEs predicted to activate the two closest off-target genes of TALE5 and 
TALE8 respectively. (A) A 4.8-fold induction of nearest target gene OSGIN2 by the 
positive control TALE-OSGIN2, and no significant change in mRNA levels of OSGIN2 
and the other four nearest target genes of TALE5 is observed in response to TALE5. The 
10x higher concentration (250ng) of TALE5 also shows no significant induction in 
mRNA levels of its off-target gene OSGIN2. (B) The positive control TALE-ZC3H10 
leads to a modest but signficant induction of nearest target gene (ZC3H10) of TALE8. 
There is no significant change in mRNA levels of the four nearest target genes of TALE8 
in response to TALE8 expression. * indicates P < 0.03. 
 
To more directly characterize the orthogonality of our synthetic TALEs to 
endogenous promoter regions in vivo, we measured mRNA expression levels from the 
most likely predicted target genes following transfection with two representative TALEs, 
TALE5 and TALE8. The nearest predicted off-target sequence for TALE5 was in the 
promoter of oxidative stress induced growth inhibitor family member 2 (OSGIN2), and 
zinc-finger CCCH-type containing 10 (ZC3H10). The
targets of each TALE chosen for analysis were determined
based on the presence of the closest off-target binding site,
having a minimum number of mismatches, in the 500 bp
region upstream of the TSS. As a positive control, we
designed two TALEs, TALE-OSGIN2 and TALE-
ZC3H10, that are predicted to effectively bind in the
500 bp upstream promoter regions of OSGIN2 and
ZC3H10, respectively. Off-target sequences for TALE5
and TALE8 and target sequences for TALE-OSGIN2
and TALE-ZC3H10 are listed in Supplementary Table
S7. All TALEs were transfected in U-2OS cells and the
fold change in mRNA level relative to a mock-transfected
control was measured at 48 h post-transfection by qPCR
(Figure 7).
Results from qPCR demonstrate that while our positive
control, TALE-OSGIN2, is capable of inducing OSGIN2
mRNA expression by 4.8-fold, no significant induction is
observed following transfection with TALE5 (Figure 7A).
Similarly, transfection with TALE-ZC3H10 leads to a sig-
nificant induction of targeted ZC3H10 mRNA, while no
significant induction is observed following transfection
with TALE8 (Figure 7B). In order to ensure that an
adequate amount of TALE transcription factor was ex-
pressed in cells, we analyzed the fold induction in
mRNA expression of off-target genes from TALE5 and
TALE8 with 10! higher amount of TALE expression
plasmid (Figure 7). We observed no significant induction
of off-target genes even in the presence of the higher
concentration of TALE expression plasmid. To further
investigate the orthogonality of our synthetic TALEs, we
assayed mRNA expression of the next four nearest
predicted target genes of TALE5 and the next three
nearest predicted target genes of TALE8 (Figure 7). In
all cases, no significant induction of potential target
genes was seen relative to mock-transfected controls,
providing further evidence for the orthogonality of these
TALEs relative to human promoter regions.
Construction and characterization of TALE repressors
Next, we designed and tested TALE repressor proteins
composed of our orthogonal TALE DNA binding
domains. We generated TALE repressors TALE5R and
TALE8R, by replacing the VP64 activation domain with
the KRAB transcriptional repression domain in TALE5
and TALE8 constructs, respectively (Figure 8A). The
ability of these TALEs to repress transcription was
tested by co-transfecting them with CMV-driven CFP
expression vectors containing the cognate TALE binding
site located on the transcriptional start site of the CMV
promoter. TALE repressors efficiently repressed CFP
expression from 36- to 97-fold compared to off-target
TALE controls (Figure 8).
Finally, we demonstrated the ability to tightly repress
gene expression to near background levels by combining
the TALE repressors with shRNAs targeting the same
transcripts. We designed expression constructs that
co-express a TALE repressor, an shRNA and the DsRed
fluorescent protein from the same promoter. The shRNAs
were generated in the miR30 context and embedded within
the SV40 intron in the DsRED red fluorescence protein
gene (40,41). We used the shRNAs, ‘FF4’ and ‘FF6’,
previously designed to target the Firefly Luciferase gene
as they are commonly used as off-target negative control
shRNAs and are reported to be orthogonal to endogenous
transcripts (41). When co-expressed, the TALE and
shRNA combination repressed CFP expression from
740- to 4853-fold. Of note, the level repression mediated
by the TALE repressors alone was at least 5-fold higher
than that of the shRNAs expressed alone.
A B
Figure 7. Characterization of TALE-mediated off-target endogenous gene activation in vivo. Fold change in mRNA levels of potential target genes
following TALE expression. mRNA levels of the most likely target genes of TALE5 and TALE8 were measured by qPCR 48 h post-transfection with
the corresponding TALE construct and plotted as fold change over mock-transfected cells. TALE-OSGIN2 and TALE-ZC3H10 are the positive
control TALEs predicted to activate the two closest off-target genes of TALE5 and TALE8 respectively. (A) A 4.8-fold induction of nearest target
gene OSGIN2 by the positive control TALE-OSGIN2, and no significant change in mRNA levels of OSGIN2 and the other four nearest target genes
of TALE5 is observed in response to TALE5. The 10! higher concentration (250 ng) of TALE5 also shows no significant induction in mRNA levels
of its off-target gene OSGIN2. (B) The positive control TALE-ZC3H10 leads to a modest but significant induction of nearest target gene (ZC3H10)
of TALE8. There is no significant change in mRNA levels of the four nearest target genes of TALE8 in response to TALE8 expression. Asterisk
indicates P< 0.03.
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for TALE8 the nearest predicted off-target sequence was in the promoter of zinc-finger 
CCCH-type containing 10 (ZC3H10). The targets of each TALE chosen for analysis were 
determined based on the presence of the closest off-target binding site, having a 
minimum number of mismatches, in the 500 bp region upstream of the transcription start 
site. As a positive control we designed two TALEs, TALE-OSGIN2 and TALE-ZC3H10, 
that are predicted to effectively bind in the 500 bp upstream promoter regions of OSGIN2 
and ZC3H10, respectively. Off-target sequences for TALEs 5 and 8 and target sequences 
for TALE-OSGIN2 and TALE-ZC3H10 are listed in Appendix II. All TALEs were 
transfected in U-2OS cells and the fold change in mRNA level relative to a mock-
transfected control was measured at 48 hours post-transfection by qPCR (Figure 3.7).   
Results from qPCR demonstrate that while our positive control, TALE-OSGIN2, 
is capable of inducing OSGIN2 mRNA expression by 4.8-fold, no significant induction is 
observed following transfection with TALE5 (Figure 3.7A). Similarly, transfection with 
TALE-ZC3H10 leads to a significant induction of targeted ZC3H10 mRNA, while no 
significant induction is observed following transfection with TALE8 (Figure 3.7B). In 
order to ensure that an adequate amount of TALE transcription factor was expressed in 
cells, we analyzed the fold induction in mRNA expression of off-target genes from 
TALE5 and TALE8 with 10x higher amount of TALE expression plasmids (Figure 3.7). 
We observe no significant induction of off-target genes even in the presence of the higher 
concentration of TALE expression plasmid. To further investigate the orthogonality of 
our synthetic TALEs, we assayed mRNA expression of the next 4 nearest predicted target 
genes of TALE5 and the next 3 nearest predicted target genes of TALE8 (Figure 3.7). In 
all cases, no significant induction of potential target genes was seen relative to mock-
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transfected controls, providing further evidence for the orthogonality of these TALEs 
relative to human promoter regions. 
Construction and characterization of TALE repressors  
Next, we designed and tested TALE repressor proteins composed of our 
orthogonal TALE DNA binding domains. We generated TALE repressors TALE5R and 
TALE8R, by replacing the VP64 activation domain with the KRAB transcriptional 
repression domain in TALE5 and TALE8 constructs, respectively (Figure 3.8A). The 
ability of these TALEs to repress transcription was tested by co-transfecting them with 
CMV-driven CFP expression vectors containing the cognate TALE binding site located 
on the transcriptional start site of the CMV promoter. TALE repressors efficiently 
repressed CFP expression from 36 – 97 fold compared to off-target TALE controls 
(Figure 3.8). 
Finally, we demonstrated the ability to tightly repress gene expression to near 
background levels by combining the TALE repressors with shRNAs targeting the same 
transcripts. We designed expression constructs that co-express a TALE repressor, an 
shRNA, and the DsRed fluorescent protein from the same promoter. The shRNAs were 
generated in the miR30 context and embedded within the SV40 intron in the DsRED red 
fluorescence protein gene (Stegmeier, Hu et al. 2005; Leisner, Bleris et al. 2010). We 
used the shRNAs, “FF4” and “FF6,” previously designed to target the Firefly Luciferase 
gene as they are commonly used as off-target negative control shRNAs and are reported 
to be orthogonal to endogenous transcripts (Leisner, Bleris et al. 2010). When co-
expressed, the TALE and shRNA combination repressed CFP expression from 740 – 
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4853 fold. Of note, the level repression mediated by the TALE repressors alone was at 
least 5 fold higher than that of the shRNAs expressed alone.  
 
Figure 3.8. Schematics and characterization of TALE repressor-shRNA constructs  
(A) The VP64 activation domain of the TALE activators was replaced with the KRAB 
repression domain and the resulting TALE repressor coding region was cloned into a 
mammalian expression vector together with a self cleaving DsRed:t2A fluorescent 
protein. Synthetic shRNAs are expressed from an intron in the DsRed gene. (B) Reporter 
constructs were generated by cloning a 20 bp TALE target sequence into the transcription 
start site of the CMV promoter. On binding its recognition site in the promoter, the TALE 
represses the constitutive expression of the downstream CFP protein. The reporter 
construct also contains 3 tandem copies of the cognate shRNA recognition sequence in 
the 3’ UTR, which when recognized by the target shRNA leads to degradation of the CFP 
transcript. (C) TALE repressors, TALE5R and TALE8R were combined with shRNAs, 
FF4 and FF6, to repress CFP expression from reporter constructs carrying cognate TALE 
and shRNA recognition sites.  Repressions ranged 6x in the case of shRNA alone to 
approx 4800x in the case of shRNA+TALE repressor combination. 
 
DISCUSSION
Robust synth tic n tw rks would nabl the ability to
sense a wide variety of cellular cues and respond in a
desired fashion to modulate cell behavior, but so far
efforts to design these networks have been limited by
the reli ce on a small set of commonly used gene
regulatory components. A large set of mutually orthog-
onal and modular regulatory components would be a
useful tool for generating such networks. Additionally,
using components for which interference with the host
cell’s machinery is minimized would help to reduce
the chance of unwanted cellular behaviors and system
failures.
TALE transcription factors present a powerful tool
with many potential applications including use as a set
of reliable gene regulatory components for synthetic
gene circuits. However, their utility is limited by degener-
ate binding and the strong potential for off-target effects
(6–8,16,19). While recent work has demonstrated the
ability of designer TALE activators to turn on expression
of desired genes, they have not b en optimized to
minimize off-target effects and likely activate the expres-
sion of genes other than those intended (Supplementary
Methods) (37). Here, we present a novel and general
method to design TALE DNA binding domains with
cognate binding sites orthogonal to a given set of
sequences. We create a set of synthetic TALE activators
and repressors that specifically recognize and act upon
20 bp binding sites that are at least 3 nt mismatches
away from 20 bp sequences contained in all putative
human promoter regions.
Applying our algorithmic approach to find TALEs that
are specific to a given endogenous gene promoter should
be relatively less computationally intensive as the search
space for such TALEs is very small compared to the ex-
ponentially large search space for TALEs orthogonal to
KRAB
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Figure 8. Schematics and characterization of TALE repressor-shRNA constructs. (A) The VP64 activation domain of the TALE activators was
replaced with the KRAB repression domain and the resulting TALE repressor coding region was cloned into a mammalian expression vector
together with a self-cleaving DsRed: 2A fluorescent protein. Synthetic shRNAs were expressed from an intron in the DsRed gene. (B) Reporter
constructs were generated by cloning a 20 bp TALE target sequence into the TSS of the CMV promoter. On binding its recognition site in the
promoter, the TALE represses the constitutive expression of the downstream CFP protein. The reporter construct also contains a single copy of
the cognate shRNA recognition sequence in the 30-UTR, which when recognized by the target shRNA leads to degradation of the CFP transcript.
(C) TALE repressors, TALE5R and TALE8R were combined with shRNAs, FF4 and FF6, to repress CFP expression from reporter constructs
carrying cognate TALE and shRNA recognition sites. Repressions ranged 6! in the case of shRNA alone to "4800! in the case of shRNA+TALE
repressor combin tion.
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DISCUSSION 
Robust synthetic networks would enable the ability to sense a wide variety of 
cellular cues and respond in a desired fashion to modulate cell behavior, but so far efforts 
to design these networks have been limited by the reliance on a small set of commonly 
used gene regulatory components. A large set of mutually orthogonal and modular 
regulatory components would be a useful tool for generating such networks. Additionally, 
using components for which interference with the host cell’s machinery is minimized 
would help to reduce the chance of unwanted cellular behaviors and system failures.   
TALE transcription factors present a powerful tool with many potential 
applications including use as a set of reliable gene regulatory components for synthetic 
gene circuits. However, their utility is limited by degenerate binding and the strong 
potential for off-target effects (Boch, Scholze et al. 2009; Christian, Cermak et al. 2010; 
Morbitzer, Romer et al. 2010; Cermak, Doyle et al. 2011; Miller, Tan et al. 2011). While 
recent work has demonstrated the ability of designer TALE activators to turn on 
expression of desired genes, they have not been optimized to minimize off-target effects 
and likely activate the expression of genes other than those intended (Appendix II) 
(Miller, Tan et al. 2011). Here we present a novel and general method to design TALE 
DNA binding domains with cognate binding sites orthogonal to a given set of sequences. 
We create a set of synthetic TALE activators and repressors that specifically recognize 
and act upon 20 bp binding sites that are at least 3 nucleotide mismatches away from 20 
bp sequences contained in all putative human promoter regions. Applying our algorithmic 
approach to find TALEs that are specific to a given endogenous gene promoter should be 
relatively less computationally intensive as the search space for such TALEs is very 
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small compared to the exponentially large search space for TALEs orthogonal to every 
human promoter. Starting from the set of all possible TALEs that can bind on a given 
promoter region, the heuristics presented here based on reverse triangle inequality 
property of hamming distance can be applied to efficiently screen for TALEs that are 
orthogonal by a given number of base pairs to the rest of the promoters in the genome. 
Our synthetic TALE activators displayed high activation of on-target reporters 
with levels of activation ranging from 10-fold up to 102-fold and are mutually orthogonal. 
These activation levels are similar to other recently reported TALEs designed to function 
in mammalian cells, although we employ a different promoter architecture for TALE 
expression (Miller, Tan et al. 2011). We further characterized the effects of binding site 
mismatches on TALE orthogonality by selecting a single TALE and generating synthetic 
target sites containing between 1 and 7 evenly-distributed mismatches. We found that the 
activation dropped off quickly with an increase in hamming distance – indicating the 
minimum hamming distance for orthogonality of our TALEs recognizing 20 bp falls in 
the range of 3-4 bp.  
We also found that the distribution of mismatches in the binding site affects 
TALE protein activity. Testing 20 bp TALE binding sites with sets of three mismatches 
located at either the 5’ end of the binding site, the 3’ end of the binding site, the middle of 
the binding site, or distributed uniformly throughout the 20-mer, we observed that 3 bp 
mismatches are able to abolish TALE activation when these mutations are introduced at 
either the 5’end or in the middle of TALE binding site (Figure 3.6C). Three consecutive 
mutations introduced at the 3’end of binding site show low off-target activity, about one 
tenth of the full factor, as did the three mutations distributed throughout the binding site. 
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These results suggest that for binding sites with a 3 bp hamming distance the position of 
the mutations should be considered. 
With these results in mind, we compared the set of 180 computationally derived 
orthogonal TALE binding sites to all possible 20-mers in 2000 bp upstream promoter 
regions of the human genome. We found that for genomic sites predicted to be the most 
likely targets for our synthetic TALEs, the longest region with perfect complementarity 
from the 5’end was less than 14 bp long for the majority of our synthetic target sites. 
Furthermore, within this small subset of target sites possessing stretches of sequence 
complementarity, 4 or more mutations are typically found between positions 13 bp – 20 
bp, suggesting that likelihood of a synthetic, orthogonal TALE efficiently binding to a 
genomic promoter site is extremely low (Appendix II). 
To provide further functional evidence for the orthogonality of our synthetic 
TALEs to genomic promoter regions in vivo, we measured mRNA expression levels from 
the 9 most likely target genes following transfection with two representative TALEs. All 
potential target genes displayed no increase in mRNA expression levels relative to 
control, while TALEs designed to specifically target two of those same genes were able 
to induce mRNA expression up to 4.8-fold. While we cannot rule out the activation of 
other potential off-target genes by our TALEs, nor the activation of genes by TALE 
binding to distant enhancer regions outside of the 2kb promoter regions, these results, 
combined with data detailing the effect of target site mismatches and bioinformatics 
approaches, provide evidence supporting the ability of our TALEs to function 
orthogonally to the human promoter regions.  
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Next, we designed TALE repressors by replacing the VP64 activation domain in 
the 3’ constant back region with the KRAB repressor domains. We assayed two synthetic 
TALE repressors made from our orthogonal TALE DNA binding domains, along with 
two synthetic shRNAs, and demonstrate that TALE repressors can provide strong 
transcriptional repression. The TALE-mediated gene repression was more potent than 
that accomplished by the two shRNAs tested using the same assay. Double repression of 
a target gene by the LacI transcriptional repressor and an shRNA was previously reported 
to be capable of tightly controlling transgene expression (Deans, Cantor et al. 2007). We 
show that such regulation is also possible by combining TALE repressors and shRNAs. 
Combined repression reduced the expression level of target protein to near background 
levels. As TALEs are highly programmable compared to LacI this result allows for the 
generation of a set of tightly repressed gene modules and opens the possibility of tightly 
regulating endogenous target genes. TALE repressors have been shown to be a powerful 
tool for regulating the expression of genes in yeast and plants (Blount, Weenink et al. 
2012; Mahfouz, Li et al. 2012). Our results demonstrate that TALE repressors can work 
efficiently in mammalian cells as well. 
Finally, it is worth noting that our proposed algorithm can easily accommodate 
additional constraints. For example it can be readily adapted to identify orthogonal 
sequences of different lengths and for different sequences including the genomes of other 
organisms. It could also be modified to find TALEs that have larger hamming distances 
to especially critical promoter regions. In addition to addressing the problem of 
generating synthetic circuit components with minimal effects on endogenous genes, the 
methods that we employ to generate TALEs are general and can be applied to any system 
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requiring specific DNA binding domains. Other potential applications of orthogonal 
TALE DNA binding domains include TALE nucleases, TALE recombinases or TALE-
based DNA methylases, and TALE transcriptional activators and repressors that 
specifically target endogenous genes. The computational approach and transcription 
factors presented here provide important tools and methods for the precise engineering of 
biological systems.  
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ABSTRACT 
The ‘re-targeting’ of a cancer patient’s T-cells to kill tumor cells using chimeric 
antigen receptors (CARs) is a promising new therapy showing recent clinical success. 
However, currently these therapies target cancer cells based on single cancer-specific 
biomarkers, limiting the number of cancers that they can treat and leading to off-target 
effects. To instead target cancers based on multiple markers we engineered a conceptual 
platform to perform receptor-level ‘logic’ in T-cells, designing novel CARs comprised of 
native co-stimulatory and co-inhibitory signaling domains. We first report the successful 
engineering of a CAR-based OR-gate for which T-cell activation occurs in response to 
target cells expressing tumor antigens CD19, CD20, or both CD19 and CD20. The 
system consists of two conventional CARs - one that responds to CD19 and one that 
responds to CD20. We demonstrate the efficacy of this system in the Jurkat T-cell line 
based on T-cell activation marker staining and cytokine release assays. We also 
demonstrate progress toward a NOT gate system that can activate T-cell signaling in 
response to CD19 but inhibit this signaling by the presence of CD20 on the same cells. 
We generated putative inhibitory CARs using the cytoplasmic domains of the CD45 and 
CD300a co-inhibitory receptors. We demonstrate successful engagement by CD20 these 
receptors in Jurkat cells but no effect on surface staining or specific target cell lysis. 
However, in follow-up assays in primary T-cells for the CD20-CD8hinge-CD300a 
receptor we observed a mild, but-significant inhibition of specific cell lysis T-cells. The 
new targeting specificities enabled by our receptor logic systems could be used to expand 
the number of cancers treatable by these targeted T-cell therapies and greatly minimize 
off-tumor effects. 
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INTRODUCTION 
Chimeric antigen receptors (CARs) are artificial T-cell receptors that allow the re-
targeting of cytotoxic T-cell activity toward cells expressing a defined surface antigen. 
CAR-based immunotherapies have recently emerged as promising treatments for cancer 
and have shown success in trials for leukemias and metastatic melanoma. In one recent 
trial treating chronic lymphocyte leukemia over 65% of patients displayed an ongoing 
complete response to therapy after 10 months (Porter, Kalos et al. 2011; Porter, Levine et 
al. 2011). 
As stated in their name, CARs are chimeric molecules consisting of T-cell 
Receptor and co-receptor cytoplasmic signaling domains, a transmembrane domain, an 
extracellular linker domain, and finally a targeting domain, most often an scFv. The 
targeting domain is modular, and by using scFvs for different antigens researchers can 
easily change the specificity of the CAR and the resulting T-cell targeting. The use of an 
an scFv for targeting instead of a normal T-cell Receptor (TCR) also allows the CAR to 
be used in patients without the need for MHC-matching as in the case of other native 
TCR-based immunotherapies (Sadelain, Riviere et al. 2003). 
The engineering of CARs has undergone three generations of development each 
including modifications to the cytoplasmic portion of the receptors. The first generation 
contained only the CD3 zeta chain from the TCR in the cytoplasm. While these receptors 
were capable of specifically activating T-cells in response to antigen, the cells did not 
survive and expand enough in mice or human patients to be effective. For the 2nd 
generation of CARs the CD28 co-receptor was added to the cytoplasmic portion of the 
protein. CD28 signaling is known to induce the cytokine IL-2 leading to prolonged cell-
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survival. These receptors had more efficacy in vivo, but in the meantime researchers 
found that adding yet another domain, the 4-1BB domain known to enhance T-cell 
expansion, in combination with the CD28 domain led to an even better in vivo response 
(Porter, Levine et al. 2011).  
While individual CARs have been developed to target many different tumor-
associated antigens, currently each therapy only uses one receptor and targets tumors via 
a single tumor-specific antigen. This single antigen targeting is limiting in many cases as 
it is often difficult to find such a specific antigen for a given cancer. Even in current 
therapies many “on-target off-tumor” effects are seen which can lead to sometimes-lethal 
levels of toxicity (Lamers, Sleijfer et al. 2006; Brentjens, Riviere et al. 2011; Kalos, 
Levine et al. 2011; Kochenderfer, Dudley et al. 2012). 
We look to reduce these “on-target off-tumor effects” and increase the number of 
cancers targetable by creating T-cell logic gates that target tumors based on the presence 
or absence of multiple antigens. Natural T-cell signaling is a process that involves many 
co-stimulatory and inhibitory receptors and so is naturally inclined toward receptor-based 
logical engineering. One very recent example of this has been demonstrated in mice by 
Kloss et al. who created an AND gate using a novel pair of CARs. Their system consisted 
of a 1st GEN CAR with a weakened scFv domain and a novel co-stimulatory CAR with a 
full strength antibody targeting a second antigen fused to the CD28 and 4-1BB signaling 
domains. The system showed efficacy in vitro and in mouse studies (Kloss, Condomines 
et al. 2012). 
 We first sought to engineer a CAR-based OR-gate that would respond to two 
individual antigens and both antigens together. To engineer this system we used a simple 
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design of expressing two 2nd GEN CARs for two different antigens in cells and analyzed 
the cells’ behavior in co-incubation assays. Interestingly while the OR-gate system does 
not add greater specificity to T-cell therapy, recent work by Landsberg et al. on clinical 
resistance to T-cell therapy pointed to an OR-gate system as a possible strategy to obviate 
resistance. They found that in response to adoptive immunotherapy targeting a single 
melanoma antigen, the melanoma cells began to differentiate via a cell defined signaling 
pathway and so as to longer express the targeted gene. They posit that targeting of the 
first antigen and a second antigen expected to be on the differentiated cells could stop this 
differentiation process and eliminate differentiated cells (Landsberg, Kohlmeyer et al. 
2012). We also sought to construct an A AND NOT B targeting system. To create this 
gate we combined a conventional CAR for positive signaling (antigen A) and generated 
putative inhibitory CARs containing fragments of known inhibitory co-receptors. For 
these inhibitory CARs we used the cytoplasmic domains of CD45 and CD300a. Both of 
these molecules contain immunoreceptor tyrosine-based inhibition motifs (ITIMs) known 
to recruit phosphatases such as SHP-1 and SHP-2 that inhibit T-cell signaling 
(Hermiston, Zikherman et al. 2009; DeBell, Simhadri et al. 2012). As the extracellular 
spacings of many inhibitory receptors are thought to be important for effects on TCR 
signaling we made different versions of these receptors with different extracellular linker 
domains (James and Vale 2012). 
 
RESULTS AND DISCUSSION 
 We first set out to generate a CAR-based OR-gate that would activate T-cells 
when faced with target cells expressing CD19, CD20, or CD19+CD20. We designed the 
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system to be comprised of two 2nd generation CARs each targeting either CD19 or CD20. 
The receptors are comprised of the CD3-zeta chain and the CD28 co-stimulatory domain 
in the cytoplasm, the CD28 transmembrane domain, and the Igg4 linker domain and an 
scFv targeting either CD19 or CD20 on the cell surface (Figure 4.1A).  
 
Figure 4.1 OR-Gate design and expression characterization 
(A)The 2-CAR OR-Gate system is expected to activate T-cell signaling in response to 
target H9 cells that are CD19+, CD20+, OR CD19+CD20+. (B) Median Fc-APC staining 
for Jurkat cells, to report on CAR expression. Fc binds to the Igg4 linker domain thus 
labeling both CARs. Of note for the OR-Gate it cannot be determined the ratio of both 
CARs only the total Fc-APC staining level. (C) Staining of the antigens on the target cells 
by CD19-APC and CD20-PE antibodies. 
 
We generated lentivirus encoding these receptors and created stable Jurkat cell 
lines encoding single CARs and the two CAR OR-gate system. We then verified 
expression of the CARs on the cell surface by staining with a dye-conjugated Fc domain 
and flow cytometry and sorted for stable cell lines based on these markers (Figure 4.1B). 
To test the system we generated three H9 target cell lines expressing CD19, CD20, or 
CD19+CD20. As H9 cells don’t naturally express either CD19 or CD20 we crated these 
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lines by transducing them with virus encoding these antigens. We verified surface 
expression of these molecules and sorted for antigen positive lines again by antibody 
staining for these markers and flow cytometry (Figure 4.1C). These cells were used as 
target cells in all co-incubation assays in this chapter. 
 
Figure 4.2 OR-Gate T-cell activation marker staining  
(A) CD69-PE staining of single CAR and OR-Gate 24hr co-incubations with H9 Target 
cells +/- std. dev. (n=3). (B) CD154-Cy710 staining of single CAR and OR-Gate 24hr co-
incubations with H9 Target cells +/- std. dev. (n=3). (C) CD62L--APC staining of single 
CAR and OR-Gate 24hr co-incubations with H9 Target cells +/- std. dev. (n=3). 
 
Next, we performed effector T-cell and target cell co-incubation assays to test for 
antigen specific activation. To distinguish between H9 and Jurkat cell lines, before the 
assay we stained all H9 target cell lines with the CellTracker dye. We then co-incubated 
Jurkat parental (JP), single 1st GEN CAR, single 2nd GEN CAR, and OR-gate cell lines 
with each of the four stained H9 target cell lines (H9P, H9+CD19, H9+CD20 and 
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H9+CD19+CD20) for 24hrs. Following this co-incubation we stained the cells for T-cell 
activation markers: CD69, CD62L and CD154, and analyzed expression of these markers 
by flow cytometry (Figure 4.2A,B,C).  Markers CD69 and CD154 are known to be up-
regualted by T-cell activation while CD62L is expected to be down-regulated. We found 
that as expected single 1st GEN and 2nd GEN CARs specifically and efficiently activated 
markers CD69 and CD154 and down-regulated CD62L in response to target cells. The 
OR-gate effector cells also functioned as desired, activating CD69 and CD154 and down-
regulating CD62L in response to target cells with single antigens or both antigens.  
 
Figure 4.3 OR-Gate IL-2 ELISA assay  
IL-2 production of single CAR and OR-Gate 48hr co-incubations with H9 Target cells 
+/- std. dev. (n=3). 
 
We then tested these same lines for another indicator of T-cell activation, IL-2 
production. IL-2 is an important survival signal produced by activated T-cells to assist in 
their expansion. Co-stimulatory signaling by CD28 is expected to enhance its production 
and addition of the CD28 to the 2nd GEN CARs is largely for this reason. We again 
performed co-incubation assays of the target cell lines with the different single CAR and 
OR-gate effector lines. Following 48hr co-incubuation we performed an ELISA for IL-2 
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activity. We found that, once again, the single CAR and OR-gate effector cell lines 
showed signs of being efficiently and specifically activated, producing IL-2 only when 
co-incubated by the correct target cells. Surprisingly the single 1st GEN CARs produced 
the highest amounts of IL-2 even though they did not contain the CD28 co-stimulatory 
domain. OR-gate and CD20 2nd GEN CAR IL-2 inductions were somewhat lower but still 
significant and specific (Figure 4.3). Interestingly, the IL-2 production and action marker 
staining did not correlate with the expression levels of the receptors as observed in Figure 
4.1A,B,C suggesting that the 1st GEN receptors could simply be more efficient at 
stimulating T-cell activation. 
 
Figure 4.4 NOT-Gate design and receptor variants  
(A)The 2-CAR NOT-Gate system is expected to activate T-cell signaling in response to 
target H9 cells that are CD19+ AND NOT CD20+. (B) The 5 NOT-gate CAR variants 
are listed combining different linker domains, transmembrane domains (Tm), and 
inhibitory cytoplasmic domains. 
 
Next, we sought to build inhibitory CARs using the CD45 and CD300a inhibitory 
signaling domains. As the extracellular dimensions of natural inhibitory signaling 
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receptors relative to TCR complexes and transmembrane domains (for signaling) have 
been shown to be important parameters for natural T-cell signaling and inhibition we 
created inhibitory CARs with differing extracellular linkers and transmembrane domains 
(Cahir McFarland and Thomas 1995; Choudhuri, Wiseman et al. 2005). We varied the 
receptor heights by using extracellular linker domains of different lengths. We generated 
DNA constructs encoding a set of putative inhibitory CARs targeting CD20 and 
additionally labeled with a co-translationally expressed TagBFP fluorescent reporter as 
outlined in Figure 4.4A. We then made lentivirus and Jurkat cell lines encoding these 
receptors alone, or with a conventional CD19 2nd GEN CAR that is tagged with a co-
translationally expressed EGFRt surface marker that can be stained by Erbitux antibody 
(Figure 4.4B). We confirmed expression of these receptors and selected positive lines by 
staining with Protein-L, a protein that is expected to bind all scFv fragments.  
We then performed co-incubation assays using these cells expressing these and 
the four H9 target target cell lines. Once again we labeled the H9 target cells with 
CellTracker dye prior to co-incubation so that we could isolate the Jurkat effector cells. 
After 24hrs we stained the cells for T-cell activation markers CD25, CD69, CD154, and 
CD62L (Figure 4.5A,B,C; Figure 4.6A,B,C). We found that while the conventional 
CD19-CAR was capable of activating and repressing the expected T-cell activation 
markers, the inhibitory receptors, did not inhibit these markers as hoped for the dual+ 
target cell lines. We did find however, that some of the CD20 inhibitory receptors were 
capable of mildly inducing some of the markers suggesting target receptor engagement. It 
is unclear what this mild activation could mean for the T-cell signaling process.  
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Figure 4.5 NOT-Gate T-cell activation marker staining for inhibitory receptors 1 
and 2  
(A) CD69-PE staining of single CAR and NOT-Gate 24hr co-incubations with H9 Target 
cells (n=1). (B) CD154-Cy710 staining of single CAR and NOT-Gate 24hr co-
incubations with H9 Target cells (n=1). (C) CD62L--APC staining of single CAR and 
NOT-Gate 24hr co-incubations with H9 Target cells (n=1). 
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Figure 4.6 NOT-Gate T-cell activation marker staining for inhibitory receptors 3,4 
and 5   
(A) CD69-PE staining of single CAR and NOT-Gate 24hr co-incubations with H9 Target 
cells +/- std. dev. (n=3). (B) CD154-Cy710 staining of single CAR and NOT-Gate 24hr 
co-incubations with H9 Target cells +/- std. dev. (n=3). (C) CD62L--APC staining of 
single CAR and NOT-Gate 24hr co-incubations with H9 Target cells +/- std. dev. (n=3). 
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As an additional assay we sought to directly look at T-cell mediated target cell 
lysis. While Jurkat cells are CD4+ T-cells and are conventionally expected to be ‘helper’ 
cells as opposed to conventional CD8+ cytotoxic T-cells, researchers have shown CD4+ 
cells are also capable of targeted cell lysis. We performed specific lysis co-incubation 
assays using the NOT gate cell lines (Figure 4.7A,B,C,D,E,F). We found the expected 
levels of lysis for the conventional CD19-CAR, however no effect in the NOT gate lines, 
we saw no inhibition of the specific lysis for the CD19+,CD20+ dual positive line 
compared to the CD19+ line. Unfortunately, these results suggest the inhibitory receptors 
are non-functional in the Jurkat T-cell line. 
 As a last ditch effort we transduced harvested CD8+ T-cells with viruses encoding 
the conventional CD19 CAR and one of the inhibitory CARs, the CD20scFv-Igg4-
CD300a inhibitory CAR. We sorted the cells for TagBFP expression and expanded them. 
We then performed specific lysis assays using these cells (Figure 4.8A,B).  We now saw  
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Figure 4.7 Specific lysis assays for Jurkat NOT-Gate cell lines 
(A) Specific lysis for the control CD19-CAR alone assayed after 4hrs+/- std. dev. (n=3). 
(B) Specific lysis for the control CD19-CAR,CD20-Inhib1 NOT-gate assayed after 
4hrs+/- std. dev. (n=3). (C) Specific lysis for the control CD19-CAR,CD20-Inhib2 NOT-
gate assayed after 4hrs +/- std. dev. (n=3). (D) Specific lysis for the control CD19-
CAR,CD20-Inhib3 NOT-gate assayed after 4hrs+/- std. dev. (n=3). (E) Specific lysis for 
the control CD19-CAR,CD20-Inhib4 NOT-gate assayed after 4hrs. +/- std. dev (n=3). (F) 
Specific lysis for the control CD19-CAR,CD20-Inhib5 NOT-gate assayed after 4hrs +/- 
std. dev. (n=3). 
 
a mild but significant inhibition in killing of the CD19+, CD20+ cell line compared to the 
CD19+ line for the CD20scFv-Igg4-CD300a NOT gate system. The CD19-CAR-only 
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system killed both target lines efficiently further suggesting the observed difference with 
the CD300a inhibitory receptor is a result of the inhibitory receptor. As this difference is  
 
Figure 4.8 Specific lysis assays for Primary NOT-Gate cell lines  
(A) Specific lysis for the control CD19-CAR alone assayed after 4hrs +/- std. dev. in 
primary T-cells (n=3). (B) Specific lysis for the control CD19-CAR,CD20-Inhib2 NOT-
gate assayed after 4hrs +/- std. dev. in primary T-cells (n=3). 
 
so mild it is unlikely to lead to any significant physiological effect in its current stage 
however, it is possible that this system could be improved to show more robust inhibitory 
behavior. One potential approach is to vary the ratio of the positive and negative 
receptors. Another potential approach would be to add more of the known ITIM domains 
in the CD300a receptor to the cytoplasmic domain to try to increase this inhibition on a 
per-receptor basis. Finally, the apparent success with this inhibitory receptor that showed 
no effect in Jurkat cells suggests that Jurkat cell assays do not reflect the real activities of 
the primary cells and that the other receptors might be more effective in the primary cells. 
 
CONCLUSION 
The targeting of cancers based on multiple antigens would grant much-needed 
additional specificity to cancer immunotherapies. We demonstrate here a functional 
CAR-based OR-gate in Jurkat T-cells. OR-gate cells show antigen targeted expression of 
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both T-cell activation surface markers and IL-2 cytokine production in an OR-gate 
manner. The next steps will be to show the efficacy of these cells in primary T-cells, and 
in tumor-targeting mouse studies. As suggested by Landsberg et al. this OR-Gate system 
could be used to block cancer resistance to immunotherapy. We next sought to create an 
A AND NOT B system, and generated several putative NOT receptors based on the 
CD45 and CD300a inhibitory receptors. All receptors were expressed and appeared to 
engage target antigen, however they had no effect on T-cell signaling in Jurkat cells. We 
then tried one of the CD300a recpetors in primary T-cells and found that the receptor had 
a mild effect on specific cell lysis. While not useful in its current state, this inhibitory 
receptor could be modified to increase its inhibitory activities either through higher 
relative expression to the positive signaling CAR or an increase in the ITIM domains on 
the receptor. 
 
MATERIALS AND METHODS 
DNA assembly and purification 
To generate CAR constructs we synthesized codon-optimized DNAs encoding the 
CD19 and CD20 scFvs, the Igg4 linker domain, the CD3zeta chain, the CD28-
cytoplasmic domain, and the CD300a cytoplasmic domain. We PCR’d the CD45 
cytoplasmic domain from a cDNA purchased from Origene technologies (Rockville, 
MD) and the CD8 linker domain from a cDNA plasmid purchased from Origene 
technologies (Rockville, MD). We created the Igg4-hinge and CD8-hinge domains by 
PCR from the longer linker forms. Using these parts we then assembled the CAR 
expression constructs using Gibson assembly, expressing them from the EF1alpha 
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promoter in the epHIV7 lentiviral vector. Plasmids were grown up in E. coli and Maxi-
prepped using Endotoxin Free Kits (Qiagen; Hilden, Germany).  
 
Virus production and transduction  
We plated HEK293T in 10cm2 plates 24hrs prior to Calphos transfection with the 
expression construct and 3 packaging plasmids using the CalPhos Transfection Kit 
(Clontech Laboratories, Inc.). 18hrs following transfection media was changed adding 
5M Sodium Butyrate. Viral supernatants were then harvested every 24hrs for 3 days. 
These harvests were centrifuged and filtered to remove cell debris, and then concentrated 
with PEG overnight. The following day these harvests were further concentrated via 
ultracentrifugation, and frozen at -80C° until further use. For transduction we thawed 
virus and added it to 5*10^4 cells with 4ug/ml polybrene.  
 
Cell culture and maintenance 
We cultured Jurkat T-cells clone E6-1 (ATCC CAT# TIB-152) and their 
derivatives and H9 Cells (ATCC CAT# HTB-176) and their derivatives in suspension in 
RPMI media supplemented with 10% FBS and 1% PenStrep (Life Technologies; 
Carlsbad, CA). For cell maintenance passaged cells every 3-5 days by diluting them 1:10. 
On the day of harvest we isolated T-lymphocytes from whole cord blood by standard 
Phycol preparation. We then stimulated and isolated CD8+ T-cells using the CD8+ T-cell 
isolation Kit from Miltenyi Biotec (Cambridge, MA). We expanded the cells by 
stimulating them with IL-15 and IL-12 cytokines every 2 days. 
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Co-incubation and surface staining assay 
For surface staining assays, we co-incubated 5*10^5 Jurkat effector cells with an 
equal number of an H9 target line in 1 mL of supplemented RPMI media in 24well plates 
for 24hrs.  Following co-incbation we moved cells to 96-well plates and washed them 
with PBS 2x. We then stained them with the antibodies at the appropriate dilutions for 30 
minutes on ice. Finally, we washed them again with PBS 2x and assayed via flow 
cytometry. Antibodies and there vendors are listed CD19-APC (Clone LT19, Miltenyi 
Biotec), CD20-PE (Clone LT20, Miltenyi Biotec), CD62L-APC (Clone DREG-56 
eBioscience), CD69 (Clone FN50, BioLegend), CD154 (Clone 24-31 eBioscience) 
Human IgG Fc-APC ([No clone] eBioscience). 
 
Co-incubation and ELISA assay 
We co-incubated 5*10^5 Jurkat effector cells with an equal number of an H9 
target line in 1mL of supplemented RPMI media in 24well plates for 48hrs. For the 
ELISA we isolated the supernatant from the wells and processed them using the IL-2 
ELISAMAX Kit from BioLegend (San Diego, CA) precisely following the supplied 
protocol.  
 
Co-incubation and specific cell lysis assay  
Prior to co-incubation we stained H9 Parental cells with CFSE dye (Life 
Technologies; Carlsbad, CA), and potential target cells with CMTMR (Life 
Technologies; Carlsbad, CA). We then co-incubated 10^4 H9-Parenal cells and 10^4 of a 
given target cell line with different ratios of each effector T-cell line being tested in 100ul 
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of RPMI media in a 96-well plate. (E:T ratios - 30:1, 10:1, 3.3:1, and 1.1:1) Following a 
4hr incubation we analyzed samples by flow cytometry and for a given effector line 
determined the ratio of CMTMR target cells: CFSE H9 Parental cells as a ratio of these 
cells in MOCK co-incubations to determine specific lysis. 
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Chapter V !
CONCLUSION 
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The future of mammalian synthetic gene networks appears to be very bright. The 
lists of possible circuit inputs and circuit functionalities are ever-expanding, and recent 
advances to creating computational frameworks and genome engineering tools will pave 
the way for building even more sophisticated circuits. In the preceding chapters we 
described our three primary contributions to the engineering of mammalian circuits 
including work on a zinc finger computing framework, orthogonal TALE transcriptional 
regulators, and chimeric antigen receptor-based T-cell targeting. Here are some 
concluding thoughts on these projects. 
The zinc finger systems we developed in Chapter II provide a large set of 
transcriptional circuit components with varying activities and approaches to building 
logic circuits. The method of increasing transcription factor (TF) regulator activity 
through transcription factor dimerization was novel for artificial regulators and perhaps 
could be applied to other TFs including those controlling endogenous gene expression. 
The split intein-based AND and NAND gates were also novel and provided a robust 
means of performing AND-logic. However, the systems are not very scalable as every 
new AND gate requires a new intein pair. Every 2-hybrid-based AND gate similarly 
requires two unique interaction domains per AND gate, however more interaction 
domains exist than split intein pairs. One potential solution to creating a more scalable 
system could be to split transcription activation and repression domains such that the 
halves have no activity on their own and must be brought together by DNA binding 
domains on the DNA. In such a system AND gates would only require new DNA binding 
domains for each successive AND gate. We also report a new protein induced intein that 
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essentially represents a 3-input AND gate, and could be of future biotechnological use in 
Appendix III. 
The orthogonal TALE transcription factors that we created are ideal circuit 
components as they are not expected to bind to any human promoter regions. In addition 
to the evidence that we provided using qRT-PCR analysis of expected off-target genes, 
and assays using synthetic off-target promoters, it will be important for these factors to be 
tested on a genome-wide scale. Recent studies examining off-target effects of zinc finger 
nucleases suggest that off-target binding by DNA binding domains might not be as 
predictable as anticipated.  
The CAR-based OR-Gate that we designed functioned very well in Jurkat cell 
line. The next steps will be to try it in primary T-cells and then in an animal model. It 
would also be interesting apply the system to target a differentiated tumor state, and thus 
block resistance to therapy. It would also be interesting to compare the activity and 
efficacy of the 2-CAR OR-gate with that of two different populations of T-cells, each 
containing only one of the 2-receptors. Such a therapy might be easier to implement than 
one requiring two receptors expressed on the same cell population, however it may have 
better functionality. The final result with the CD20-CD8hinge-CD300a CAR-based NOT 
system was very mildly positive. This result perhaps could be improved by increasing the 
ratio of negative to positive receptor in the cells, or by increasing the number of ITIMs on 
the cytoplasmic domain. If these changes don’t lead to an increase in inhibition, there are 
also many other inhibitory co-receptors available to try. In particular the KIR and LIR 
NK cell receptors are promising as their engagement with target cells leads directly to 
suppression of cytotoxic signaling. It will also be interesting to see if it is possible to 
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create novel CARs to suppress immune responses using tolerogenic receptors to combat 
auto-immune diseases.  
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Supplemental Information: A tunable zinc finger-based framework for Boolean 
logic computation in mammalian cells 
Jason J. Lohmueller1,2, Thomas Z. Armel1 & Pamela A. Silver1,2 
1 Department of Systems Biology, Harvard Medical School, Boston, Massachusetts 02115, 
USA 
2 Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, 
Massachusetts 02115, USA 
 
 
 
 
 
Reproduced from Lohmueller JJ, Armel TZ, Silver PA. (2012). A tunable zinc finger-
based framework for Boolean logic computation in mammalian cells. Nucleic Acids Res. 
Jun;40(11):5180-7. Copyright (2012), with permission from Oxford University Press. 
 
Jason J. Lohmueller contributed all data for figures in collaboration with Thomas Z. 
Armel. 
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Inventory of Supplemental Information 
Figure S1.1 relates to Figure 2.1, showing flow cytometry gating strategy 
Figure S1.2 relates to Figure 2.1B, showing fluorescence microscopy of 
BCR_ABL-1 activators 
Figure S1.3 relates to Figure 2.1C, showing fluorescence microscopy of all ZF 
activators 
Figure S1.4 relates to Figure 2.1C, showing ZF activator orthogonality flow 
cytometry data 
Figure S1.5 relates to Figure 2.1C, showing ZF activator orthogonality 
fluorescence microscopy 
Figure S1.6 relates to Figure 2.2B, showing fluorescence microscopy of 
BCR_ABL-1 repressors 
Figure S1.7 relates to Figure 2.2C, showing Fluorescence microscopy of all ZF 
repressors 
Figure S1.8 relates to Figure 2.1C, showing ZF repressor orthogonality flow 
cytometry data 
Figure S1.9 relates to Figure 2.1C, showing ZF repressor orthogonality 
fluorescence microscopy 
Figure S1.10 relates to Figure 2.3A, showing OR gate flow cytometry data  
Figure S1.11 relates to Figure 2.3A, showing OR gate fluorescence microscopy 
Figure S1.12 relates to Figure 2.3B, showing NOR gate flow cytometry data 
Figure S1.13 relates to Figure 2.3B, showing NOR gate fluorescence microscopy 
Figure S1.14 relates to Figure 2.4D, showing ZF-TF split site fluorescence 
microscopy 
Figure S1.15 relates to Figure 2.4, showing ZF-TF split site model structure 
Figure S1.16 relates to Figure 2.5A, showing AND gate fluorescence microscopy 
Figure S1.17 relates to Figure 2.5B, showing NAND gate fluorescence 
microscopy 
 
Table S1.1 relates to Figures 2.1-2.5, showing transfected plasmids 
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Figure S1.1 Example of raw data and overview of flow cytometry gating strategy 
CFP vs. mCH scatter plot and histograms for BCR_ABL-1:GCN4 (blue dots and traces) 
and No ZF control (red dots and traces) co-transfection experiments with the 6x-BCR 
CFP reporter. The scatter plot shows live cells gated by mCH and CFP expression. The 
histograms show mCH+ and mCH+/CFP+ gating. Numbers represent the frequency of 
the cells that are mCH+ of total live cells (center) and cells that are CFP+ of total live 
mCH+ cells (right). mCH+ and CFP+ gates were determined by gating on a no DNA 
transfection control sample. 
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A 
 
 
 
B 
 
Figure S1.2 Fluorescence microscopy of BCR_ABL-1 activators  
(A) Fluorescence microscopy images of BCR_ABL-1 activators driving cyan fluorescent 
protein (CFP) reporter expression. Each column shows U-2 OS cells transfected with a 
BCR_ABL-1 activator fused to either no leucine zipper (LZ), a c-Jun LZ (Jun), or a 
GCN4 LZ (GCN4). Each activator was co-transfected with a CFP reporter plasmid 
containing either 2, 4, or 6 copies of the 9bp BCR_ABL target site driving expression of 
2x copies of CFP. (B) Fluorescence microscopy images of mCherry expression for the 
same cells as in A. As each activator construct was tagged with a t2A:mCherry 
fluorescent protein, these images mark transfected cells and confirm activator expression. 
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A 
 
B 
 
Figure S1.3 Fluorescence microscopy of all ZF-based activators 
(A) Fluorescence microscopy images of all synthetic ZF-based activators driving CFP 
reporter expression. Cells were transfected with one of 5 ZF-based activators 
(BCR_ABL-1; BCR_ABL-2; erbB2; HIV-1; HIV-2) fused to either no leucine zipper 
(No LZ), a c-Jun LZ (Jun), or a GCN4 LZ (GCN4). Each activator was co-transfected 
with a CFP reporter plasmid containing 6 copies of the corresponding 9bp target site 
driving expression of 2x copies of CFP. (B) Fluorescence microscopy images of mCherry 
expression for the same cells as in A. confirming activator expression and marking 
transfected cells. 
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Figure S1.4 Flow cytometry data demonstrating ZF activator orthogonality  
Flow cytometry data of cells transfected with one of 5 ZF-based activators (BCR_ABL-1; 
BCR_ABL-2; erbB2; HIV-1; HIV-2) fused to the GCN4 leucine zipper. Each activator 
was co-transfected with a CFP reporter plasmid containing 6 copies of the 9bp target site 
for either a BCR_ABL ZF, an erbB2 ZF, or an HIV ZF driving expression of 2x copies of 
CFP. Fold activations are calculated over total CFP values for co-transfections with each 
individual ZF reporter and an off-target control. All error bars indicate the standard 
deviation with n=3. 
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A 
 
B 
 
Figure S1.5 Fluorescence microscopy demonstrating the mutual orthogonality of 
ZF-based activators.  
(A) Fluorescence microscopy images of synthetic ZF-based activators driving CFP 
reporter expression as described in Figure S1.3. (B) Fluorescence microscopy images of 
mCherry expression for the same cells as in A. confirming activator expression and 
marking transfected cells. 
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Figure S1.6 Fluorescence microscopy of BCR_ABL-1 repressors  
(A) Fluorescence microscopy images of BCR_ABL-1-mediated CFP reporter repression. 
Cells were transfected with a BCR_ABL-1 repressor fused to either no leucine zipper (no 
LZ), a c-Jun LZ (Jun), or a GCN4 LZ (GCN4). Each repressor was co-transfected with a 
constitutively active CFP reporter plasmid containing either 2, 4, or 6 copies of the 9bp 
BCR_ABL target site inserted into the transcriptional start site of the CMV promoter 
driving expression of 2x copies of CFP. (B) Fluorescence microscopy images of mCherry 
expression for the same cells as in A. confirming repressor expression and marking 
transfected cells. 
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A 
 
B  
 
Figure S1.7 Fluorescence microscopy of all ZF-based repressors  
(A) Fluorescence microscopy images of synthetic ZF repressors mediating CFP reporter 
repression. Cells were transfected with one of 5 ZF-based repressors (BCR_ABL-1; 
BCR_ABL-2; erbB2; HIV-1; HIV-2) fused to either no leucine zipper (no LZ), a c-Jun 
LZ (Jun), or a GCN4 LZ (GCN4). Each repressor was co-transfected with a CFP reporter 
plasmid containing 6 copies of the corresponding 9bp target site driving expression of 2x 
copies of CFP. The “no ZF” images shown for ZF pairs BCR_ABL-1 and BCR_ABL-2 
and HIV-1 and HIV-2 are identical as each pair uses the same reporter construct. (B) 
Fluorescence microscopy images of mCherry expression for the same cells as in A. 
confirming repressor expression and marking transfected cells. 
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Figure S1.8 Flow cytometry data demonstrating ZF repressor orthogonality 
Flow cytometry data of cells transfected with one of 5 ZF-based repressors (BCR_ABL-
1; BCR_ABL-2; erbB2; HIV-1; HIV-2) fused to the GCN4 leucine zipper. Each 
repressor was co-transfected with a CFP reporter plasmid containing a repressible 
promoter with 6 copies of the 9bp target site for either a BCR_ABL ZF, an erbB2 ZF, or 
an HIV ZF driving expression of 2x copies of CFP. Fold activations are calculated over 
total CFP values for co-transfections with each individual ZF reporter and an off-target 
control. All error bars indicate the standard deviation with n=3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
115 
 
A 
 
B 
 
Figure S1.9 Fluorescence microscopy demonstrating the mutual orthogonality of 
ZF-based repressors 
(A) Fluorescence microscopy images of synthetic ZF-based repressors driving CFP 
reporter expression as described in Figure S1.7. (B) Fluorescence microscopy images of 
mCherry expression for the same cells as in A. confirming repressor expression and 
marking transfected cells. 
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Figure S1.10 Characterization of ZF-based Boolean OR gates 
OR gate reporter constructs were engineered with various numbers and combinations of 
ZF activator target sites. Each OR gate reporter construct was co-transfected with either a 
single corresponding ZF-activator alone, or with both activators present together. Input A 
represents the BCR_ABL-1:GCN4 activator, and input B represents the erbB2:Jun 
activator. Columns marked with 0 indicate that the corresponding input was not present 
in that experiment and was replaced bu the off-target ZF control (Zif268-t2a-mCherry). 
Columns marked with 1 indicate that the corresponding input was present in that 
experiment. All error bars indicate the standard deviation with n=3. The fold CFP 
expression was determined via flow cytometry analysis of mCherry positive cells and 
calculated as the ratio of total CFP for cells transfected with ZF-activator inputs to cells 
transfected with the off-target control. 
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A 
 
B 
 
Figure S1.11 Fluorescence microscopy of ZF-based Boolean OR gates  
(A) Fluorescence microscopy images of OR gate systems described in Figure S1.9. (B) 
Fluorescence microscopy images of mCherry expression for the same cells as in a. 
confirming input and off-target control expression and marking transfected cells. 
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Figure S1.12 Characterization of ZF-based Boolean NOR gates  
NOR gate reporter constructs were engineered with various numbers and combinations of 
ZF repressor target sites inserted into the transcriptional start site for 2x CFP. Each NOR 
gate reporter construct was co-transfected with either a single corresponding ZF-repressor 
alone, or with both repressors together. Input A represents the BCR_ABL-1:GCN4 
repressor, and input B represents the erbB2:Jun repressor. Columns marked with 0 
indicate that the corresponding input was not present in that experiment, and was 
replaced with the off-target ZF control (Zif268-t2a-mCherry). Columns marked with 1 
indicate that the corresponding input was present in that experiment. All error bars 
indicate the standard deviation with n=3. The fold CFP expression was determined via 
flow cytometry analysis of mCherry positive cells and calculated as the ratio of total CFP 
for cells transfected with ZF-repressor inputs to cells transfected with a non-DNA 
binding control. 
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A 
 
B 
 
Figure S1.13 Fluorescence microscopy of ZF-based Boolean NOR gates 
(A) Fluorescence microscopy images of synthetic NOR gate systems described in Figure 
S1.11. (B) Fluorescence microscopy images of mCherry expression for the same cells as 
in A. confirming input and off-target control expression and marking transfected cells. 
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Figure S1.14 Fluorescence microscopy of ZF-TF split sites  
Fluorescence microscopy images of the split-intein ZF activator split site assay described 
in Figure S1.13.  Images are shown for the Split pairs and the C-fragment alone. Split 
sites that lead to a >3 fold activation over the C-fragment alone are underlined. 
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Figure S1.15 Zinc finger structure overlaid with split sites  
(A) Amino Acid sequence alignment of BCR_ABL-1 (amino acid residues 19-102) with 
the sequence of Zif268 (amino acid residues 103-186) from PDB 1A1L and alignment 
statistics generated using the ‘needle’ function from the EBI Tools Package (Laberga et 
al. 2007). (B) The ZF split sites assayed for splicing are labeled in the primary sequence 
of BCR_ABL1 and highlighted on the crystal structure of Zif268 PDB ID 1A1L (Elrod-
Erickson et al. 2003). Residues in blue are split sites with splicing efficiencies of >3 fold 
over the C-fragment alone, and residues in red are split sites with no significant splicing 
activity. Effective split sites are all within protein loop regions. 
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A 
 
B 
 
Figure S1.16 Fluorescence microscopy of ZF-based Boolean AND gates  
(A) Fluorescence microscopy images of AND gate induced CFP reporter expression from 
BCR_ABL activator reporter constructs. Cells were transfected with the 6x BCR_ABL 
activator reporter along with either input A alone, input B alone, or both inputs present 
together.  Here, Input A is the modified N-terminal BCR_ABL-1:GCN4 :intein* activator 
fragment, and input B is the C-terminal BCR_ABL-1:GCN4:intein activator fragment. 
Columns marked with 0 indicate that the corresponding input was not present in that 
experiment, whereas columns marked with 1 indicate that the corresponding input was 
present in that experiment. (B) Fluorescence microscopy images of mCherry expression 
for the same cells as in A. confirming input and off-target control expression and marking 
transfected cells. 
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A 
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Figure S1.17 Fluorescence microscopy of ZF-based Boolean NAND gates  
(A) Fluorescence microscopy images of NAND gate induced CFP reporter repression 
from BCR_ABL repressor reporter constructs. U-2 OS cells were transfected with the 6x 
BCR_ABL repressor reporter along with either input A alone, input B alone, or both 
inputs present in tandem.  Here, Input A is the modified N-terminal BCR_ABL-
1:GCN4:intein* repressor fragment, and input B is the C-terminal BCR_ABL-
1:GCN4:intein repressor fragment. Columns marked with 0 indicate that the 
corresponding input was not present in that experiment, whereas columns marked with 1 
indicate that the corresponding input was present in that experiment. (B) Fluorescence 
microscopy images of mCherry expression for the same cells as in A. confirming input 
and off-target control expression and marking transfected cells. 
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Table S1.1 DNA plasmids co-transfected for each ZF experiment  
Plasmids and plasmid amounts transfected for each activator, repressor, and logic gate 
experiment. These amounts were chosen based on preliminary titration experiments. Note 
that transcription factor and reporter amounts differ between the activator and repressor 
experiments. The repressor systems have a high ZF-TF:reporter plasmid ratio as in the 
transient assays the repressible promoter has a ‘head-start’ to produce CFP protein before 
sufficient repressor is made to repress CFP expression.  
 
Activators 
ZF Construct Off Target Reporter Empty Vector 
Activator Expression 
Construct 
intC-BCR1-
GCN4-C1 
Activator 
Reporter pCDNA5-ins 
No ZF -- 10ng 990ng 0ng 
ZF 10ng -- 990ng 0ng 
 
Repressors 
ZF Construct Off Target Reporter Empty Vector 
Repressor 
Expression 
Construct 
intC-BCR1-
GCN4-C1 
Repressor 
Reporter pCDNA5-ins 
No ZF -- 100ng 10ng 890ng 
ZF 100ng -- 10ng 890ng 
 
OR Input A  Input B Off Target Reporter Empty Vector 
Input 
A 
Input 
B 
Activator: 
BCR_ABL-
1-GCN4 
Activator:      
erbB2-Jun 
Off-target 
ZF 
OR gate 
Reporter 
pCDNA5-
ins 
0 0 -- -- 20 ng 980 ng 0 ng 
1 0 10 ng -- 10 ng 980 ng 0 ng 
0 1 -- 10 ng 10 ng 980 ng 0 ng 
1 1 10 ng 10 ng -- 980 ng 0 ng 
       
NOR Input A  Input B Off Target Reporter Empty Vector 
Input 
A 
Input 
B 
Repressor: 
BCR_ABL-
1-GCN4 
Repressor:    
erbB2-Jun 
Off-target 
ZF 
NOR gate 
Reporter 
pCDNA5-
ins 
0 0 -- -- 200 ng 10 ng 790 ng 
1 0 100 ng -- 100 ng 10 ng 790 ng 
0 1 -- 100 ng 100 ng 10 ng 790 ng 
1 1 100 ng 100 ng -- 10 ng 790 ng 
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Table S1.1 (Continued). 
AND Input A  Input B Off Target Reporter Empty Vector 
Input 
A 
Input 
B 
BCR_ABL1-
N1-IntN* 
Activator: 
intC-
BCR_ABL1-
C1-GCN4 
Off-target 
ZF 
Activator: 
6x-
BCR_ABL 
pCDNA5-
ins 
0 0 -- -- 100 ng 900 ng 0 ng 
1 0 50 ng -- 50 ng 900 ng 0 ng 
0 1 -- 50 ng 50 ng 900 ng 0 ng 
1 1  50 ng 50 ng -- 900 ng 0 ng 
       
NAND Input A  Input B Off Target Reporter Empty Vector 
Input 
A 
Input 
B 
BCR_ABL1-
N1-IntN* 
Repressor: 
intC-
BCR_ABL1-
GCN4 
Off-target 
ZF 
Repressor: 
6x-
BCR_ABL 
pCDNA5-
ins 
0 0 -- -- 200 ng 10ng 790 ng 
1 0 100 ng -- 100 ng 10ng 790 ng 
0 1 -- 100 ng 100 ng 10ng 790 ng 
1 1 100 ng 100 ng -- 10ng 790 ng 
 
ZF Splits 
N-Fragment C-Fragment Reporter Empty Vector 
BCR1-N#-
intN 
Activator: 
intC-  
BCR1-C#-Jun 
Activator: 6x-
BCR_ABL pCDNA5-ins 
C-only -- 150 700ng 150ng 
N+C 150ng 150ng 700ng 150ng 
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Supplemental Information: Engineering synthetic TAL effectors with orthogonal 
target sites 
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1Department of Systems Biology, Harvard Medical School, Boston, Massachusetts 02115, 
USA 
2Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, 
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Reproduced from Garg A, Lohmueller JJ, Silver PA, Armel TZ. (2012). Engineering synthetic 
TAL effectors with orthogonal target sites..Nucleic Acids Res. Aug;40(15):7584-95. Copyright 
(2012), with permission from Oxford University Press. 
Abhishek Garg contributed data for Supplemental Information in collaboration with Jason J. 
Lohmueller and contributions from Thomas Z. Armel. 
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Inventory of Supplemental Information 
Figure S2.1 relates to Chapter III, showing reverse-triangle inequality heuristic 
Figure S2.2 relates to Chapter III, showing TALE cloning strategy 
Figure S2.3 relates to Figure 3.5, showing TALE expression  
Figure S2.4 relates to Chapter III, showing the distribution of 18bp TALE binding 
sites in the human genome 
Figure S2.5 relates to Chapter III, showing the distribution of 20bp TALE binding 
sites in the human genome 
Figure S2.6 relates to Chapter III, showing a ROBDD representation 
Figure S2.7 relates to Chapter III, showing an ADD of the hamming distance 
Table S2.1 relates to Figure 3.5, showing fold induction of CFP reporter by 
synthetic TALEs 
Table S2.2 relates to Chapter III, showing optimal target sequence of synthetic 
TALEs and their closest endogenous target sequence in 2000 bp promoter regions 
Table S2.3 relates to Chapter III, showing the position of mismatches between the 
optimal target sequences of the synthetic TALEs 
Table S2.4 relates to Table 3.1, showing subparts used to assemble each of the 
synthetic TALEs 
Table S2.5 relates to Figure 3.7, showing target DNA sequences of TALEs in the 
endogenous promoter regions 
Table S2.6 relates to Figure 3.7, showing reverse and forward strand primer 
sequences used in qPCR experiments 
Table S2.7 relates to Figure 3.8, showing constructs used in TALE repressor- 
shRNA co-expression experiments 
Supplementary Methods relates to Chapter III. 
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Figure S2.1 Schematic representation of the reverse-triangle inequality heuristic 
used to generate orthogonal 20-mers 
The complete set of genomic 20-mers is divided into smaller subsets (circles) and 
represented by a single sequence (central point). The zoomed-in subset shows individual 
sequences (points) are all 7bp or closer to the representative sequence (central point).  
Orthogonal sequences that are at a minimum 10 bp from the representative sequence 
(central point) are at least 3bp away from every sequence in the subset. 
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(A) 
 
(B) 
 
Figure S2.2 TALE cloning strategy  
(A) TALE proteins were assembled from a pool of sub-parts that include repeat regions 
for RVDs and half RVDs targeting nucleotides A, C and T, and RVD pairs targeting all 
combinations of A, C, and T. TALE subparts were assembled by digesting the plasmid 
containing the 5’- RVD with the restriction enzymes BbsI and PstI and the plasmid 
containing 3’- RVD with the restriction enzymes Alw26I and PstI. The two DNA 
fragments were then ligated to generate a construct containing both RVD domains while 
also reconstituting the flanking enzyme sites. The BbsI and Alw26I sticky ends combine 
to generate the first four bases of the second RVD domain, thus leaving no nucleotide 
scar between ligated RVD domains. (B) Hierarchical assembly of a representative 
synthetic TALE. The small circles associated with each step represent the ligation of two 
parts. Using this method, a synthetic TALE engineered to recognize a 20 bp target 
sequence can be efficiently assembled in 4 cloning steps.  
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TALE1 TALE2 TALE3 TALE4 TALE5 TALE6 TALE7 TALE8
BS-1
BS- 2
BS- 3
BS- 4
BS- 5
BS- 6
BS- 7
BS- 8
 
Figure S2.3 Fluorescent microscopy images of mCherry expression as a marker for 
TALE expression  
Each column of the 8x8 matrix represents U-2OS cells co-transfected with a synthetic 
TALE and reporter constructs for each 20-mer binding site (BS). All TALE expression 
constructs were tagged with autocatalytically cleaved t2A:mCherry as a marker for 
protein expression. The presence of mCherry fluorescence in each well indicates that our 
TALE constructs are efficiently expressed in all samples. 
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Figure S2.4 The distribution of promoter specific 18 bp TALE binding sites in the 
human genome  
The bins on the X-axis represent the number of sites in a single 200 bp upstream region 
or 500 bp upstream region for which a TALE targeting that specific promoter region can 
be designed. The Y-axis represents the corresponding percentage of human genes that fall 
into each bin. 
 
Figure S2.5 The distribution of promoter specific 20 bp TALE binding site in the 
human genome  
The bins on the X-axis  represent the number of sites in a single 500 bp upstream region 
for which a TALE targeting that specific promoter region can be designed. The Y-axis 
represents the corresponding percentage of human genes that fall into each bin.
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Figure S2.6 A ROBDD representation of the Boolean function 
 
 
Figure S2.7 An ADD of the hamming distance between a set of 2-mers {TT,AA} in a 
Boolean representation using Equation S2 
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Table S2.1 Fold induction of CFP reporter by synthetic TALEs  
Each column of the 8x8 matrix represents U2-OS cells co-transfected with a synthetic 
TALE and reporter constructs for each 20-mer binding site (BS). The level of CFP 
expression in each sample was measured by flow cytometry and the fold induction was 
calculated for each binding site relative to transfection with an off-target reporter. The 
asterisk indicates a sample for which only a single repeat is present due to machine error. 
 TALE 1  TALE 2  TALE 3  TALE 4  TALE 5  TALE 6  TALE 7  TALE 8  
BS-1  20.89  1.23  1.57  1.71  1.56  0.85  1.29  1.22  
BS-2  0.93  9.82  0.98  0.89  0.98  1.01  0.81  0.79  
BS-3  1.01  1.36  65.67  1.17  1.17  1.27  1.09  0.99  
BS-4  0.86  0.82  0.74*  10.2  1.02  0.9  0.79  0.78  
BS-5  0.81 1.15  1.09  1.58  58.4  0.77  1.21  1.04  
BS-6  0.77  0.88  0.79  1.06  1  101.68  1.01  0.83  
BS-7  1.14  0.99  0.81  1.34  1.25  0.98  74.15  1.1  
BS-8  0.96  0.98  1.21  1.12  0.92  1.1  0.9  85.71  
 
Table S2.2 Optimal target sequence of synthetic TALEs used in this paper and their 
closest endogenous target sequence in 2000 bp promoter regions 
The optimal target sequence and the endogenous sequence that has the minimum 
hamming distance to the optimal target sequence are listed along with the number of 
mismatches between the two sequences. The position of the mismatches between the two 
sequences are listed numerically from 5’!3’. The first base pair position corresponding 
to ‘T’ is considered as 0.  
TALE 
ID 
Target Sequence 
(5’!3’) 
Endogenous Sequence 
(5’!3’) 
Number of 
Mismatch 
Positions of 
Mismatch 
TALE-1 TCAATACTTACAAACTCC
TT 
TCAATGTTTATAAACTCC
TT 
3 5 6 10 
TALE-2 CCACCAAATTCAACACT
TT 
CAAGCAACTTCAACACT
TT 
3 2 4 8 
TALE-3 CATCTACAACACTACTA
TT 
CATCTACAACCCTGCAA
TT 
3 11 14 16 
TALE-4 CCCAATACACTATAACA
CA 
CACAACACACTATAAGA
CA 
3 2 6 16 
TALE-5 T ACTTACCTTCTCAACA
CA 
T ACGTACCTTGTCACCA
CA 
3 4 11 15 
TALE-6 T TCCTCTTACAATATCC
CA 
T TCCTCTTATTACATCCC
A 
3 10 11 13 
TALE-7 T CTTACCCTAACCCAAT
TT 
TACTTACCCTATACAAAT
TT 
3 11 12 14 
TALE-8 ATACTATCCAATCCAAC
TT 
ACACCATCCAATCCATC
TT 
3 2 5 16 
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Table S2.3 The position of mismatches between the optimal target sequence of the 
synthetic TALEs and their endogenous target sequence  
The longest stretch of sequence from the 5’-end without any mismatches found in a 2000 
bp upstream promoter region in the human genome is listed. The position the mismatches 
are ordered numerically from 5’!3’. The first base pair position corresponding to ‘T’ is 
considered as 0.  
TALE 
ID 
Optimal Target Sequence 
(5’!3’) Endogenous Sequence (5’!3’) 
Positions of 
Mismatch 
TALE-
1 
TCAATACTTACAAACTCCTT TCAATACTTACAGCCCACAC 12 13 15 16 18 19  
TALE-
2 
TCCACCAAATTCAACACTTT TCCACCAAATTCACAAAACC 13 14 16 17 18 19  
TALE-
3 
TCATCTACAACACTACTATT TCATCTACAACACAGAGTTG 13 14 15 16 17 19  
TALE-
4 
TCCCAATACACTATAACACA TCCCAATACACTCTGCCTCC 12 14 15 17 19   
TALE-
5 
TAACTTACCTTCTCAACACA TAACTTACCTTCTATGCTAA 13 14 15 17 18   
TALE-
6 
TATCCTCTTACAATATCCCA TATCCTCTTACATTAAAGCA 12 15 16 17    
TALE-
7 
TACTTACCCTAACCCAATTT TACTTACCCTAAGCTCTCCC 12 14 15 16 17 18 19 
TALE-
8 
TATACTATCCAATCCAACTT TATACTATCCAAAGGCCACT 12 13 14 15 16 17 18 
 
 
Table S2.4 Subparts used to assemble each of the synthetic TALEs used in this study 
 
 
TALE 
ID Subpart composition (5’!3’) 
TALE 
1 
HD-
L NI-NI NG-NI 
HD-
NG NG-NI HD-NI NI-NI 
HD-
NG 
HD-
HD NG-L NG-S   
TALE 
2 
HD-
L HD-NI 
HD-
HD NI-NI NI-L 
NG-
NG HD-NI NI-L HD-NI 
HD-
NG NG-L 
NG-
S  
TALE 
3 
HD-
L NI-L 
NG-
HD NG-NI HD-NI NI-L HD-NI 
HD-
NG NI-L 
HD-
NG NI-L 
NG-
L 
NG-
S 
TALE 
4 
HD-
L HD-L HD-NI NI-L NG-NI HD-NI 
HD-
NG NI-L NG-NI NI-L 
HD-
NI 
HD-
L NI-S 
TALE 
5 NI-L NI-L 
HD-
NG NG-NI HD-L 
HD-
NG 
NG-
HD 
NG-
HD NI-L NI-L 
HD-
NI 
HD-
L NI-S 
TALE 
6 NI-L 
NG-
HD 
HD-
NG 
HD-
NG NG-NI HD-NI NI-L NG-NI 
NG-
HD 
HD-
HD NI-S   
TALE 
7 NI-L 
HD-
NG NG-NI 
HD-
HD 
HD-
NG NI-NI 
HD-
HD HD-NI NI-L 
NG-
NG NG-S   
TALE 
8 NI-L NG-NI 
HD-
NG NI-L 
NG-
HD HD-NI NI-L 
NG-
HD HD-NI NI-L 
HD-
NG 
NG-
S  
TALE  
Control NI-L HD-NI HD-NI 
HD-
HD NI-L HD-NI 
NG-
HD NI-L 
NG-
NG NI-L 
NG-
NG 
NG-
S  
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Table S2.5 Target DNA sequences of TALEs in the endogenous promoter regions 
TALE ID Gene Name Off-
target/On-
Target 
Target DNA Sequence in 
Promoter 
TALE-
OSGIN2 
OSGIN2 On-target TCCTCCCCACCTTTAATTTT 
TALE-
ZC3H10 
ZC3H10 On-target TACCATATCCCATCCAACTC 
TALE 5 OSGIN2 Off-target TAAAATACCTGCTCATCACA 
TALE 5 CRYBG3 Off-target TAGCTTCCATTTTCAACACA 
TALE 5 IL8 Off-target TAAATTACCTCCCCAATAAA 
TALE 5 Spats2l Off-target TAAATTATATTATCCACACA 
TALE 5 PRC1 Off-target TAACTTACCTATTCACCCCC 
TALE 8 ZC3H10 Off-target TACCATATCCCATCCAACTC 
TALE 8 CAP2 Off-target TAAAGTAACCAAACCCACTT 
TALE 8 TMEM14C Off-target TATTATCTCCATTCCCACTT 
TALE 8 VGLL4 Off-target TATAATATCCATTTACACTT 
 
Table S2.6 Reverse and Forward strand primer sequences used in qPCR 
experiments 
RefSeq ID Gene  Name   
Primer Sequences (5’ to 3’) 
Forward Primer Reverse Primer 
NM_004337 OSGIN2 GCGCGAGGAAATGCCCAAAGAAAC 
TCGCCCCAAGTTGTCACCAA
AGT 
NM_153605 CRYBG3 TTCGAGGTTGCTGGCTCCTCT 
GCTGGGCAACCGCAGGAAG
T 
NM_000584 IL8 TGACTTCCAAGCTGGCCGTGG 
ACTGCACCTTCACACAGAGC
TGC 
NM_001100
422 Spats2l ACCCGAGAGAGGCGTGAGCA 
ATAGGCCCTGGGAATCCACA
GCAA 
NM_003981 PRC1 ACCTGGAGCTCAACGGCAGC AGGGACGGATCCTTCGCAAACTC 
NM_032786 ZC3H10 TCGGGTAGGCGGCTCTTTGT ACATCGCTGCTGGGTTCTGCC 
NM_006366 CAP2 AGCTGTCAGCCGCCTGGAGT GGAGGGTGCCACACCTGCAAT 
NM_016462 TMEM14C CTGCGCAGGCACAACAGAGC GCCTGCACCGGTCTCACGAA 
NM_001128
219 VGLL4 
TGGGGCAAAAGCAAAGAGCT
GGT 
GCAGCTTCGCCTTCGTAGCA
CA 
NM_002046 GAPDH GAAATCCCATCACCATCTTCCAGG GAGCCCCAGCCTTCTCCATG 
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Table S2.7 Constructs used in TALE repressor- shRNA co-expression experiments 
Off-target shRNAs and TALEs are used to validate fold repression achieved for TALE 
only and shRNA only experiments, respectively. An off-target shRNA and TALE 
combination is used to determine the unrepressed CFP signal for each reporter. 
Experiment/Reporter BS-8 / FF4' BS-8 / FF6' BS-5 / FF4' BS-5 / FF6' 
Off-Target Control 
TALE 5R  
+  
shRNA FF6 
TALE 5R 
 +  
shRNA FF4 
TALE 8R  
+  
shRNA FF6 
TALE 8R  
+  
shRNA FF4 
shRNA only 
TALE 5R  
+  
shRNA FF4 
TALE 5R  
+  
shRNA FF6 
TALE 8R  
+  
shRNA FF4 
TALE 8R  
+  
shRNA FF6 
TALE only 
TALE 8R  
+  
shRNA FF6 
TALE 8R  
+  
shRNA FF4 
TALE 5R  
+  
shRNA FF6 
TALE 5R  
+  
shRNA FF4 
TALE+shRNA 
TALE 8R  
+  
shRNA FF4 
TALE 8R  
+  
shRNA FF6 
TALE 5R  
+  
shRNA FF4 
TALE 5R  
+  
shRNA FF6 
 
Supplementary Methods 
Analysis of potential TALE binding sites 
To demonstrate the importance of considering off-target effects when designing 
synthetic TALEs to target endogenous genes, we analyzed the promoter regions of the 
human genome for the number of potential sites in each promoter region for which 12 bp, 
18 bp and 20 bp TALE binding sites specific to a promoter can be designed. We found 
that TALEs designed to target 12 bp nucleotides sequences are unable to specifically 
target the promoter of any single gene as the target binding sites are too short, even if the 
promoter region is restricted to 200 bp from the TSS, and a designed TALE will always 
have an off-target binding site in the promoter of another gene. By extending the target 
nucleotide sequence to 18 bp it becomes possible, though difficult, to design TALEs 
specific to a promoter for a fraction of genes. If the promoter region is restricted to the 
200 bp region upstream of the TSS, only 84% of genes have at least one target site in the 
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promoter region for which TALEs specific to that promoter can be designed. Of these 
84% of genes, only 35% have more that 10 promoter specific 18 bp target sites, which is 
a small sequence space for attempting to design synthetic TALEs that function in a 
promoter specific manner. If the targetable promoter region for these TALEs is expanded 
to 500 bp, fewer than 7% of genes have more than 10 potential 18 bp TALE target sites 
that are specific (Figure S2.4). For the case where TALEs are presumed to function when 
they bind to an 18 bp sequence within the 2000 bp region upstream of the TSS, it is not 
possible to design a TALEs that interacts specifically with only one promoter. However, 
when we searched for potential 20 bp binding sites to which synthetic TALEs can be 
targeted without binding to off-target promoter sequences, we find that the design space 
is much larger. For 20 bp target sequences, 98% of human genes have more that 10 
promoter specific binding sites present in 500 bp upstream regions, and many options are 
available to design TALEs that specifically target the expression of nearly every human 
gene (Figure S2.5). This suggests that future efforts seeking to utilize TALEs without 
unwanted off-target effects should consider designing proteins that bind target sites of at 
least 20 bp. 
 An algorithm to compute orthogonal 20-mers 
We used Boolean algebra and symbolic modeling techniques to compute 20-mers 
at a given hamming distance from a set of genomic 20-mers. We translated N-mers, 
representing DNA sequences of length N over the alphabets {A, C, G, T}, into a Boolean 
vector x of length 2N. Boolean encoding 00, 01, 10 and 11 is used to represent alphabets 
A, C, G and T respectively. Using this Boolean encoding, a base pair at position i in a 
given N-mer is represented by two consecutive bit positions x2i-1 and x2i of the 
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corresponding Boolean vector . In order to perform efficient set operations such as 
intersection, a set of N-mers can be represented by Boolean functions. An example 
demonstrating a Boolean representation of N-mers and a Boolean function representation 
of a set of N-mers is given below. 
Example: Given a set of 2-mers, S = {TT, AA}, its Boolean representation is given by 
SB= { , }, where  stands for logic negation of . The 
corresponding Boolean function for set SB is given by: 
                                                               
The hamming distance between two N-mers is defined as the number of base pair 
positions at which the two N-mers differ. The hamming distance for Boolean vector 
encoding of N-mers is defined as the number of consecutive bit positions at which the 
two Boolean vectors are different. For example, the hamming distance between Boolean 
vectors 0001 and 0110 is 2 as the two vectors differ at positions {1,2} and {3,4}. The 
hamming distance between two Boolean vectors  and  of length N can be calculated 
using the Boolean function in Equation S-I, where symbols  and  stand for Boolean 
operations XOR and OR respectively. 
                                                    (S-I)          
Our algorithm first computes the Hamming distance function between Boolean 
vectors corresponding to all possible genomic N-mers. Then, given a Boolean vector  
and the hamming distance function H, all Boolean vectors that are above a given 
hamming distance d from the vector  can be quickly computed by restricting the 
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hamming distance function H to threshold d (represented by Hd) and applying the 
Boolean function in Equation S-II.  
                                                                                                (S-II) 
The symbol !   in Equation S-II represents existential quantification, which 
essentially drops all variables in  by iteratively assigning them values of 0 and 1. The 
resulting Boolean function ,  after applying the existential quantification, represents 
all Boolean vectors at the hamming distance above the threshold d from the input vector 
. In order to compute N-mers at a given hamming distance from every element in a set 
of Boolean vectors, we apply Equation S-II to all Boolean vectors in the set and then take 
the intersection of resulting Boolean functions. 
In order to efficiently represent a large set of Boolean vectors and perform 
Boolean operations on them, we use symbolic representation and modeling techniques 
based on Reduced Ordered Binary Decision Diagrams (ROBDDs) (46,47). ROBDDs are 
directed top-to-bottom graphs, where a top node represents the Boolean function being 
evaluated, each intermediate node represents a Boolean variable, and two leaf nodes (0 
and 1) represent whether the Boolean function evaluates to true (i.e. 1) or false (i.e. 0). 
Every intermediate node has two outgoing edges representing whether the Boolean 
variable is assigned the value ‘0’ or ‘1’. Each path from the top node to the leaf node has 
the same order of Boolean variables and represents a Boolean vector assignment. A path 
leading to leaf node ‘1’ or ‘0’ represents the Boolean variable assignment for which 
Boolean function evaluates to true or false respectively. An example of a ROBDD 
representing the set of Boolean vectors in the example given above is shown in Figure 
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S2.6. All Boolean logic functions such as AND, OR and NOT can be efficiently 
performed on ROBDD representations of Boolean functions.  
The hamming distance function in Equation S-I can also be represented using 
Algebraic Decision Diagrams (ADDs), which are a modified form of ROBDDs such that 
the leaf nodes can take values from the set of real numbers instead of only Boolean 
values 0 and 1 (46). In our case, ADDs corresponding to the hamming distance function 
in Equation S-I will take integer values from 0 to N representing the number of base pairs 
at which the two N-mers differ. An ADD representing the hamming distance between the 
set of N-mers in the above example is shown in Figure S2.7.  
Our algorithm first constructs an ADD to represent the hamming distance 
between Boolean vectors of all possible N-mers. In our case N=20, therefore such an 
ADD would represent the pair-wise hamming distance between all possible 420 20-mers. 
If one is interested in only Boolean vectors that have a hamming distance above a 
threshold d, then an ADD can be converted to a corresponding ROBDD by changing all 
the leaf nodes above the value d to ‘1’ and all the remaining leaf nodes to ‘0’. The widely 
used Binary Decision Diagrams modeling package CUDD, was used to perform all 
ROBDDs and ADDs representation and manipulation in this manuscript (48).  
Cloning scheme for TALEs 
Restriction sites for EcoRI, XbaI, PstI and Alw26I were designed at the 5’end and 
restriction sites for BbsI, SpeI, NotI and PstI were designed at the 3’end in all sub-
modules corresponding to repeat domains. The constant 5’- region and constant 3’- 
region sub-modules had similar restriction sites to repeat domains sub-modules except 
that Alw26I and BbsI sites are absent in the constant 5’- and 3’- region constructs, 
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respectively. The pidSmart vector (Integrated DNA Technology, Coralville, IA) was used 
for cloning and assembling TALE fragments into complete TALE sequences using 
standard molecular biology techniques and all DNA constructs were verified by 
sequencing. Figure S2.2 further describes the TALE assembly scheme. 
 143 
Appendix III 
 
Protein Scaffold-Activated Protein Trans-Splicing in Mammalian Cells 
Daniel F. Selgrade,1 Jason J. Lohmueller1,2, Florian Leinert1,2 & Pamela A. Silver1,2 
1 Department of Systems Biology, Harvard Medical School, Boston, Massachusetts 
02115, USA 
2 Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, 
Massachusetts 02115, USA 
 
 
 
 
Reprinted (adapted) from Selgrade DF, Lohmueller JJ, Lienert F, Silver PA. (2013). 
Protein Scaffold-Activated Protein Trans-Splicing in Mammalian Cells. J Am Chem Soc. 
May 8. [Epub ahead of print]. Copyright (2013) American Chemical Society. 
 
Jason J. Lohmueller designed all experiments and wrote the manuscript with input from 
Daniel F. Selgrade. Daniel F. Selgrade carried out all experiments and produced all of 
data with mentorship from Jason J. Lohmueller and collaboration with Florian Leinert. 
 144 
Protein Scaﬀold-Activated Protein Trans-Splicing in Mammalian Cells
Daniel F. Selgrade,†,§ Jason J. Lohmueller,†,‡,§ Florian Lienert,†,‡ and Pamela A. Silver*,†,‡
†Department of Systems Biology, Harvard Medical School, Boston, Massachusetts 02115, United States
‡Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts 02115, United States
*S Supporting Information
ABSTRACT: Conditional protein splicing is a powerful
biotechnological tool that can be used to rapidly and post-
translationally control the activity of a given protein. Here we
demonstrate a novel conditional splicing system in which a
genetically encoded protein scaﬀold induces the splicing and
activation of an enzyme in mammalian cells. In this system the
protein scaﬀold binds to two inactive split intein/enzyme extein
protein fragments leading to intein fragment complementation,
splicing, and activation of the ﬁreﬂy luciferase enzyme. We ﬁrst
demonstrate the ability of antiparallel coiled-coils (CCs) to
mediate splicing between two intein fragments, eﬀectively creating two new split inteins. We then generate and test two versions
of the scaﬀold-induced splicing system using two pairs of CCs. Finally, we optimize the linker lengths of the proteins in the
system and demonstrate 13-fold activation of luciferase by the scaﬀold compared to the activity of negative controls. Our protein
scaﬀold-triggered conditional splicing system is an eﬀective strategy to control enzyme activity using a protein input, enabling
enhanced genetic control over protein splicing and the potential creation of splicing-based protein sensors and autoregulatory
systems.
■ INTRODUCTION
Protein splicing is a post-translational modiﬁcation that can
control the activity of a protein by assembling it from inactive
fragments. Analogous to RNA splicing, protein splicing is the
process by which an intervening protein domain, or intein, self-
excises out of a larger polypeptide, ligating the two ﬂanking
polypeptidestermed exteinsinto a single protein.1 Protein
splicing can occur in cis- or in trans-.2−4 For trans-splicing the
intein sequence is split into two fragments, and the splicing
reaction occurs between two distinct polypeptides. Intein
domains are highly modular and have been used by researchers
to assemble several diﬀerent proteins in various experimental
contexts.5−8
The development of conditional protein splicing has enabled
researchers to post-translationally control protein activity in
response to speciﬁc molecular inputs and has already become a
useful research tool. By engineering split inteins that contained
the rapamycin ligand-binding domains, Mootz et al. ﬁrst
demonstrated that trans-splicing could be induced by the small
molecule rapamycin.6 Other conditional splicing systems have
been generated to induce splicing in response to temperature,
light, and chemical ligands such as 4-HT.9−13
Here we propose a novel conditional splicing system in
which splicing is induced by the presence of a genetically
encoded protein scaﬀold. In contrast to previously developed
conditional splicing systems activated by exogenously admin-
istered inducers (small molecules and light), a protein inducer
can be directly linked to endogenous biological pathways. This
characteristic enables the potential to monitor or rewire
biological pathways at the protein level. The engineering of
synthetic post-translational signaling pathways reﬂects a
common strategy used by natural systems and is a major
research focus. However, only a few general approaches
exist.14−18 The protein-induced protein splicing system oﬀers
a general mechanism to post-translationally convert a protein
input into a fully formed output protein through engineered
binding domains. The general reaction mechanism demon-
strated by our work also suggests methods to create splicing-
based protein sensors and autoregulatory systems.
Biomolecular scaﬀolds have previously been used to increase
the yield of biochemical synthesis pathways by bringing
together enzymes operating in a pathway.19−22 We hypothe-
sized that protein scaﬀolds could also be used to bring together
split inteins and trigger protein splicing. Our system consists of
two fusion proteinseach containing split intein/extein
domains fused to a scaﬀold binding domainand the input
scaﬀold protein. In the presence of the scaﬀold the two fusion
proteins bind to the scaﬀold leading to association of the intein
fragments, splicing, and activation of the output protein.
We constructed, tested, and optimized a scaﬀold-induced
splicing system comprising well-characterized protein compo-
nents. We used two pairs of previously characterized
antiparallel coiled-coils termed LZA/LZB and EE/RR.23−25
LZA is known to bind strongly to LZB and EE to RR, but no
binding is expected to occur between proteins in the diﬀerent
pairs. These coiled-coils drive the speciﬁc association of the
intein/extein fusion proteins and the synthetic scaﬀold. We
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chose to use the Saccharomyces cerevisiae vacuolar ATPase
(VMA) split intein because these split fragments display very
weak splicing activity in the absence of outside protein-binding
domains.8,26 For the output protein we used ﬁreﬂy luciferase, as
it has a sensitive biochemical readout and previously
determined extein split sites.8,27 After demonstrating the ability
of the CCs to mediate splicing, we optimized the linker lengths
of the individual component proteins of the system. Finally, we
showed that our protein scaﬀold system had comparable
eﬃcacy to that of the established rapamycin-induced splicing
system.8
■ RESULTS AND DISCUSSION
We ﬁrst sought to determine whether coiled-coil binding could
mediate trans-splicing between proteins containing split VMA
intein fragments in mammalian cells. We generated Cytomega-
lovirus (CMV) promoter driven expression plasmids encoding
fusion proteins comprising a CC domain fused by a ﬂexible
glycine-serine (GS) linker to an N- or C-terminal split VMA
intein domain and an N- or C-terminal ﬁreﬂy luciferase extein
fragment, respectively (Figure 1A). Amino acid sequences of
the coiled-coil domains are listed in Supporting Information,
Table S1. We expected that complementary CCs (LZA with
LZB and EE with RR) would bind, leading to split intein
complementation, protein splicing, and luciferase activity.
Conversely, we anticipated that proteins with noncomplemen-
tary CCs would not interact, resulting in ineﬃcient splicing and
low luciferase activity (Figure 1B,C).
To test for CC-mediated splicing we transiently cotrans-
fected diﬀerent combinations of N-intein and C-intein
expression plasmids into U2OS osteosarcoma cells and assayed
Figure 1. Coiled-coil-mediated protein trans-splicing. (A) Schematic representation of the expression system used to test trans-splicing of CC-
intein/extein fusion proteins. Each CC-intein/extein fusion protein is expressed from the CMV promoter. Coiled-coil domains CC and CC′ are
fused to split inteins and luciferase exteins, IntN/LucN and LucC/IntC, via ﬂexible glycine-serine linkers (GS). (B) Schematic representation of the
complementary CC binding assay design. CC-intein/extein pairs tested are in boldface, and those connected by lines are expected to interact. (C)
Binding of complementary coiled-coil domains leads to intein fragment complementation and splicing and activation of ﬁreﬂy luciferase. (D) Activity
of recombinant intein pairs as measured by luciferase output. Shaded boxes represent transfection with an empty expression vector. Data are
presented as mean ± s.d., n = 3. Two asterisks, P < 0.01; three asterisks, P < 0.001.
Journal of the American Chemical Society Article
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for luciferase activity at 48 h. The speciﬁc CC combinations
that we built and transfected are shown in boldface, and
connecting lines indicate expected interactions in Figure 1B.
We found that luciferase activity was signiﬁcantly higher
when the coexpressed proteins contained complementary CCs,
indicating that CCs can coordinate speciﬁc protein trans-
splicing. Proteins containing the EE/RR pair showed higher
overall luciferase activity than the LZA/LZB pair (5360 RLU
and 2360 RLU, respectively) (Figure 1D). This result agrees
with higher activities reported for other protein systems using
the EE/RR CC pair compared to those using the LZA/LZB
pair.23,26
Importantly, Schwartz et al. previously demonstrated that any
luciferase activity observed from the intein/extein pairs used in
the scaﬀold system is due to protein splicing and not protein
fragment complementation.8 Expression constructs encoding
intein/extein protein fragments lacking CCs and single CC-
intein/extein fragment transfections showed no signiﬁcant
luciferase activity above the vector-only control, further
supporting the role of coiled-coil binding in mediating the
splicing reaction (Figure 1D). Given the large number of CC
pairs present in the literature, these results suggest that
combining CCs with the VMA split intein fragments could be a
general strategy to produce a large number of new functionally
Figure 2. Protein scaﬀold-activated protein trans-splicing. (A) Schematic representation of the expression system used to test conditional splicing of
CC-intein/extein fusions in response to CC scaﬀolds. (B) Schematic representation of the expected complementary CC binding for each synthetic
scaﬀold and CC-intein/extein pair. Proteins tested are in boldface, and those connected by lines are expected to interact. (C) Recombinant inteins
containing noncomplementary coiled-coil domains CC-1 and CC-2 associate only in complex with a protein scaﬀold containing complementary
CCs, CC-1′ and CC2′. Presence of the scaﬀold results in the splicing and activation of ﬁreﬂy luciferase. (D) Induction of splicing between EE and
LZA split inteins of varying GS linker lengths by a protein scaﬀold. Constructs encoding each intein pair were cotransfected with a construct
encoding an ON-target scaﬀold RR-GS1-LZB (gray) or an OFF-target scaﬀold LZA-GS1-EE (white). The ‘No Scaﬀold’ control consists of the 3 GS
linker EE and LZA split inteins transfected with an empty vector instead of a scaﬀold. The ‘No CCs’ control represents cotransfections of inteins not
fused to coiled-coils. Data presented as mean ± s.d., n = 3. One asterisk, P < 0.05; two asterisks, P < 0.01; three asterisks, P < 0.001.
Journal of the American Chemical Society Article
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orthogonal intein pairs with minimal cross-reactivity.28 Addi-
tionally, the low levels of luciferase activity for protein pairs
with noncomplementary CCs indicate that these proteins could
potentially serve as substrates in a scaﬀold-induced conditional
splicing system.
Next, we investigated whether we could induce trans-splicing
of two noninteracting CC-intein/extein proteins using a protein
scaﬀold. In this system the scaﬀold protein is comprised of two
CCs that are complementary to the CCs of the CC-intein/
extein fragments. We expect both CC-intein/extein fragments
to bind to the scaﬀold leading to split intein complementation,
splicing of the luciferase exteins, and luciferase activity (Figure
2A,B,C). We ﬁrst focused on scaﬀolding the LZA/EE pair of
CC-intein/extein fragments. As previous results indicated the
importance of spacing between scaﬀolded molecules, we
created scaﬀolds and CC-intein/extein proteins with ﬂexible
linkers of varying lengths.19,20,29 We generated CMV expression
constructs encoding fusion proteins with 1-, 2-, or 3-copies of
the glycine-serine linker (GGGS)3 between CCs and the split
intein/extein domains (Figure 2A). To test for scaﬀold-
mediated splicing and the eﬀect of CC-intein/extein linker
length we cotransfected diﬀerent combinations of expression
plasmids encoding the N-intein and C-intein proteins with
diﬀerent linker lengths along with an ‘ON-target’ RR-LZB
scaﬀold or an ‘OFF-target’ LZA-EE scaﬀold. We assayed for
luciferase activity at 48 h. The expected CC interactions for the
scaﬀolds and intein fragments that we tested (in boldface) are
shown with connecting lines in Figure 2B.
The results of the luciferase assays demonstrated that the
protein scaﬀold could induce speciﬁc trans-splicing of two
noninteracting intein/extein proteins. We found that the ON-
target scaﬀold led to signiﬁcantly higher levels of luciferase
activity than the OFF-target scaﬀold for all linker lengths of the
LZA/EE proteins tested (2.4−6.3 fold). The CC-intein/extein
proteins with 3-GS linkers exhibited the highest luciferase levels
(∼2600 RLU) (Figure 2D). These 3-GS linker proteins also
exhibited signiﬁcantly higher levels of luciferase in the presence
of the ON-target scaﬀold compared to the ‘No Scaﬀold’
control. Neither scaﬀold aﬀected the splicing and luciferase
activity of the control intein/extein proteins containing no CCs.
We also found that the behavior of this system was robust to
changes in amounts of DNA transfected (Supporting
Information [SI], Figure 1).
Next, we investigated the eﬀect of the scaﬀold linker length
on scaﬀold-induced splicing. We created DNA constructs
encoding scaﬀolds with 0−3 × GS linkers. We also generated
expression constructs encoding CC-GS3-intein/extein proteins
with the LZB/RR CC pair. The full list of constructs generated
and their subparts are listed in SI, Table S2. We transfected
these CC-intein/extein constructs and scaﬀolds with diﬀerent
linker lengths and assayed for luciferase activity.
We found that most of the scaﬀolds of diﬀerent GS-linker
lengths were capable of inducing splicing and that the linker
length had variable eﬀects on luciferase activity (Figure 3A).
For the LZA/EE-intein/extein system the luciferase activity was
highest for the shortest, 0-GS linker, scaﬀold and correlated
negatively with the length of the scaﬀold GS linker. The 0-, 1-,
and 3-GS scaﬀolds all induced higher splicing levels than both
the OFF-target scaﬀold and ‘No Scaﬀold’ controls. The 2-GS
scaﬀold showed no signiﬁcant induction of splicing activity,
possibly due to steric constraints (Figure 3A).29 While the
induction levels for the LZB/RR-intein/extein system were
lower than those of the LZA/EE system, the 1-and 2-GS LZB/
RR systems showed signiﬁcantly higher levels of luciferase with
ON-target scaﬀolds compared to ‘OFF-target’ and ‘No Scaﬀold’
controls (Figure 3B). Of note, observed diﬀerences in the
activity of the LZA/EE-intein/extein system in Figures 2D, 3A,
4B are most likely due diﬀerences in the luciferase assay kits
used. While experiments within a single ﬁgure used the same
Figure 3. Eﬀects of scaﬀold linker length on scaﬀold-induced protein splicing. (A) Luciferase activity of the LZA-GS3-intC/LucC and LucN/IntN-
GS3-EE proteins induced by CC scaﬀolds with GS linkers of varying lengths. CCs for both ON-target (RR-LZB) and OFF-target (EE-LZA)
scaﬀolds were fused together by 0−3 GS linkers. (B) Luciferase activity of the RR-GS3-LucC/LucC and LucN/IntN-GS3-LZB proteins induced by
CC scaﬀolds with GS linkers of varying lengths. CCs for both ON-target (EE-LZA) and OFF-target (RR-LZB) scaﬀolds were fused together by 0−3
GS linkers. The ‘No Scaﬀold’ control consists of the intein pair transfected with an empty vector instead of a scaﬀold. The ‘No CCs’ control
represents cotransfections of inteins not fused to coiled-coils. Data presented as mean ± s.d., n = 3. One asterisk, P < 0.05; two asterisks, P < 0.01;
three asterisks, P < 0.001.
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assay kit and can be quantitatively compared, results between
ﬁgures should not be directly compared.
Finally, we compared the eﬃcacy of the scaﬀold-induced
splicing system to that of the established rapamycin-induced
splicing system reported in Schwartz et al. In this system the
rapamycin-binding domains FRB and FKBP bind simulta-
neously to rapamycin, leading to split intein complementation,
protein splicing, and luciferase activity. We cloned CMV
expression plasmids encoding the rapamycin inducible system,
transfected it into U2OS cells and assayed for activity following
48 h. For the rapamycin system transfected cells were incubated
with rapamycin or DMSO-only (Figure 4A). We found that
rapamycin successfully induced luciferase activity 6.5-fold
compared to the DMSO-only vehicle control. In comparison,
under the same experimental conditions our scaﬀold-induced
system exhibited similar behavior with a 7-fold induction in the
presence of scaﬀold (Figure 4B). It should be noted that the
rapamycin-inducible system has been previously shown to have
optimal activity at 25 °C in Drosophila S2 cells; however,
whenever implemented in mammalian cells, reactions are
performed at 37 °C.8 These results demonstrate that the
eﬃcacy of our scaﬀold-induced system is similar to that of an
established conditional splicing system.
The successful implementation of our protein scaﬀold-
induced splicing system provides the mechanistic foundation
for further adaptations and applications. As the VMA split
inteins have been used in various organisms and contexts, it is
likely that the scaﬀold-induced system could also be adapted to
control protein activity in a number of instances.5−8 Addition-
ally, the modularity of the VMA split intein with respect to
binding domains and extein proteins suggests that other CCs or
protein binding domains such as the PDZ, SH3, or zinc ﬁnger
domains could be used and that the system could be adapted to
splice together other output proteins.30−33 That the scaﬀold is a
protein allows for the potential to link its presenceand thus
also the activation of the splicing reactionto other biological
processes in vivo. This goal could be accomplished by
expressing the scaﬀold from a promoter speciﬁc to the desired
process, or by post-translationally controlling its activity or
localization.14 Converting the presence of one protein into the
production of a second protein also implies a design for a
general protein sensor in which the protein being sensed serves
as the scaﬀold protein for the splicing reaction (Figure 5A).
Finally, the eﬃcacy of this protein-induced system using two
separate pairs of inteins with little cross-reactivity provides the
basis for higher-order functioning systems. These systems could
include autoregulatory networks such as protein splicing
cascades or ampliﬁers analogous to established DNA-based
systems (Figure 5B).34
■ CONCLUSIONS
We have developed a novel conditional splicing system in
which a genetically encoded protein scaﬀold induces the trans-
splicing and activation of an enzyme. We ﬁrst demonstrated the
ability of complementary CCs to mediate protein trans-splicing
between two proteins, eﬀectively generating two new sets of
orthogonal inteins. We then demonstrated the eﬃcacy of the
scaﬀold-induced splicing system with two diﬀerent sets of
complementary CC proteins. We optimized the system based
on component linker lengths, yielding a system capable of 13-
fold induction over the ‘No scaﬀold’ and ‘OFF-target’ controls.
Finally, we showed that the system had comparable eﬃcacy to
that of an established conditional protein splicing system. In
sum, the protein scaﬀold-induced splicing system adds to the
repertoire of modular approaches that researchers can employ
to precisely control protein activity and biological functions in
living cells.
■ EXPERIMENTAL SECTION
Recombinant DNA constructs. Recombinant plasmids were
created using the Biobrick Cloning method. DNA sequences encoding
the VMA intein fragments, LZA, LZB, EE, RR, FRB, FKBP were
ﬂanked with Biobrick ends and synthesized for order by Integrated
DNA Technologies (IDT). The intein−luciferase fusion parts were
constructed via PCR and BspQI restriction enzyme methods. The
complete list of constructs and their constituent BioBrick parts can be
found in Table S2 of SI. Sequences of all BioBrick subparts are listed in
Table S3 of SI. For CMV expression constructs coding regions were
cut with Xba1 and Not1 and cloned into the NheI and NotI sites of
the CMV expression plasmid “pCDNA5ins.”35
Mammalian Cell Culture and Transfection. Human osteosar-
coma-derived U2OS cells (ATCC no. HTB-96) were cultured at 37
°C, 5% CO2 in growth medium (McCoy’s 5A medium, 10% FBS, 100
U/mL penicillin, and 100 mg/mL streptomycin). For transfections,
cells were plated in 12-well plates at ∼150,000 cells per well in 1 mL
growth medium. Transient transfections were performed 24 h after
plating at 80% conﬂuency using Lipofectamine LTX with Plus
Figure 4. Comparison of the protein scaﬀold-induced splicing system
to the rapamycin-induced splicing system. (A) Schematic representa-
tion of the expression system used to test rapamycin-induced
conditional splicing. Rapamycin-binding domains FRB (two copies)
and FKBP were fused via ﬂexible linkers L2 and L3 to split intein-
ﬁreﬂy luciferase extein fusions.8 (B) Comparison of luciferase activity
of the rapamycin-induced splicing system and the scaﬀold-induced
system (LZA-GS3-LucC and LucN-GS3-EE and GS1 scaﬀolds). The
‘No Scaﬀold’ control consists of the intein pair transfected with an
empty vector instead of a scaﬀold. Data presented as mean ± s.d., n =
3. One asterisk, P < 0.05; two asterisks, P < 0.01; three asterisks, P <
0.001.
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(Invitrogen) and a total of 1 μg DNA per reaction according to the
manufacturer’s protocol. All transfections were performed in triplicate
with the precise DNAs and amounts as speciﬁed in Table S4 of SI.
Transfected cells were incubated at 37 °C for 48 h prior to analysis by
luciferase assay.
Luciferase Assay. Luciferase activity of transfected cells was
measured using Dual Luciferase Reporter Assay (Promega) according
to manufacturer’s instructions. Brieﬂy, a luciferase lysis buﬀer (1 ×
passive lysis buﬀer supplemented with 1 μM ZnCl) was used to lyse
the cells and inhibit background splicing. To each transfection well we
added 250 μL of the modiﬁed buﬀer, and the plates sat on the shaker
for 15 min prior to aliquotting in a 96-well plate. For each transfection
well, 100 μL of Luciferase Assay Buﬀer (LARII) was pipetted over 20
μL of cell lysate and photometer readings were taken for each well.
Luciferase activity is reported in relative light units (RLU) calculated
by subtracting the raw output of each transfection well by an initial
blank value taken on a well containing only cell lysate. All charts
contain data collected in a single assay run using pooled LARII buﬀer.
■ ASSOCIATED CONTENT
*S Supporting Information
DNA titration of LZA-EE scaﬀold system, DNA constructs and
subparts, DNA transfection amounts, DNA subpart sequences,
amino acid sequences of the coiled-coil domains. This material
is available free of charge via the Internet at http://pubs.acs.org.
Figure 5. Potential applications of the protein-induced protein splicing system. (A) Schematic representation of a general protein sensor. The sensor
comprises two fusion proteins consisting of protein binding domains (PBDs) for an arbitrary protein - Protein 1, split intein fragments IntN and
IntC, and exteins of the output protein - Protein 2. Upon binding to Protein 1, the intein fragments complement and Protein 2 is spliced and
activated. (B) Potential protein-based autoregulatory networks. The scaﬀold circuit described in this manuscript is represented in abbreviated
diagrammatic form. In a hypothetical protein ampliﬁcation circuit, Protein 1 induces the splicing of additional Protein 1, creating positive feedback
and ampliﬁcation of Protein 1. For a protein cascade circuit, Protein 1 induces the splicing of Protein 2 which in turn catalyzes the splicing of Protein
3.
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